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SUMMARY
The binding of bacterial, viral or parasitic antigens with specific antibody and the 
formation of immune complexes (IC) in the circulation is a natural event in infectious 
diseases. In autoimmune immune complex diseases, such as RA and SLE, the 
development of circulating IC depends on the binding of autoantibodies to autoantigens. 
In either case complement is activated with the generation of activation products. As the 
extent of complement activation is likely to be proportional with the disease severity, the 
measurement of complement activation products in biological fluids could be used as a 
measure of disease activity.
In order to be able to measure complement activation in biological fluids, three 
avidin-biotin sandwich ELISA procedures were developed for the quantification of the 
Cls:Clr:Cl-inhibitor (Cls:Cl-INH), C3bBbP (C3:P) and SC5b-9 (C5b-9) complexes. 
The three assays were optimized and had sensitivity limits of 0.75ng Cl-INH/ml for 
C ls:C l-IN H , 0.92ng C3/ml for C3:P and 0.9ng C5/ml for C5b-9. All three 
complement activation complexes were found to be stable during 4 hours incubation 
periods at 20° C and 37° C.
These ELISA procedures were used for the measurement of the complement 
activation complexes in the serum and plasma of patients with rheumatoid arthritis and 
systemic lupus erythematosus. Significantly elevated levels in all three complexes were 
found in both groups of patients (p<0.0001) in comparison with normals. There were 
significant correlations between the three complement activation complexes and serum 
levels of rheumatoid factors (IgM-RF, IgG-RF and IgA-RF) in the sero-positive 
rheumatoid arthritis patients. However, as the same results were obtained when 
F(ab')2 fragments of ELISA-coating antibodies were used to measure complement 
activation products, and as the addition of purified IgM-RF to sera which were sero­
negative for IgM-RF, did not influence the ELISA results, it was concluded that these 
correlations were not the result of RF interference with the assays.
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Experiments were undertaken to determine the properties of IC which resulted in 
complement activation. Complement activation was stimulated in vitro with nascent 
and preformed BSA anti-BSA and thyroglobulin anti-thyroglobulin IC, at antigen 
antibody ratios ranging from 16-times antibody-excess to 16-times antigen-excess. 
Activation was quantified by measuring levels of Cls:Cl-INH, C3:P and C5b-9. The 
interpretation of the data was assessed by measuring levels of C4a, C3a and C5a on the 
same samples, as indices of activation of C l, C3 and C5 respectively.
The result of the investigation showed:
1) Nascent and preformed IC produced dose-dependent increase in complement 
activation as assessed by Cls:Cl-INH, C5b-9, C4a, C3a and C5a formation, whereas 
a clear dose-response effect was not seen with C3:P
2) The antigen antibody ratio influenced complement activation. When 
thyroglobulin anti-thyroglobulin IC were studied, more complement activation occurred 
(as assessed by Cls:Cl-INH, C4a, C3a and C5a) when IC were formed at 4-times 
antibody-excess. When C5b-9 generation was measured, activation was greatest when 
IC were formed at 16-times antibody-excess. When BSA anti-BSA IC were used, Cl 
activation was greatest at equivalence, whereas C5b-9 activation was greatest at 16- 
times antibody-excess.
3) The antigen in the IC influenced complement activation, as BSA containing IC 
activated complement more efficiently at equivalence, while IC containing thyroglobulin 
activated complement more efficiently in antibody-excess. In addition, C5 activation 
was greater with thyroglobulin anti-thyroglobulin IC than with BSA anti-BSA IC.
4) Preformed IC activated C3 and C5 better than nascent IC, whereas nascent IC 
produced more Cl activation than did preformed IC.
5) The role of the alternative pathway was established by repeating the experiments 
in serum containing EGTA (lOmM.L'*) and MgC^ (2.5mM.L-^). Cl activation did 
not occur, while C3a and C5a production were reduced by approximately 50%. Thus, 
half of the C3 and C5 convertase activity generated was dependent upon the alternative 
pathway.
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6) Differences between the rate and extent of formation of Cls:Cl-INH and C4a 
and C5b-9 and C5a showed that although each pair is considered to be an index of Cl 
activation and C5 activation respectively, the results show that Cls:Cl-INH and C5b-9 
are not absolute measures of Cl and C5 activation respectively.
7) Levels of C3:P showed no relationship to those of C3a and thus it is unlikely 
that C3:P determinations can be used as an index of C3 turnover.
The explanation for reduced levels of C3:P with high concentrations of IC at certain 
antigen-antibody ratios was investigated. Although the explanation was not 
forthcoming, it was shown that it was not due to insolubility of the IC.
As complement activation in the blood occurs in the presence of blood cells (mainly 
erythrocytes), the effect of erythrocytes on IC-mediated complement activation was 
investigated. Levels of C4a, C3a and C5a were unaltered when activation occurred in 
the presence of erythrocytes, which demonstrated that they do not affect complement 
activation. However, in the presence of erythrocytes the levels of the Cls:Cl-INH 
were increased, levels of C3:P were reduced and those of C5b-9 were probably 
elevated slightly. The explanation for increased Cls:Cl-INH was not clear, but could 
have been related to the binding of IC to erythrocytes which render IC-bound Cl more 
susceptible to the action of Cl-INH. Reduced levels of C3:P were shown to depend on 
the presence of the C3b receptor (CR1) on erythrocytes. The precise mechanism by 
which CR1 affects C3:P levels requires investigation, but the two main possibilities are 
binding of C3:P to CR1 or degradation of C3b in the C3:P complex by the action of 
factor I with CR1 acting as a cofactor.
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1.1. HISTORY OF THE COMPLEMENT SYSTEM
Complement activity was probably first described by John Hunter, who noted that 
putrefaction proceeded more slowly in blood than in other tissues (Osier, 1976). In 
1889 Buchner described a heat labile protective activity which he termed "alexin", and 
this was thought to be enzymatic in nature. In 1894 Pfeiffer observed that the 
intraperitoneal inoculation of Vibrio cholera bacilli into guinea pigs which had 
recovered from an earlier infection with this organism, resulted in their rapid 
destruction.
In 1896 and 1898 Bordet confirmed Pfeiffer's findings by showing that fresh 
serum from immune animals contained a heat-sensitive bacteriolytic substance which 
was active in the presence of specific antibodies. He also demonstrated that in the 
presence of specific antibody fresh serum was able to lyse erythrocytes and suggested 
that haemolytic assays could be used as an easy way to demonstrate the presence of 
alexin in sera.
In 1900 Ehrlich and Morganroth introduced the term "complement" (something 
which completes or makes perfect), as a more appropriate term than alexin. In 1901 
Bordet and Gengou formulated the complement fixation test, which proved helpful in 
identifying antibodies to different antigens. Friedberger (1910) showed that fresh 
serum lost its haemolytic activity after incubation with varying substances including 
agar, and this treatment produced anaphylactic shock when the serum was injected into 
guinea pigs.
In 1911 Sachs and Omorokow described a heat-stable functional activity of 
complement which was destroyed when the serum was treated with cobra venom. In 
1913 Weil showed that this component acts after the first and second components of 
complement, and called it C3, as C4 was unknown at that time. In 1914, Coca reported 
that C3 activity was abolished by incubating serum with yeast.
During the 1940's Ecker and Pillemer explored the chemical constituents of the 
complement system for the first time, and attempted to determine their properties.
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These studies were based on euglobulin precipitation, heat-sensitivity, treatment with 
zymosan or cobra venom and ammonia-sensitivity. The conclusions obtained from 
these studies were as follows:
a) Complement component (1) is a heat-labile globulin which is precipitated by 
dialysis against distilled water (0° C for 18-36 hours).
b) Complement component (2) is heat-labile and not precipitated by dialysis.
c) Complement component (3) is heat-stable protein which adsorbed strongly to 
polysaccharides (for example zymosan).
d) Complement component (4) is heat-stable protein but it is sensitive to dilute alkali 
(for example ammonia).
The subsequent use of more advanced protein fractionation techniques has 
permitted the purification and characterization of the proteins which constitute the 
complement system.
1.2. NOMENCLATURE OF COM PLEM ENT COMPONENTS
It is now known that the plasma complement system consists of at least twenty 
proteins (Table 1.1). For the sake of simplicity the plasma complement system is 
divided into 4 group of proteins; those which comprise the classical pathway, the 
alternative pathway, the terminal complex and finally a group of control proteins.
The components of the classical pathway and the terminal complex are denoted by 
the letter C followed by a number and are listed in the order of their interaction as 
follows: C l, C4, C2, C3, C5, C6, C7, C8 and C9. Cl is a trimolecular complex 
containing Clq, C lr and C ls (Lepow et ai, 1963 ; Ziccardi and Cooper, 1977). The 
alternative pathway components are termed "factors" and each component is represented 
by a letter: factor B, factor D and factor P. Sometimes the prefix factor is om ffcted and 
they are described as B, D and P. Control proteins are referred to by their trivial 
names, eg Cl-inhibitor (Cl-INH), C3b inactivator (factor I), C4 binding protein 
(C4bp) and factor H.
When a complement component is fragmented by proteolysis, the cleavage products
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are denoted by lower case letters; eg. C3a, C3b, C3c and C3d. When a complement 
component is composed of more than one chain, the different polypeptide chains are 
designated by Greek letters, the largest being a  then p and so on; eg C4a, C4P and 
C4y. In the past when a complement protein acquires an enzymatic activity, a 
horizontal bar was placed over the symbols, eg. Cl, Cls, D, and C4b2a. With the 
exception of Cl and its subcomponents, the use of bars over letters has been dropped 
because of difficulties in using them on word processors.
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Table 1.1 Characteristics of complement proteins.
Component Molecular
Weight
Electrophoretic
Mobility
Serum Polypeptide 
Conc.(fig/ml) Chain Structure
Genetic
Polymorphism
Cleavage
Products
C lq 400 000 a 75 18(6x3) + —
C lr 90 000 p 100 1 ? A&B
C ls 90 000 p 80 1 ? A&B
C4 204 000 p 430 3 + C4a, C4b 
C4c, C4d
C2 100 000 p 20 1 + C2a, C2b
B 93 000 p 150 1 + Ba, Bb
D 25 000 a 2 1 9 —
P 220 000 Y 30 4 9 —
C3 190 000 P 1300 2 + C3a, C3b 
C3c, C3dg
C5 180 000 P 75 2 - C5a, C5b
C6 128 000 P 60 1 + —
C l 121000 P 60 1 + —
C8 153 000 Y 80 3 + —
C9 79 000 P 50 1 - —
Cl-INH 105 000 a 180 1 + —
C4bp 540 000 P ? 8 ? —
Factor I 90 000 P 50 2 - —
Factor H 150 000 P 300 1 ? —
S-protein 88 000 
Anaphylatoxin
a 505* 1 ? —
Inactivator 300 000 a ? 8 ? —
(Table cited from McPhaden et al, 1982) 
(*) Cited from Miiller-Eberhard, 1986.
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1.3. THE CLASSICAL PATHWAY
The classical pathway C3 convertase, C4b2a, is generated by the interaction of five 
proteins, C lq, C lr, Cls, C4 and C2 (Fig 1.1). This process is regulated by three 
plasma proteins, Cl-inhibitor (Cl-INH, Pensky et ai, 1961; Ratnoff et ai, 1969), C4 
binding protein (C4bp) and factor I (C3b/C4b inactivator, Gigli al, 1985).
1.3.1. C l Macromolecule
Cl is a macromolecular complex composed of five molecules, one C lq and two of 
each of Clr and C ls (Naff et al, 1964; Dodds et al, 1978). Approximately 70% of Cl is 
present in serum in the complex macromolecular form (Ziccardi and Cooper, 1977). 
The Cl macromolecule is held together by calcium ions, (Ca++) and after treatment 
with the chelating agent EDTA, Cl dissociates into its three subcomponents (Colomb et 
1984). Activation of C l, initiates activation of the classical pathway (Lepow et aL 
1963).
Clq
The recognition subcomponent of C l, is a large complex molecule having a 
molecular weight of about 410kD, which, because of its extreme cationic nature, 
expresses slow y2 mobility on immunoelectrophoresis (Cooper, 1985). Electron- 
microscopic examination of C lq showed that the molecule is composed of three distinct 
parts: a central subunit, six peripheral globular heads and six fine strands connecting 
the central core to the heads (Shelton et ai, 1972).
Biochemically, C lq is composed of 18 polypeptide chains, 6A, 6B and 6C, which 
are assembled to form six triple helices where each triple helix is composed of 1 A, IB 
and 1C chain. Disulphide bridges are present between each A and B chains (A-B) and 
2C chains (C-C). The interchain disulphide bonds between the C chains together with 
hydrophobic and electrostatic interactions join the six triple-helices together to form the 
central core. The C-terminal end of each triple helix terminates in a globular head which 
contains the immuonoglobulin binding site of Clq (Reid and Porter, 1976).
Clr
Clq
I- ------------- Activator(IC) 
Clq* (undergoes conformational changes)
Ca + + j Cls
Clr i
\  Cls
C4 I
C2
C4a* ■'
(C4bp)<;. C4b2a
C3a
C3 C3b
Figure 1.1: Diagrammatic representation of the classical pathway of complement 
activation.
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Amino acid analysis of C lq revealed that it contains a high proportion of glycine, 
hydroxylysine and hydroxyproline, which are the major constituents of collagen and the 
proteins which compose the cellular basement membranes. Moreover, the amino acid 
sequence of the A, B, and C chains revealed the repeating triplet Gly-X-Y which is 
peculiar to collagen and is responsible for the triple helical structure (Reid, 1976). It 
has been found that the point of divergence of the collagen like strands corresponds 
with an interruption in the Gly-X-Y triplet (Reid, 1977; Porter and Reid, 1978). The 
average divergence angle of each of the stalks with the axis of the central stalk is 
approximately 60° (Gilmour et al, 1980).
Apart from its function as the recognition subcomponent of C l, C lq  offers the 
assembly site for the zymogens C lr and Cls, which exist as a Clr2:Cls2 tetramer. 
The association constant as well as the attachment site of this tetramer with C lq will be 
discussed later.
The C-terminal globular heads of C lq  bind to the CH2 domain of IgG (Kehoe and 
Fougereau, 1969) and the CH3 domain of IgM (Hurst et ai, 1975). IgA, IgD and IgE 
do not bind C lq whether in the monomeric or aggregated form (Ishizaka and Ishizaka, 
1969; Augener&aL 1971; Garredgt al, 1989).
Human IgG subclasses exhibit different binding affinities to Clq; IgG3 binds most 
efficiently, then IgGl followed by IgG2. IgG4 does not have any demonstrable Clq 
binding activity (Schumaker elaL  1976). This has been attributed to the steric 
hindrance created by the proximity of the F(ab')2 to the Fc portion of the 
immunoglobulin (Isenman £t al, 1975). Recently it has been demonstrated, using 
human monoclonal antibodies, that although IgGl is less efficient in binding Clq than 
IgG3, the number of C4 molecules activated by the Cl macromolecule is 10 fold higher 
for IgGl than for IgG3. This behaviour was not due to favoured binding of C4 to 
IgGl, but appeared to depend upon increased activation of C4 by C ls when Cl is 
bound to IgGl (Bindon al, 1988).
The affinity of C lq to monomeric immunoglobulin is weak, with the association
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constant ranging from 4xl03 to 5xl04 M '1 (Sledge and Bing, 1973; Schumaker et aL 
1976; Hughes-Jones and Gardner, 1978). Thus, plasma IgG is incapable of binding 
and/or activating C l (Borsos and Rapp, 1965). The affinity of C lq  for 
immunoglobulin increases with aggregation by chemical (Tschopp et al, 1980) or 
physical (Dodds and Porter, 1979) procedures, or after the formation of immune 
complexes (IC). The association constant of C lq  binding to complexed IgG was 
determined as 10 -^10** M'* (Hughes-Johnes and Gardner, 1978; Lin and Fletcher, 
1978). This increase in affinity may be attributed to the polyvalent binding of C lq to 
the complexed IgG. The binding of C lq to IC is temperature independent (Borsos gt 
ai, 1964) and after binding it undergoes a reversible conformational change (Dodds gt 
ai, 1978), which has been confirmed by the detection of neo-antigenic determinants 
within C lq (Golan et al, 1982).
The number of IgG molecules which can be bound by a single C lq  molecule 
remains controversial. Schumaker gt a! (1976) reported that a single Clq molecule can 
bind from 12-18 IgG molecules, while Tschopp et ai, 1980, who used chemically 
cross-linked IgG dimers and electron-microscopy, showed that the C lq  molecule 
accepts only 3 IgG dimers. There is also disagreement over the number of complexed 
IgG molecules which are required for activation. Goers gt a! (1977) reported that a 
single IgG molecule complexed with monovalent hapten is capable of activating the 
classical pathway,* others (Hyslop et aL 1970) suggested that complexes with less than 
4 IgG molecules are incapable of activating complement,* while other workers have 
reported that two or three complexed IgG molecules are sufficient (Cohen, 1968; 
Mannik gt ai, 1971). Kijlstra gt ai (1981) found that four or more IgG molecules per 
complex are required to activate complement. The differences in the conclusions of 
these groups is probably due to variations in the experimental procedures.
Clr
The purified proenzyme form of C lr is present in serum as a Ca++-independent
C O  OH
C O O H
Figure 1.2: Schematic representation of the subcomponent Clr. The proenzyme form 
(1) is composed of two non-covalently linked monomers. During activation (2) each 
monomer is cleaved near its C-terminus, giving rise to the formation of two disulphide 
linked chains. The active enzymatic site is located on the C-terminal light chain (Assimeh 
eta!, 1978).
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dimer, which is composed of two single glycosylated polypeptide chains (Fig 1.2) 
having a molecular weight of 83-91kD (Sim £t al, 1977; Arlaud etM, 1980). The 
electrophoretic mobility of C lr varies according to the availability of Ca++. In the 
presence of Ca++ it exhibits y  mobility whereas in the presence of EDTA it has P 
mobility (Ziccardi and Cooper, 1976a). Electron-microscopy revealed that the C lr 
dimer consists of two dumb-bell-shaped molecules which are bound together near the 
junction between the rod and one of the globular domains to form an assymetrical X 
(Fig 1.3) with two closely located inner globules and two outer globules (Weiss 
1986).
Upon activation each subunit of the proenzyme form of C lr is cleaved into two 
disulphide-linked polypeptide chains, designated as A and B. The A chain, 51-56kD, 
is derived from the N-terminus, while the B chain, 27-36kD, which contains the 
enzymatically active site of the protein (Fig 1.2) is derived from the C-terminus (Simgt 
a!, 1977; Arlaud and Gagnon, 1983; Arlaud etal, 1987).
The A chain is composed of 446 amino acid residues (MW 51200), with two 
carbohydrate moieties attached to the polypeptide chain via asparagine residues at 
positions 108 and 204 (Arlaud et jti, 1987). Amino acid sequencing of the B chain 
showed that it contains 242 amino acid residues (MW 27096), and exhibits strong 
homology with other mammalian serine proteases. The active site serine residue is 
located at position 191 and carbohydrate moieties are attached via asparagine residues at 
positions 51 and 118 (Arlaud and Gagnon, 1983).
Cls
Cls consists of a single polypeptide chain with molecular weight of about 86kD. It 
exists in two forms; the proenzyme or precursor form and the activated form (Valet and 
Cooper, 1974). On immunoelectrophoresis the proenzyme form migrates as a P- 
globulin, while the activated form behaves as an a-globulin (Sakai and Stroud, 1973; 
Laurell £t al, 1976).
Electron-microscopic investigations reveal that monomeric C ls is an asymmetrical
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dumb-bell (Fig 1.3), where the large spherical globular domain contains the catalytic 
site of the activated molecule. The smaller domain is located on the N-terminus of the 
polypeptide chain and contains the Ca++-binding interaction domain upon which 
dimerization and interaction with Clr2 depend (Tschopp et al, 1980). Thus, under 
physiological conditions, C lr and C ls exist in plasma as a tetramer consisting of two 
molecules of C lr and two molecules of C ls (Clr2:Cls2) (Laurell and Martensson,
1974).
The proenzyme C ls is the natural substrate of Clr, and upon activation it is cleaved 
into two chains of unequal size which are connected by disulphide bonds (Naff and 
Ratnoff, 1968). The heavy chain is designated as the A chain with molecular weight of 
59kD while the light chain or B chain has molecular weight of 28kD and bears the 
enzymatically active site (Arlaud et ai, 1977).
Cls consists of 673 amino acid residues (Mackinnon el al, 1987). The heavy chain 
derived from the N-terminus (422 amino acid residues) is similar to that of C lr and 
contains 5 domains, while the C-terminal derived light chain (251 residues) contains the 
serine protease domain of C ls (Mackinnon et al, 1987). An overall amino acid 
sequence homology of 40.5% exists between Cls and Clr, and the location of cysteine 
residues for disulphide bond formation is identical (Kusumoto et al, 1988).
Modelling of the light chains of C lr and Cls proteolytic (A) chains reveal that the 
greatest difference between these two subcomponents lies in the external loops of their 
three-dimensional structure (Carter et aL 1984). This possibly explains the differences 
in their substrate specificities.
C lr2:C ls2 tetramer
Electron-microscopic visualization of the Clr2:C ls2 tetramer which had been 
reconstituted from equimolar amounts of C lr2 and C ls in the presence of Ca++, 
showed it to be an elongated S-shaped structure comprising domains of unequal sizes 
(Tschopp el al, 1980). The arrangement of these domains has been investigated, using
Figure 1.3: Schematic representation of the Clr2:Cls2 complex. The X shaped Clr2 
molecule is centrally located with the binding domains (1 I I) attached with those of the 
terminally located Cls molecules (•■’••'*). The catalytic domains of C lr (^ = ) and those 
of C ls (llllllllll) are oriented towards the exterior of the tetramer (Weiss et ai, 1986).
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a ferritin labelled avidin-biotin system, and revealed that the tetramer is joined through 
the interaction of the N-terminal domains (smaller domains) of C lr and Cls, while the 
C-terminal domains of C lr are joined in the centre of the tetramer and those of C ls are 
located at the distal ends of the tetramer (Fig 1.3) (Weiss £t al, 1986). The Clr2:Cls2 
tetramer interacts with the collagen-like part of Clq, as pepsin-digested Clq, which 
lacks the globular heads of the molecule, was found to compete with intact C lq  in the 
Clr2:Cls2 tetramer interaction (Reid et al, 1977). Further, the association constant of 
the tetramer with pepsin-digested C lq was determined to be 2xl07 M"1 which is 
similar to that with intact Clq (Siegel and Schumaker, 1983). Electron-microscopy of 
reconstituted Cl macromolecules, from purified Clq, C lr and Cls, revealed that the 
Clr2:Cls2 complex appeared as a folded structure around the point at which the Clq 
stalks diverge from the central core (Strange et al, 1982). Despite the low association 
constant of the C lr2:C ls2 tetramer for C lq, approximately 70% of the Cl 
subcomponents in plasma circulate within the Cl macromolecule (Ziccardi and Cooper, 
1977). The association constant of the tetramer for C lq increases approximately 10- 
fold when Cl binds to IC (Hughes-Jones and Gorick, 1982).
1,3.2. Activation of C l
The precise mechanism of Cl activation remains an enigma. It is generally accepted 
that a conformational change occurs in the C lq molecule after the binding of Cl to IC. 
This acts as the initiation signal for C lr activation which can only occur after some 
rearrangement within the C lr molecule which results in the exposure of a susceptible 
peptide bond to an enzymatic site on the same molecule and thus to the cleavage of C lr 
(Dodds et al. 1978).
Ziccardi and Cooper (1976a, b) reported that after incubation for 10 minutes at 
37°C, purified C lr acquires the ability to activate Cls. SDS-PAGE analysis revealed 
that C lr underwent auto-activation with molecular cleavage. Many workers have 
confirmed this phenomenon (Assimeh el ai, 1978; Lin and Fletcher, 1980; Kasahara et
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al, 1985). However, Dodds et ai (1978) suggested that the activation of purified C lr in 
solution was most probably due to traces of contaminating proteinases. They reported 
that the rate of activation of purified C lr showed no correlation with its concentration, 
indicating that the activation noticed was not due to an intramolecular auto-catalytic 
process. Thus, present evidence suggests that activation of C lr will only occur within 
the intact Cl macromolecule.
The molecular arrangement of the three C 1 subcomponents that permit this auto- 
catalytic process is unclear. All the present models of Cl activation assumes that a 
conformational change occurs in Clq. Hanson e te i  (1985) speculated that upon 
binding of C lq heads to an activator, the stalks may be held in a slightly more open or 
more closed conformation which in turn initiates activation of the Cl proenzyme. 
Alternatively, the globular heads of Clq, which are bound to antibody, rotate and 
produce rotation of the collagen-like stalks around their axis. Such a change would 
initiate a conformational change in Clr2:Cls2 complex with activation of Cl (Kilchherr 
et al. 1985). The flexible structure of the C lq molecule would allow either process to 
occur.
The arrangement of Clr2:Cls2 tetramer around the Clq molecule must permit C lr 
activation. A number of models have been proposed. Colomb et el (1984) suggested 
that the flexible rod-like structure of the Clr2:Cls2 tetramer is folded around two arms 
of C lq in a figure eight shape, with the catalytic domains of C lr and C ls inserted 
inside the cone defined by Clq stalks. Cooper (1986) assumed that the Clr2:Cls2 
tetramer forms two identical C-shaped C lr:C ls which stacked together vertically and 
wrapped around the outside of the Clq stalks near their attachment with the central 
core. This model was presented as allowing free access of Clr2:Cls2 to Cl-INH, C4 
and C2. Another model has been presented, in which the catalytic domains of C lr are 
located inside the cone formed from the C lq stalks, and the rest of the tetrameric 
complex is wound outside the rest of the stalks where during activation the catalytic 
domain of C ls folds back to the inside of the cone, allowing contact with the catalytic 
domains of C lr and activation of Cls by activated C lr take place (Weiss ei al, 1986).
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Each of these models has its supporters and opponents and further structural studies 
will be required to resolve the outstanding issues.
1.3.3. Activators of C l
Immune complexes are the main class of C l activators (already discussed), but it 
has also been shown that many "non-immune activators" are capable of binding and 
activating Cl. Gram-negative bacterial lipopolysaccharides, polyanions, certain viruses 
and some gram-positive bacteria can also bind Clq and activate the classical pathway of 
complement. The lipid-A component of gram-negative bacterial lipopolysaccharides is 
responsible for the binding and activation of Cl (Vukajlovich et al, 1987). Studies on 
intact bacterial cells and mycoplasma showed that Escherichia coli, Klebsiella 
pneumoniae and Mycoplasma pneumoniae bind directly to Cl via Clq. Experiments 
on a mutant strain of Salmonella minnesota showed that bactericidal action of serum is 
dependent on C l, C4, C2 and calcium ions. Peitch et ai (1987), described two classes 
of non-antibody activators of the classical pathway of complement. These activators 
were categorized according to their activation potency into "strong" activators such as 
cardiolipin vesicles, which are mitoplasts derived from human heart mitochondria, and 
semi-rough strain of Escherichia coli designated as J5. The weak activators include 
smooth strains of E. coli, DNA and human heart mitochondria. Strong activators 
activate Cl in the presence of Cl-INH, while the weak activators do not.
Another activator of the classical pathway is a polysaccharide derived from the 
venom of the tropical ant species Pseudomyrmyx. This polysaccharide was found to 
cause depletion of the fourth and the second complement components, through its 
activation of Cl (Schultz et al> 1980).
1.3.4. Cl-inhibitor and regulation of C l
Cl-inhibitor (Cl-INH) is a heat labile a-glycoprotein (lOOkD), consisting of a 
single chain polypeptide chain (478 amino acid residues) (Davis et al, 1986; Bock et al, 
1986), which can regulate many serum proteases such as plasmin (Harpel and Cooper,
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1975), kallikrein (Schapira et ai, 1982), C lr and Cls. Its serum concentration is about 
137|ig/ml so that the C1-INH:C1 molar ratio is about 7:1 (Schumaker £i al, 1987). Cl- 
INH exerts two regulatory activities on Cl; 1) It prevents spontaneous activation of Cl 
under physiological conditions or during the presence of weak non-immune activators 
like heparin or DNA or weak immune activators like IC formed at antigen-antibody 
ratios far from equivalence. 2) It is a stoichiometric inhibitor of C l. Upon activation 
of complement by IC, Cl-INH does not prevent Cl activation, since this type of 
activation is beyond its positive regulatory control. The reason for that can be attributed 
to the extremely rapid rate of Cl activation induced by IC (Ziccardi, 1982a,b; Ziccardi, 
1983, 1984). However, Cl-INH interacts with Cl by binding to the active sites of C lr 
and C ls leading to irreversible dissociation of the Clr2:Cls2 tetramer into two (Cl- 
INH)2-Cls-Clr complexes (Sim et ai, 1979). The released complex, (Cl-INH)2-Clr- 
Cls, is stable under conditions that dissociate non-covalently linked complexes (Harpel 
and Cooper, 1975). During binding to Cl a small peptide is released from Cl-INH 
(Salvesen e ia i, 1985), with the formation of a covalent bond between Cl-INH and 
C lr2:C ls2 (Chesne et ai, 1982). Investigation of the interaction of Cl-INH and 
activated C l on IC showed that Cl-INH first binds rapidly to C ls and then more 
slowly to Clr. When binding to C lr is completed the Cl macromolecule is dissociated 
and (Cl-INH)2Clr-Cls complex is liberated to the fluid-phase (Sim et ai, 1979; 
Ziccardi and Cooper, 1979), leaving C lq bound to the activator. The activator (IC) 
bound C lq  may be controlled by Clq-inhibitor that prevents the binding to fresh 
Clr2:Cls2 (Conradie ei ai, 1975).
1.3.5. Component C4
The fourth component of complement, C4 (Fig 1.4), consists of three polypeptide 
chains a , p, and y, with molecular weights of 93, 78 and 30kD respectively. These 
chains are bound by disulphide bridges and non-covalent forces. On electrophoresis, 
C4, migrates as a p-globulin (Schreiber and Miiller-Eberhard, 1974). Staining of
C4a
I------- 1
C4b
Hydrolysis v i th Cls
oc Chain 
P Chain 
y Chain
Figure 1.4: Schematic representation of C4 molecule which is composed of 3 
polypeptide chains; a  chain (93kD), p chain (78kD) and y  chain (30kD). These are 
linked by disulphide bridges. During activation the a  chain is cleaved with C ls with the 
liberation of a 6kD fragment (C4a).
35 .
reduced C4 on SDS-PAGE with periodic acid Schiff (PAS) reagent revealed that 
carbohydrate is attached to all three chains (Gigli et al, 1977).
C4 is synthesised as a single chain precursor, pro-C4, which is then cleaved twice 
during secretion to become the disulphide-bonded three-chain plasma molecule (Hall 
and Colten, 1977). The complete amino acid sequence of the pro-C4 molecule has been 
determined and shown to be composed of 1722 amino acids (Belt et al, 1985). The 
arrangement of the polypeptide chains in pro-C4 are in the order p-a-y (Goldberger and 
Colten, 1980). C4 is a highly polymorphic protein and its synthesis is controlled by 
two genes, located in the HLA class III region of the major histocompatability complex 
(MHC) on chromosome 6 of man (O'Neill et al, 1978; Raum et al, 1981). These two 
genes (C4A and C4B) which are closely linked and thought to have occurred as a result 
of gene duplication (Belt et al, 1985), encode two structurally and functionally distinct 
C4 isotypes (C4A and C4B) and are encoded by these two genes (O'Neill et al, 1978). 
The structural differences between C4A and C4B are confined to their C4d fragments, 
in which five primary amino acid sequence variations have been detected at residues 
94, 141, 142, 145 and 146 out of the total 346 amino acid residues which compose 
C4d (Heilman g ia l, 1984). These variations are responsible for the functional 
differences between C4A and C4B.
The C4 molecule has an internal thiol-ester bond located in the a-chain. Upon 
activation with Cl or Cls, the a-chain is cleaved at the N-terminus with the liberation 
of a short polypeptide fragment (C4a, 6kD) into the fluid-phase (Budzko and Miiller- 
Eberhard, 1970). Simultaneously with the cleavage of the a-chain, the thiol-ester is 
exposed to allow the larger fragment C4b (135kD) to bind covalently to the activating 
surface (Janatova and Tack, 1981). This binding of C4b occurs after the generation of 
a metastable reactive acyl group which is transferred from the thiol to a hydroxyl or 
amino group on the acceptor molecule (Campbell et al, 1981). The isotype C4B reacts 
preferentially with hydroxyl groups to form ester bonds, while C4A tends to react with 
amino groups on the target surface to form amide bonds (Law gt al, 1984).
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1.3.6. Component C2
C2 is a (3-globulin composed of a single polypeptide chain with a molecular weight 
of 102kD and a serum concentration of 15(ig/ml (Kerr and Porter, 1978). The 
carbohydrate content of C2 is about 15.9% (Tomana et&i, 1985). C2 and the 
alternative pathway component factor B are the products of closely linked genes within 
the MHC class III region, which in the human is located on chromosome 6 (Robson 
and Lamm, 1984). Electron-microscopic examination of C2 and B revealed that both 
proteins have three globular domains of similar size (Smith et al, 1984). Analysis of 
the deglycosylated forms of C2 and B showed that they had similar molecular weights 
(Smith et al, 1984). Thus, the higher carbohydrate content of C2 in comparison with 
factor B (MW 93000) which contains only 8.6% (Tomana et ai, 1985) may account for 
the molecular weight difference between the two native components. The structural and 
functional similarities of C2 and factor B support the hypothesis that the two loci 
encoding them arose by gene duplication.
C2 is activated by C ls in the absence of C4b but its binding to target bound C4b 
makes it more susceptible to cleavage by Cl or C ls (Gigli and Austen, 1969). Cls 
cleaves C2 at an x-lys bond with the production of two fragments of unequal size, C2a 
(73kD) and C2b (34kD) (Polley and Miiller-Eberhard, 1968; Kerr and Porter, 1978; 
Kerr, 1979). The C-terminal fragment C2a carries the enzymatic site of the classical 
pathway C3 and C5 convertases (Kerr, 1979).
1.3.7. Assembly of the classical C3 convertase (C4b2a)
During the activation of C4 by Cl in the presence of IC, a very small proportion (7- 
10%) of activated C4 (C4b) becomes covalently bound to the IC. The thiolester of the 
remainder reacts with water to become fluid-phase C4b (Goers and Porter, 1978). The 
IgG binding site for C4b is located on the N-terminal half of the IgG heavy chain (Fd 
region) or on the antigen (Campbell et al, 1980; Ejzemberg £1&1, 1983). The molar 
ratio of bound C4b to IgG in the C4b-IgG complex is 1:1 (Campbell et ai, 1980). 
Surface bound C4b has an Mg++-dependent binding site for C2, which is also a natural
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substrate for C ls (Kerr, 1980). The convertase (C4b2a) may be formed in the fluid- 
phase by adding C ls to a mixture of C4 (or C4b) and the C2 (but not pre-activated C2) 
(Miiller-Eberhard et al, 1967). The mechanism of binding of C2 to surface bound C4b 
and the generation of the classical C3 convertase, C4b2a, has been investigated by a 
number of workers (Miiller-Eberhard s i al, 1967; Nagasawa and Stroud, 1977; Kerr, 
1980). It has been shown that the C2 molecule binds to surface bound C4b through its 
C2b domain by Mg++-dependent binding site on C4b (Oglesby eta!, 1988). Once 
bound, C2 is cleaved by Cl into C2b and C2a, the smaller fragment, C2b, is liberated 
to the fluid-phase, and the larger fragment, C2a, which carries the enzymatic site of the 
classical pathway C3 convertase, C4b2a, remains attached to C4b. The convertase is 
composed of an equimolar complex of C4b and C2a. Once this bimolecular complex 
has been formed, Mg++ is no longer required (Kerr, 1980). C4b2a is an extremely 
labile enzyme, having a half life of 10 seconds at 37° C. Oxidation of C2 with a weak 
solution of iodine produces a stable C3 convertase in comparison to that produced with 
native C2 (Kerr, 1980). The classical C3 convertase exhibits similarities with the 
alternative C3 convertase (Table 1.2).
1.3.8. Assembly of the classical C5 convertase (C4b2a3b)
The classical C5 convertase is generated after the binding of one or more activated 
C3 molecules to the C3 convertase, C4b2a (Cooper and Miiller-Eberhard, 1970). The 
role of C3b in this enzyme is to bind to and modulate the configuration of C5 to render 
it susceptible to cleavage by C4b2a (Vogt et al, 1978). It has been shown that a nascent 
C3b molecule generated by the C3 convertase, binds covalently to the a-chain of C4b 
through an ester bond with the generated C4b-C3b dimer exhibiting high-affinity 
(Ka=2.1xlO^M~1) for the C5 molecule (Kinoshita et el, 1987). Blocking the surface- 
bound C4b-C3b dimer with anti-C4 produced an 80% reduction in C5 binding to 
EAC4b3b cells. Thus, it was concluded that the C4b-C3b dimer serves as the binding 
site for C5 (Kinoshita £t el, 1987). C4b-C4b dimers have been reported to be produced
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during C4 activation (Campbell et al, 1980), and because of the structural similarity 
between C4 and C3 (Sottrup-Jensen et al, 1985), the possibility exists that C4b-C4b 
dimers behave like C4b-C3b dimers in binding and presenting C5 for cleavage by 
C4b2a. The observation that C5 activation occurred when C4b2a prepared with 
oxidized C2 was added to C3-deficient serum, supports this notion (Kitamura et a[, 1984).
1.3.9. Regulation of C4b2a/C4b2a3b assembly
C4b2ais an unstable enzyme with a half-life of 1.5 minutejat 30°C and 10 seconds 
at 37° C. The catalytic subcomponent C2a dissociates rapidly from C4b to enter the 
fluid-phase in the inactive form (Kerr, 1980). However, if C l is still present, fresh 
convertase can be formed by the binding and activation of fresh C2 (Borsos et ai, 
1961). Apart from its intrinsic lability, the formation of C4b2a is regulated by specific 
plasma proteins at different stages of its generation. These proteins are C4 binding 
protein (C4bp), C3b/C4b inactivator (I), decay accelerating factor (DAF), membrane 
cofactor protein (MCP), complement receptor type 1 (CR1) and complement receptor 
type 2 (CR2). Recently it has also been demonstrated that nascent C3b and C4b 
fragments produce an inhibitory feedback on IC mediated complement activation by 
binding to the catalytic domains of C lr and/or Cls (Ziccardi, 1986).
C4 Binding protein (C4bp)
C4bp, is a glycoprotein (570kD) that regulates the classical pathway C3 convertase 
as a result of its binding to C4b (Scharfstein et al, 1978). It is composed of seven 
70kD, identical subunits which are linked at the C-terminus by disulphide bridges, 
giving the molecule a "spider"-like structure (Dahlback e la L  1983). Under 
physiological conditions, C4bp can bind 4 C4b molecules (Ziccardi et al, 1984). C4 bp 
regulates the classical pathway C3 convertase by; 1) binding C4b to prevent uptake of 
C2, 2) by acting as a cofactor for I mediated degradation of C4b and 3) by accelerating 
the decay of the pre-existing convertase by dissociating C2a from C4b2a (Fujita et ai,
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1978; Gigli et al, 1979; Nagasawa et al, 1980).
Cl which has escaped the regulatory action of Cl-INH will catalyse the formation 
of C4b2a, which can be regulated by C4bp. It has been noted that certain IC, such as 
some mixed cryoglobulins, are capable of binding and activating C l, but incapable of 
generating the classical C3 convertase (Hayday gi aL 1980). It has been proposed that 
C4 bp and I inactivate C4b and inhibit C3 convertase formation (Brown gt aL 1983).
C3b/C4b Inactivator (I)
Factor I (88kD) is a serine protease composed of two polypeptide chains (38kD and 
50kD) present in plasma in the active form (Fearon, 1977). The smaller chain contains 
the active site of the enzyme. In order to exert its proteolytic activity on C3b, I requires 
H (Whaley and Ruddy, 1976), or CR1 (Medof g ia l, 1982) as cofactors, and for 
inactivation of C4b it requires C4 bp (Fujita et al, 1978; Scharfstein g lal, 1978). I 
produces two cleavage sites on the a-chain of C4b yielding three polypeptides of 47kD, 
25kD, and 17kD. The 47kD peptide (C4d) is released from the N-terminus and 
remains covalently attached to the target surface, while the remaining part of C4b (C4c) 
which consists of the intact p and y  chains and the two a  chain fragments are released 
into the fluid-phase (Fujita and Nussenzweig, 1979).
Membrane-associated regulatory proteins
These including decay accelerating factor (DAF), membrane cofactor protein 
(MCP), complement receptor type 1 (CR1).
DAF: This membrane protein consists of a single polypeptide chain (70kD) which 
is attached to the membrane through a C-terminal phosphotidyl inositol glycolipid 
anchor (Medof glal, 1986). It is widely distributed in tissues, including erythrocytes, 
leucocytes, platelets, epithelial cells and connective tissues (Kinoshita et al, 1985; 
Medof gi aL. 1985). DAF accelerates the decay of the C3 and C5 convertases of the 
classical and the alternative pathways by binding to the C2a and Bb components 
respectively (Fujita gt al, 1987). It has also been suggested that DAF functions by
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competitively inhibiting the uptake of C2 or factor B, and preventing the assembly of 
the C3 convertases (Kinoshita et al, 1986).
M CP: Membrane cofactor protein is a 45-75kD glycoprotein occurring in all 
human leucocytes and platelets, but does not appear to be present on erythrocytes (Cole 
SiaL 1985; Seya gt al, 1986). It binds to C3b and C4b and acts as a cofactor for their 
cleavage by factor I. In this respect it is approximately 50 times more effective than 
CR1 or H (Seya £t al, 1986). Cleavage of C3b by factor I in the presence of MCP only 
progresses to the iC3b stage (see below).
CR1: This component will be discussed later.
1.3.10. Com ponent C3
C3 is the most abundant complement component in serum (serum concentration 
1.3mg/ml) and plays a central role in complement activation, where it is involved in the 
generation of the classical pathway C5 convertase and in the the formation of the 
alternative pathway C3 and C5 convertases. It is synthesised as a single chain 
precursor, pro-C3, which is then cleaved once during secretion to become the 
disulphide-bonded two-chain plasma molecule (Brade et ai, 1977).
C3 is a (3 globulin, which contains 2.7% carbohydrate and has a molecular weight 
of 190kD. The molecule is composed of two polypeptide chains (Fig 1.5), a  (120kD) 
and (3 (70kD) which are held together by disulphide bridges and non-covalent bonds 
(Tack and Prahl, 1976; Law and Levine, 1977). The a  chain of C3 contains an internal 
thiolester bond formed between a y-carbonyl group of a glutamic acid residue and a 
thiol group on an adjacent cysteine residue. This bond is separated from the N- 
terminus by a mass of about 46kD (Pangburn and Miiller-Eberhard, 1980; Sim et aL 
1981; Tack £t ai, 1980). Upon activation, the a-chain of C3 is cleaved by C3 
convertase, with the liberation of a 9kD peptide, C3a from the N-terminus. The 
remaining part of the molecule C3b (181kD) consisting of the cleaved a-chain and the 
intact p-chain (Sim et al, 1981; Tack et al, 1979), simultaneously with the conversion
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of C3 to C3b the internal thiolester undergoes hydrolysis to provide nascent C3b with 
the capacity to covalently bind to the activating surfaces through the transfer of an acyl 
group from the thiol on C3b to a hydroxyl group on the acceptor surface (Law et al, 
1980). This binding capability is metastable and exists for approximately 60 
microseconds (Janatova et ai, 1980, Law et ai, 1980; Kulics et ai, 1983). Nascent C3b 
binding to activating surfaces is mediated through covalent and hydrophobic forces 
(Law and Levine, 1977). Binding of C3b to IgG is probably dependent on the 
distribution of carbohydrate in the antibody molecule (Capel et ai, 1978). It has been 
shown that C3b binds covalently to IgG through certain binding sites on the Fc and Fd 
portion of the gamma chain (Gadd and Reid, 1981; Kulics et ai, 1983). This is 
determined by the distribution of available hydroxyl groups that can react with the labile 
binding site on the thiol group of nascent C3b. C3b molecule provides binding sites for 
C4b, C5, factor B, properdin, factor H and factor I, thus C3b can be described as a 
crowded molecule.
1.3.11. Breakdown fragments of C3
Conversion of C3b into iC3b involves factor I mediated cleavage of the a — 
polypeptide chain of C3b (Fig 1.5), at two closely adjacent sites with the release of a 
3kD fragment, C3f. The resulting molecule, iC3b, remains covalently bound to the 
surface. The iC3b molecule (Fig 1.5) is composed of two a-chain fragments (acdg, 
68kD and ab, 43kD) which remain bound to the intact p-chain by disulfide bridges 
(Harrison and Lachmann, 1980; Sim et al, 1981). Conversion of C3b to iC3b requires 
factor H (Whaley and Ruddy, 1976), CR1 (Fearon, 1979) or MCP (Seya et ai, 1986) 
which act as cofactors for factor I. iC3b does not bind to B, properdin, C5 but does 
bind to CR2 and CR3 (Ross, 1980) and weakly recognizes CR1 (Micklem et al, 1984).
Further degradation of the iC3b a-chain produced two fragments, C3dg (a2D) 
(40kD), which remain covalently attached to the activator surface, as it contains the 
thiolester bonds, and C3c (140kD) which is liberated into the fluid phase. The enzyme 
that is responsible for this cleavage remains unidentified. However, it has been
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Figure 1.5: Diagrammatic representation of C3 molecule and its degradation 
fragments.
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suggested that factor I may be responsible for this cleavage in the presence of CR1 
(Medicus et al, 1983). Cleavage of C3dg by leucocyte tryptic enzymes produces two 
fragments, C3d and C3g (Lachmann £i afr 1982). The cleavage fragments of C3 have 
the ability to bind cell membrane receptors, such as CR1 to C3b, CR2 to C3d and iC3b 
and CR3 to iC3b.
1.4. THE ALTERNATIVE PATHWAY OF COMPLEMENT
In 1925 Whitehead and colleagues described the action of the yeast cell powder 
(zymin) on the third component of complement. Pillemer and associates (1941) 
purified the insoluble polysaccharide fraction of yeast following tryptic digestion, and 
this fraction was called "zymosan" by San Clemente and Ecker in 1943. Pillemer et ai 
(1954) described first the existence of an alternative pathway of complement activation, 
and reported that C3 could be inactivated by a complex that was generated from the 
interaction between serum properdin and zymosan. They called it the C3 shunt, or the 
properdin pathway, and postulated that the sole events in this pathway are dependent on 
a serum protein which they called "properdin" which is derived from the Latin word 
"perdere" which means to eradicate or destroy. Considerable doubt arose regarding 
the concept of the properdin or alternative pathway for complement activation, and it 
was not until the 1960s when further research proved its existence.
Schur and Becker (1963) showed that IC formed with the F(ab')2 fragment of 
antibody were able to deplete the terminal complement components, while sparing the 
classical pathway components. The discovery that endotoxin and zymosan produced 
activation of C3 in guinea pigs with an inherited deficiency of C4 proved conclusively 
the existence of the alternative pathway (Ellman et ai, 1971; Frank et aL 1971; Root et ai, 
1972).
The alternative pathway of complement activation is now known to be composed of 
three proteins C3, B and D which interact to generate the amplification C3 (C3bBb) and 
C5, ((C3b)nBb) convertases. These enzymes are regulated by properdin, H, I,
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complement receptor type 1 (CR1), decay accelerating factor (DAF) and membrane 
cofactor protein (MCP).
1.4.1. Proteins and their activation 
Component C3
C3 (section 1.3.10) is the basic component for the initiation of the alternative 
pathway of complement, where the binding of C3b to B and the cleavage of B by D 
leads to the generation of the alternative C3 convertase, C3bBb, and the binding of one 
or more extra C3b molecules converts the enzyme to a C5 convertase. The extra C3b 
molecule in the C3 convertase binds C5 and renders it susceptible to cleavage by Bb 
(Vogt et si, 1978; Isenman et al, 1980). It has recently been shown that the extra C3b 
molecule binds to the original C3b in the C3 convertase to form the C5 convertase 
(Kinoshita et al, 1987).
Factor D
Factor D is a single chain plasma protein having a molecular weight between 23- 
25kD with a plasma concentration of 2jJ.g/ml (Lesavre and Miiller-Eberhard, 1978). In 
the presence of Ca++ it has y electrophoretic mobility which changes to p in the 
presence of EDTA (Davis ei si, 1979). The complete amino acid sequence of factor D 
revealed that the protein is composed of 222 amino acid residues, and exhibits structural 
homology with plasmin (40%), trypsin (35%) and thrombin (30%) (Niemann et al, 
1984). It is now known that factor D and the adipocyte enzyme adipsin are identical 
(White et si, 1989). Factor D is present in human plasma in the active form only and is 
not inhibited by serum protease inhibitors or by spontaneous decay. It is a substrate 
specific enzyme, cleaving factor B only when it is in the Mg++ dependent C3b bound 
form (Lesavre and Miiller-Eberhard, 1978).
Factor B
This protein was recognized by Pillemer et s i (1953) who described it as a heat 
labile factor that forms a complex with zymosan and has the ability to inactivate the late
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components of complement without consumption of C l, C4 and C2. Factor B was 
reported to bind to cobra venom factor, which is cobra C3, to form a stable enzyme 
which was capable of cleaving C3 (Miiller-Eberhard et al, 1966). Factor B (MW 
93000) is a (3-globulin consisting of a single polypeptide chain and containing 7.3% 
carbohydrate (Curman et al, 1977). Synthesis of factor B is encoded on a single locus, 
Bf, which contains about 10 alleles of which BfS and BfF are the most common (Mauff 
et al, 1978). The structural similarities between factor B gene (Bf) and that of C2 as 
well as their close association, within class III of the MHC, has led to the assumption 
that these two loci have resulted from gene duplication (Perlmutter et al, 1984). 
Complete amino acid sequencing of B revealed that the molecule is composed of 739 
amino acid residues, and cleavage by D produces two fragments, Ba and Bb with 234 
and 505 amino acid residues respectively (Gagnon, 1984).
Cleavage of the C3b-bound Factor B by D at an arginyl-lysine bond near the N- 
terminus, resulted in the liberation of a 33kD peptide, Ba, to the fluid-phase (Lesavre et 
al, 1979). The Bb fragment, 60kD, which contains the enzymatic site, remains attached 
to C3b, probably through its N-terminus (Medicus et al, 1976; Lesavre and Miiller- 
Eberhard, 1978) giving rise to the alternative C3/C5 convertase, C3bBb and (C3b)nBb 
(Medicus et al, 1976; Miiller-Eberhard and Schreiber, 1980).
Properdin
Properdin is composed of identical 53kD glycoprotein subunits (Minta and Lepow, 
1974). Electron-microscopy of purified protein revealed a heterogeneous mixture of 
cyclic dimers, trimers, tetramers and high molecular weight oligomers. Monomers are 
undetectable, and the functional activity of properdin was found to be directly 
proportional with the increase of the oligomer size (Smith e ta l, 1984). During 
activation of the alternative pathway, the central event is the interaction between C3b, B 
and D and the generation of the alternative C3/C5 convertase. The role of properdin is 
to amplify activation by binding to the convertase and to render it more stable by 
slowing the intrinsic decay of Bb from the enzyme (Fearon and Austen, 1975). Studies 
on the interaction of properdin with C3, its split products and factor B, failed to detect
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any interaction with C3 or iC3b, while there was a weak interaction with cell bound 
C3b. This interaction was enhanced in the presence of Bb (Farries et al, 1988a). 
Binding of properdin to C3bBb is mediated through direct interaction between Bb and 
P, which results in increasing the affinity of both of these components to C3b (Farries 
fitaL 1988b).
1.4.2. A ctivation of the alternative pathway of complement and 
activators
Activation of the alternative pathway (Fig 1.6) is comprised of three phases: 1) The 
initiation of the convertase formation, 2) Discrimination between self and non-self and 
3) The phase of the positive feed-back amplification.
Assembly of the initial C3 convertase
The mechanism which results in the generation of the first C3b molecule, which is 
essential for the initiation of the alternative pathway, is still uncertain. However it is 
proposed that a native C3 molecule undergoes a conformational change, which permits 
it to interact with factor B, in the fluid-phase. Cleavage of B by D results in the 
formation of the complex, C3Bb, which possesses a C3 convertase activity (Fearon and 
Austen, 1975; Schreiber e ta !, 1978). Accordingly, this mechanism permits a 
continuous low grade formation of a fluid-phase C3 convertase. It has been suggested 
that the initial conformational change in C3 occurs because the internal thiolester bond 
undergoes hydrolysis at a slow rate giving rise to a functionally active C3 molecule 
C3(H20). This molecule has similar properties to C3b as it is able to bind B to 
generate C3 convertase [C3(H20)Bb] before it becomes susceptible to inactivation by 
H and I (Isenman et al, 1981; Pangbum et al, 1981). This assumption is supported by 
the fact that C3 haemolytic activity decays spontaneously in aqueous solution (Miiller- 
Eberhard and Nilsson, 1960). This unstable,low-efficiency, fluid-phase C3 convertase 
cleaves C3 and a proportion of the resulting C3b molecules binds to cell membranes 
and proteins in the vicinity of the convertase. The deposition of C3b molecules on
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Figure 1.6: Diagrammatic representation of the alternative pathway of complement 
activation.
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surfaces results in the formation of more C3 convertase, C3bBb, and each newly 
formed C3b molecule has the potential to form alternative pathway convertase together 
with B and D with the result of more rapid production of C3b on surface and in solution 
(Fearon and Austen, 1977; Schreiber et al, 1978). The incorporation of additional C3b 
molecules to the C3bBb results in the formation of (C3b)nBb which expresses a C5 
convertase activity. The enzyme, C3bBb, is unstable due to the decay of Bb from the 
complex, and can be reconstituted after the addition of more B in the presence of D 
(Fearon et al, 1973). The half-life of the enzyme is 90 seconds at 37°C (Fearon and 
Austen, 1975) and is shortened by the regulatory protein H which binds to C3b and 
displaces Bb from the complex (Whaley and Ruddy, 1976; Weiler et al, 1976). 
Properdin increases the half-life to 20 minutes at 37° C (Fearon and Austen, 1975; Ross 
and Medof, 1985).
Discrimination between self and non-self
As C3b binds to all surfaces, yet only a few are activators of the alternative 
pathway, it follows that the composition of the surface to which the C3b has bound 
must be able to be recognized as an activator or a non-activator. This ability to 
discriminate between activators and non-activators is the basis for alternative pathway 
activation.
Activators of the alternative pathway include a wide variety of immune and non- 
immune activators. The immune activators include complexed IgA and IgG, including 
its sub-classes which are unable to activate the classical pathway, such as IgG4. The 
essential site on the immunoglobulin molecule for the assembly of the alternative 
pathway C3/C5 convertase was found to be located on the F(ab')2 region of the 
molecule (Reid, 1971; Fujita et al, 1977).
The non-immune activators of the alternative pathway include surfaces of bacteria 
and fungi (Pangbum and Miiller-Eberhard, 1978).
Amplification phase of alternative pathway activation
Once C3b has bound to the surface of an alternative pathway activator, uncontrolled
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assembly of the C3 convertase occurs. As a result of further C3 cleavage more C3b 
binds to the surface to form more C3 convertase. Some of the C3b binds covalently to 
C3b which is already bound, and that then forms the alternative C5 convertase 
(C3b)nBbP (Kinoshita et aL 1987). Thus, on the surface of an alternative pathway 
activator the uncontrolled assembly of C3/C5 convertases prepares microorganisms for 
phagocytosis by coating them with C3b and for lysis by assembly of the membrane 
attack complex (see below).
1.4.3. Regulation of the alternative pathway of complement
On non-activating surfaces factor H controls the expression of C3bBb by binding to 
the C3b subunit and mediating three inhibitory effects; 1) preventing uptake of B by 
C3b, 2) accelerating the decay dissociation of C3bBb by displacing Bb from the 
complex and 3) acting as a cofactor for the inactivation of C3b by I (Whaley and 
Ruddy, 1976; Conrad et al, 1978). Thus, under normal circumstances alternative 
pathway complement activation cannot occur on the surfaces of non-activators. The 
affinity of surface bound C3b to H is inversely related to the activation potency of that 
surface. Activating surface bound C3b and C3/C5 convertase are relatively protected 
from the regulatory effect of H and I (Fearon and Austen, 1977a). It has been 
proposed that the nature of the constituents of the activating surface modulate the 
binding of H to bound C3b. For instance, the absence of sialic acid on certain 
activating surfaces is associated with increased binding of B to C3b and reduced 
binding of H to C3b (Kazatchkine et al, 1979). C3b bound to IgG is also protected 
against inactivation by H and I in comparison with free C3b or C3b bound to other 
serum proteins (Fries et al, 1984).
Regulation of the alternative pathway by CR1, DAF and MOP has been discussed 
elsewhere (sections 1.3.9 and 1.8).
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Table 1.2: Similarities between the classical and alternative pathways.
Classical Pathway
C4b 1. Binds C2 (Mg++-Dependent)
2. Degraded by factor I + C4bp
C2 1. Single polypeptide chain
2. Cleaved by Cls into C2a + C2b
3. Enzymatic site on larger 
fragment (C2a)
4. Decays from C4b2a
5. Structural genes on 
chromosome 6
C ls  Serine protease cleaves C4 
and C2
I Enzymatically inactivates C4b
in the presence of C4bp
C4bp 1. Binds to C4b
2. Cofactor for I in C4b 
cleavage
3.Accelerates decay of C4b2a
Alternative Pathway
C3b 1. Binds C2 (Mg++-Dependent) 
2. Degraded by factor I + H
B 1. Single polypeptide chain
2. Cleaved by D into Ba + Bb
3. Enzymatic site on larger 
fragment (Bb)
4. Decays from C3bBb
5. Structural genes on 
chromosome 6
D Serine protease cleaves B
I Enzymatically inactivates C3b
in the presence of H
H 1. Binds to C3b
2. Cofactor for I in C3b 
cleavage
3. Accelerates decay of C3bBb
(Cited from Whaley, 1987).
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1.5. THE MEMBRANE ATTACK COMPLEX (MAC)
Although Buchner noticed that cell-free human serum was able to lyse bacteria in 
1889, it was not until 1959 that Green el al, reported that complement produces holes in 
cell membranes. The "One-hit" theory which was postulated by Mayer in 1961, 
attributed each single membrane lesion to a single "effective" complement molecule, and 
that a single lesion was sufficient to induce lysis of an erythrocyte. It is known that the 
membrane attack complex consists of five proteins, C5, C6, C7, C8 and C9 (Nelson et 
al, 1966; Lachmann and Thompson, 1970; Gotze and Miiller-Eberhard, 1970). In 
1972 Mayer suggested that the late five complement proteins assemble to form a large 
hydrophobic protein channel within the lipid bilayer of the target cell membrane. It 
was later suggested that polymerized tubular C9 in the C5b-9 complex comprises the 
structural basis for the MAC channel (Podack and Tschopp, 1982a). This hypothesis 
was confirmed by Ramm £t al (1985) using resealed erythrocyte ghosts and finding that 
each complex is comprised of one molecule of C5b, C6, C7, C8 and varying numbers 
of C9 molecules in the polymerised form.
1.5.1. The MAC proteins and their organization 
C5
C5 is a 190kD glycoprotein composed of two chains, a  (115kD) and p (75kD) 
which are linked by disulphide bridges. The general structure of C5 is similar to that of 
C3 and C4, and there is 27% and 25% homology respectively with their amino-acid 
sequence (Wetsel et &1, 1988). C5 lacks a thiolester bond (Law et al, 1980; DiScipio et 
al> 1983) which is present on C3 (Tack et al, 1980) and C4 (Campbell et al, 1981, 
Harrison et al, 1981). This occurs as a result of the replacement of the cysteine and 
glutamine residues which are required for the thiolester formation, with serine and 
alanine respectively (Lundwall et al, 1985).
C5 is synthesized as an intracellular single molecule precursor, pro-C5, in 
hepatocytes (Patel and Minta, 1979) and macrophages (Ooi and Colten, 1979). Pro-C5 
which is synthesized in the (3-a chain orientation (Lundwall et al, 1985), is processed
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and secreted as a two-chain glycoprotein molecule (Tack et al, 1979). The gene 
encoding C5 in humans is located on chromosome 9 (Wetsel et al, 1988).
C6 and C7
These are similar single chain p-glycoproteins with molecular weights of 128 and 
121kD respectively, each having a serum concentration of 50-70|ig/ml (Arroyave and 
Miiller-Eberhard, 1971; Podack et al, 1979). The complete amino acid sequence of C6 
revealed that the molecule is composed of 913 amino acids (DiScipio and Hugli, 1989), 
while that of C7 is 821 amino acid residues with the N-terminal two thirds of the C7 
molecule exhibiting homology with the C8a, C8(3 and C9 (DiScipio et al, 1988). The 
genetically determined polymorphisms of both C6 and C7 are controlled by closely 
linked loci (Hobart et al, 1978) and their structural similarities support the notion that 
both molecules exist as a result of gene duplication.
C8
C8 is a y-glycoprotein (150kD) (Manni and Miiller-Eberhard, 1969) which is 
composed of 3 non-identical polypeptide chains. The a  (64kD) and the y (22kD) are 
linked by disulphide bridges, while the p chain (64kD) is non-covalently bound to the 
a  and y chain complex (Kolb and Miiller-Eberhard, 1975). Synthesis of each of the 
three C8 subunits is controlled by separate genes. The genes encoding the a  and p 
chains in the human are located on chromosome 1, whereas the gene encoding the y 
chain is located on chromosome 6 (Kaufman et al, 1989).
Both a  and p chains of C8 are essential for its functional activity, as a C8 derivative 
composed of only a  and P-chains was found to be as functionally active as the normal 
C8 protein (Brickner and Sodetz, 1984). The P-chain carries the recognition domain 
through which C8 molecule binds the C5b-7 trimolecular complex (Monahan and 
Sodetz, 1981). The a-chain is also responsible for the cytolysis generated by C5b-8, 
through its integration into the target cell membrane (Stackel et al, 1983; Amiguet et al,
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1985). C8a acts as a receptor for C9 and promotes its polymerization. Distinct 
domains on C8a are responsible for each of these effects.
C9
C9 is a single chain a-globulin with a molecular weight of 79kD (Hadding and 
Miiller-Eberhard, 1969), which consists of at least five independently folding domains 
(Stanley and Hertz, 1987). One of these domains probably corresponds to the 
membrane insertion region of C9, as it is resistant to proteolysis after the membrane 
insertion of C9 (Hammer el al, 1977). The complete amino acid sequence of C9 shows 
that the molecule consists of 537 residues, and the C-terminal half is characteristically 
hydrophobic in nature which is important in the insertion of C9 into cell membranes
(DiScipio et al, 1984).
Recently it has been demonstrated that the gene encoding C9 is located on 
chromosome 5 (Abbott etal, 1989).
1.5.2. Activation and assembly of MAC
Assembly of the MAC (Fig 1.7) is initiated after the cleavage of the N-terminus of 
the a  chain of C5 at the peptide bond 74/75 (Fernandez and Hugli, 1978; Tack et al,
1979) by the classical pathway C5 convertase, C4b2a3b (Goldlust et al, 1974), or the 
alternative pathway C3/C5 convertase, (C3b)nBbP (Schreiber et al, 1978) with the 
liberation of a short polypeptide, C5a, (MW 11200) into the fluid-phase. During C5 
cleavage a labile binding site, which is available for about 2-3 minutes at 37°C, is 
generated on C5b and this fragment is capable of forming a stable complex with C6 
(Cooper and Miiller-Eberhard, 1970). The presence of C3b on the target membrane 
potentiates the hydrophobic interaction of C5b with the membrane (Hammer et al,
1976). Electron microscopic examination reveals that the C5b-6 complex (MW 
325000) is an elongated and slightly curved structure (Podack et al, 1980). This 
complex may be released from the target surface and the binding of C7 generates a
C4b2a (C 3b)nBbP
1 /  P ‘
C5 — — ---------- *-------------  ► C5b----------C5b6
S-protein
\
*
Y Z1
C5b678(9)n ■*— ----------C5b678 + -------- ^ -----------C5b67
MAC C9 C8
Figure 1.7: Diagrammatic representation of the assembly of the membrane attack 
complex.
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stable binding site which enables the trimolecular complex (C5b-7) to anchor itself 
firmly on the lipid surface of the target membrane through a hydrophobic interaction. 
Assembly of C5b-7 in the fluid-phase may result in its binding to any membrane lipid 
surface in its immediate vicinity (Lachmann and Thompson, 1970). The C5b-7 
complex inflicts no harm on the membrane until the binding of the C8 and C9. C8 
binds the membrane bound C5b-7 through its (3 chain and this binding results in the 
insertion of C8a into the membrane lipid bilayer (Monahan and Sodetz, 1981). The 
C5b-8 complex has the ability to lyse erythrocytes slowly providing a large number of 
complexes are present (Gee et al, 1980). Morgan el al (1987) demonstrated the lytic 
effect of C5b-8 on nucleated mammalian cells and also showed it to be dependent on the 
presence of a large number of C5b-8 molecules. Assembly of C5b-9 occurs with the 
binding of C9 to the a-chain of C8. C9 undergoes a slow conformational change with 
the exposure of hydrophobic regions which are capable of inserting themselves into the 
target membrane (Whitlow et al, 1985). The next C9 molecule then binds to the already 
inserted C9 molecule and undergoes the same configurational changes and inserts itself 
into the cell membrane. Thus, polymerization and insertion of C9 occurs by the 
sequential binding of individual C9 molecules in the same manner (Podack and 
Tschopp, 1982b). After the activation of the first C9 molecule, which is a C5b-8 
dependent process, the polymerization of C9 becomes independent of C5b-8 
(Silversmith and Nelsestuen, 1986). The completed form of MAC is composed of one 
molecule of each of C5b, C6, C7, C8, and 12-16 molecules of C9 (Tschopp et al, 
1982; Bhakdi and Tranum-Jensen, 1984), with the final number of C9 molecules being 
dependent on the concentration of C9 in the medium (DeLisi et al, 1980). The MAC is 
a hollow structure with a characteristically hydrophobic exterior, which facilitates 
penetration through the membrane lipid bilayer, and a hydrophilic interior, which 
allows the influx of water and ions freely into the cell with the end result of its 
destruction (Mayer, 1972). It has been shown, using phospholipid vesicles containing 
trapped macromolecules of different sizes, that the extent of the release of each type of 
these molecules is proportional to the C9 content of MAC, where smaller molecules can
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be released with lower C9/C5b-8 ratio while higher ratios are required for the release of 
larger molecules (Malinski and Nelsestuen, 1989).
Different cells, like erythrocytes and nucleated cells, exhibit different sensitivity to 
the lytic action of complement. This was demonstrated by the experiments of Mayer 
and colleagues (Koski g£ al, 1983) who showed that unlike erythrocytes which require a 
single hit for their lysis, nucleated mammalian cells require multiple hits for their lysis. 
This behavior of nucleated cells was found to be associated with a shorter life-span of 
C5b-9 on the surface of these cells (1-3 minutes at 37°C) (Morgan et al, 1984; Ramm 
££ al, 1983a) in comparison with erythrocytes where the MAC remains for several days 
(Ramm gt al, 1983b). On nucleated cells the MAC is either internalized and degraded or 
capped and shed into the surrounding medium (Carney el al, 1985).
1.5,3. Regulation of MAC
MAC assembly and insertion are regulated at a number of stages in the generation 
sequence. Apart from C4bp, H and I which regulate C5 convertase expression, two 
plasma proteins, S protein (Podack et al, 1977), and the newly described Sp 40:40 
(Murphy et al, 1988) regulate MAC expression. S protein binds to the hydrophobic 
binding site on C5b67 so that this complex, which is assembled on or is closely 
adjacent to a cell membrane is unable to be inserted (Podack et al, 1977). The 
remaining components (C8 and C9) are still able to be assembled on the complex but 
C9 polymerization is inhibited. The resulting complex is hydrophilic SC5b-9 (MW 
668000), and is composed of one molecule each of C5b, C6, C7, C8 and three 
molecules of C9 and three molecules of S protein can be detected in the fluid-phase 
(Podack g£ al, 1977). The SC5b-9 complex has no haemolytic activity (Kinoshita gt al,
1979). The Sp 40:40 protein appears to act at the C5b67 stage, although its mode of 
action has not yet been clarified. In addition to these plasma proteins, there are at least 
three membrane proteins which protect cells against attack by homologous complement 
and are therefore called homologous restriction factors. DAF which regulates the
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expression of the C3/C5 convertase and exhibits homologous restriction, has been 
discussed above.
Homologous restriction factor (HRF) is a protein of 70 kD which is identical with 
C8 binding protein (C8bp) (Zalman 1986) and probably identical with the 
membrane inhibitory protein (MIP) (Watts £ la l, 1988; Yamamoto £ i£ i, 1990). 
HRF/C8bp/MIP recognizes homologous C8 and prevents its insertion into the cell 
membrane. It also inhibits the binding of C9 to C8 and thus prevents C9 
polymerization.
A third homologous restriction factor has been described recently. It is a 18.5-20 
kD protein which has been called HRF 20 and has been identified as the protein 
recognized by monoclonal antibodies to CD59 (Davies et ai, 1989; Okada e£ al, 1989). 
The mode of action of HRF20/CD59 has not yet been elucidated. The presence of three 
distinct types of homologous restriction factors on cell membranes indicates that strict 
regulation of MAC assembly and insertion is maintained in order to protect cells from 
autologous complement attack. The distribution of these homologous restriction factors 
on different cells and in different tissues has not been ascertained.
1.6 BIOLOGICAL ACTIVITIES OF THE COMPLEMENT SYSTEM
The role of the complement system in maintaining human health can be illustrated 
by the development of diseases particularly immune complex diseases or severe 
recurrent bacterial infections in individuals who are congenitally deficient of an 
individual complement component or a regulatory protein. These disorders include 
SLE, glomerulonephritis, recurrent bacterial infections and angioedema. The biological 
activities of complement can be classified as cytolytic, pro-inflammatory and opsonic, 
although other miscellaneous activities have been identified. The biological activities of 
complement comprise the following:
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1.6.1. Cvtolvtic (Discussed earlier, see section 1.5)
1.6.2. Opsonic
The opsonic effects of complement are mediated by the interaction of complement- 
coated targets with membrane complement receptors. The major ligands are C3b, its 
cleavage products iC3b and C3dg, and C4b, although receptors for other complement 
components such as C lq have been defined. Although stimulation of phagocytosis and 
bacterial killing are the events which come naturally to mind when one considers 
opsonization, the covalent binding of C3b to IC plays a significant role in protection 
against immune complex diseases. The interaction of complement with IC is 
considered in details later (see section 1.9).
After their reaction with specific antibodies and in the presence of serum 
complement, micro-organisms were observed to adhere to human erythrocytes and 
phagocytes (Nelson, 1953). The nature of this behavior was attributed to the 
deposition of C3b molecules (Gigli and Nelson, 1968) and/ or C4b (Cooper, 1969) 
which act as ligands for the C3b/C4b receptor (CR1) which is present on the surfaces 
of different cells, including erythrocytes, polymorphnuclear leucocytes, macrophages 
and monocytes (Fearon, 1980). The adherence between complement coated micro­
organism or immune complexes and human erythrocytes is called immune adherence. 
This process is important for the removal of these opsonized particles from the blood 
(Medofgtal, 1982a).
Macrophages possess receptors for C4b/C3b (CR1) and iC3b (CR3) (Lay and 
Nussenzweig, 1968, Fearon, 1980). The latter receptor is a member of the LFA-1 
family of leucocyte adhesion molecules (Sanchez-Madrid et al, 1983) and is probably 
the most important receptor in the adhesion between C3b/iC3b coated targets and 
macrophages.
On resident macrophages and monocytes, C3b/iC3b will permit binding of the 
target to the phagocytes but will not promote phagocytosis unless IgG antibody is also 
bound (Mantovani, 1975). Although IgG antibody alone will trigger phagocytosis, the
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presence of C3b/iC3b potentiates this effect (Mantovani, 1975). In contrast, on 
activated macrophages C3b/iC3b-coated target will trigger phagocytosis in the absence 
of antibody (Wright and Silverstein, 1983). Resident macrophages and monocytes will 
phagocytose C3b/iC3b coated targets in the absence of IgG antibody only if the target is 
a particulate alternative pathway activator. This occurs because alternative pathway 
activating particles are able to bind to specific receptors on phagocytes (Czop et al, 
1978). This receptor-ligand interaction appears to substitute for the Fey receptor-ligand 
interaction.
Another form of synergism between Fc receptors and CR1 has recently been 
documented, which involves the clearance of IC from the circulation. Simultaneous 
infusion of IC with a murine monoclonal antibody (Fcylll) to FcyRIII resulted in the 
prevention of the liver and spleen macrophages to clear the infused IC which remain 
bound to the monkey erythrocytes through the CR1 (Kimberly et al, 1989).
1.6.3. Pro-inflammatorv
The anaphylatoxins C3a, C4a and C5a have direct effects on the microvasculature 
which is characterized by vasoconstriction, platelet aggregation and increased plasma 
leakage to the extravascular environment. The three anaphylatoxins act on mast cells to 
release histamine which also increase vascular permeability (Johnson et al, 1975). The 
active site of C3a was reported to be the octapeptide C-terminal portion and removal of 
of the C-terminal arginine residue, by carboxypeptidase N, abolished the biological 
activity of C3a. The product of this reaction, C S a ^ ^ g ,  can not bind to C3a receptors 
(Hugli and Erickson, 1977). Removal of C-terminal arginine from C5a and C4a 
likewise removes their anaphylatoxin activity. C5a is the most potent anphylatoxin, 
C3a the next while C4a is the least potent.
C5a and C S a ^ ^ g  are potent chemotactic agents which lead to the accumulation of 
neutrophils, eosinophils and monocytes at the site of inflammation (Damerau et al, 1978; 
Fernandez et al, 1978). C5a and C S a ^ ^ g  also produce neutrophil aggregation and 
activation. Thus, they stimulate release of prostaglandins (Goldstein et al, 1978) which
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produce smooth muscle relaxation and vasodilatation and stimulate release of toxic 
oxygen radicals (Maly et al, 1983) and proteolytic enzymes (Harlan s la l ,  1981; 
McCarthy and Henson, 1979) both of which may produce endothelial damage with 
vascular leakage.
1*6.4 M iscellaneous
Perfusion of isolated rat femora with IC-activated serum caused a massive increase 
in the release of leucocytes from the bone marrow. This is due to the presence of a C3- 
derived leucocyte migration factor (Rother, 1972). The active fragment has been 
identified as an acidic peptide with molecular weight of 10-12kD that arises from 
cleavage of one of the a-chain fragments of the C3c, and has been designated as C3e 
(Ghebrehiwet and Miiller-Eberhard, 1979). The C3e fragment was also found to 
stimulate neutrophils to secrete lysosomal enzymes (Ghebrehiwet, 1984). Another 
fragment (C3d-K) which is produced by the digestion of iC3b with kallikrein was 
found to possess a C3e-like activity (Meuth et al, 1983). Leucocytosis has also been 
produced with a synthetic nonapeptide that corresponds to the N-terminal part of C3d-K 
(Hoeprich et al, 1985). It is probable that C3e and C3d-K are overlapping peptides.
1.6.5. Regulation of immune response
Although C3-deficient individuals appear to be otherwise immunologically normal, 
there is a body of experimental evidence which shows that cleavage products of C3 and 
other complement components may influence immune responses.
In vitro studies have shown that target cell-bound C3b plays an important role in 
potentiating antibody-dependent cell mediated cytotoxicity (Ghebrehiwet £i al, 1979). 
The C3d-K fragment of C3 inhibits proliferation of human T-lymphocytes (Meuth el al, 
1983). Depletion of C3 with cobra venom factor was shown to prevent the 
development of B-cell memory cells in thymectomised mice (Klaus and Humphrey,
1977). The interaction of complement with lymphocyte function may be attributed to
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the presence of receptors for C3 fragments on the surfaces of these cells. It has been 
reported that the cytotoxicity of killer (K) and natural killer (NK) cells was doubled in 
the presence of complement (Yefenof £t al, 1984). This finding of the effect of C3 on 
NK cells is not in agreement with earlier report which stated the inhibitory effect of this 
component on these cells (Charriaut si &1, 1982). Bird and Lachmann (1988) reported 
that an intact classical pathway was necessary for IgG4 synthesis by B-cells. The Bb 
fragment of B has been shown to share antigenic determinants with the B-cell growth 
factor which is secreted by activated T-cells, and has also been shown to act as a 
growth factor for B-Cells (Peters et al, 1988).
1.7. COMPLEMENT AND IMMUNE COMPLEXES
1.7.1. Solubilisation of immune complexes
During the interaction of complement with preformed insoluble IC, it has been 
observed that the covalent binding of C3 to these complexes resulted in the disruption 
of their lattice structure rendering them soluble (Miller and Nussenzweig, 1975). The 
process of solubilisation of IC was shown to be dependent on an intact alternative 
pathway, as sera which had been depleted of the alternative pathway components D, B 
or P failed to solubilise the immune precipitates unless the missing component had been 
replaced (Takahashi et al, 1978). The results of these experiments were supported by 
the observation that solubilisation could be produced by incubating immune precipitates 
with the purified components of the alternative pathway (C3, B, D, properdin, H and I) 
(Fujita et al, 1981). However, although C2 or C4 deficient sera were shown to be able 
to solubilise immune precipitates, the onset was delayed and the final extent of 
solubilisation was reduced in comparison with solubilisation in normal serum. 
Furthermore, complexes formed with F(ab')2 fragments were shown to be solubilised 
more slowly than complexes formed from whole IgG molecules (Miller and 
Nussenzweig, 1975). It has therefore been concluded that although the classical 
pathway is not essential for solubilisation to occur, it is required for maximum speed
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and efficiency (Czop and Nussenzweig, 1976).
Solubilisation of IC proceeds in three phases. The first phase is the deposition of 
C3b on the activating complexes, which occurs rapidly when the classical pathway is 
activated (Takahashi al, 1978). However, when the alternative pathway alone is in 
operation, the deposition of C3b occurs slowly as it takes time for the fluid-phase turn­
over to deposit sufficient C3b on the IC to generate an efficient amplification convertase 
(Czop and Nussenzweig 1976). As a result of the initial deposition of C3b on the IC, 
the second phase of solubilisation occurs, in which bound C3b molecules generate the 
positive feed-back loop through the assembly of the alternative C3 convertase, 
C3bBbP, with the result of more C3b deposition on the IC lattice. The inability of the 
classical pathway alone to induce solubilisation may be due to the lower level of C4 
and C2 compared with C3 and B or to the short half life of the classical pathway C3 
convertase, C4b2a, in comparison with C3bBbP. The other possibility is that C3b 
generated from the alternative C3 convertase tends to propagate in many sites beyond 
the original convertase site due to the generation of more molecules of the alternative 
pathway C3 convertases (Ross and Medof, 1985). Prior to the onset of solubilisation 
large number of C3b molecules are incorporated into the precipitate. This step has been 
investigated by incubating IC with serum for a few minutes, and the presolubilised 
complexes were washed and then incubated with purified C3. This resulted in rapid 
incorporation of C3b into the complexes prior to solubilisation taking place (Takahashi 
al, 1977). The final phase of disruption of the IC lattice probably depends upon the 
intercalation of C3b (Takahashi £t al, 1978). This intercalation possibly reduces the 
antibody affinity for the antigen (Miller, 1977), as IC formed from high affinity 
antibody are solubilised more slowly than complexes made from low affinity antibody 
(Czop and Nussenzweig, 1976; Johnson al, 1987). Alternatively binding of C3b on 
the hinge region of IgG reduces the antibody flexibility and interferes with the cross 
linking of antigen. Deposition of C3b on the Fc portion of IgG may interfere with the 
Fc-Fc interactions which are known to promote lattice growth (Nisonoff and Pressman, 
1958; Moller, 1979; Rodwell et al, 1980). The solubilised IC lose their ability to
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activate the classical or the alternative pathways of complement system and accordingly 
called the "end-stage" IC (Takahashi et al, 1977).
Solubilisation of IC may play an important role in preventing tissue damage by 
already deposited IC. This suggestion has been supported by the finding that there is a 
delay in IC removal from the glomeruli of de-complemented rabbits with experimental 
serum sickness (Bartolotti and Peters, 1978).
1.7.2. Prevention of immune precipitation (PIP)
It has been suggested (Schifferli et al, 1980) that IC are unlikely ever to be formed 
in the absence of complement. Thus, solubilisation may be a laboratory artifact and one 
should study the effects of complement on the solubility of IC as they are formed. 
Indeed, when IC were formed in serum at equivalence or antibody-excess they 
remained soluble, whereas when formed in buffer they precipitated (Schifferli et al,
1980). This complement-mediated process is called prevention of immune precipitation 
(PEP) or inhibition of immune precipitation (IIP).
Sera which had been inactivated by heat (56°C for 30 minutes) or EDTA were 
unable to sustain PEP, while sera which had been depleted of B, D or properdin retained 
PIP activity (Schifferli et al, 1980; Naama et al, 1983). Thus, the alternative pathway 
does not appear to play a significant role in PEP and by implication PIP is dependent 
upon an intact classical pathway. This conclusion was supported by the finding that IC 
formed in sera which were deficient of one of the Cl subcomponents, C4, C2 or C3 
precipitated, whereas they remained soluble in C5-deficient or C7-deficient serum 
(Schifferli et al, 1980, 1982; Naama et al, 1983). Thus, the classical pathway is 
essential for PIP, but the terminal components beyond C3 are not required. This 
conclusion was confirmed by showing that IC remained soluble when formed in the 
presence of purified C l, C4, C2 and C3 and the addition of C5b-C9 or the alternative 
pathway components did not improve the efficiency of the process (Naama el al, 1984, 
1985). The incorporation of C3 into the IC lattice is essential for PIP with molar ratio
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of C3b to IgG being 2:5 (Naama et al, 1985). In the case of solubilisation, the molar 
ratio of C3:IgG is 1:1 (Fujita et al, 1981), which indicates that less C3 is required to 
prevent the precipitation of IC than that required for the solubilisation of IC precipitates.
PIP is probably mediated through the binding of C3b to Fd region of IgG to 
prevents the formation of Fc-Fc interactions which are important for the lattice 
formation (Moller, 1979; Rodwell 1980) but it is also probable that C3b binding 
to the antigen may prevent the formation of some antigen-antibody bonds. The 
properties of antigen and antibody are thought to play an important role in the ability of 
IC to precipitate when formed in serum and their ultimate precipitation in tissues. In 
vitro studies have shown that IC formed from a small antigen, such as bovine serum 
albumin (BSA), can be prevented from precipitation easily whereas IC formed from a 
larger antigen, such as bovine thyroglobulin, are relatively difficult to keep in solution 
(Whaley, 1987). The nature of antibody was also found to affect the IC precipitation, 
where IC formed from IgA monoclonal anti-DNP antibodies precipitate rapidly, 
whereas IgGl and IgM antibodies produced IC which remained soluble (Johnson et al, 
1987).
Since the classical pathway is essential for PIP but not for solubilisation and as 
patients with deficiencies of the classical pathway components are predisposed to 
develop IC diseases, it can be concluded that prevention of immune precipitation is 
more important than solubilisation.
1,8. IN TER A C TIO N  OF C O M PLEM EN T-PRO CESSED  IC W ITH  
HUMAN ERYTHROCYTES (THE ROLE OF COMPLEMENT RECEPTOR 
TYPE 1. CR11
Complement receptor type 1, CR1, is a large single chain membrane glycoprotein. 
It mediates the binding, processing and transport of C3b or C4b bearing IC, or particles 
and plays a role in the regulation of complement activation (Hourcade et al, 1988). 
Four polymorphic variants of human CR1 have been identified, CR1-A (220kD); CR1-
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B (250kD); CR1-C (190kD) and CR1-D (280kD) (Dykman et al, 1985a, b). The cells 
which express CR1 include polymorphnuclear leucocytes, monocytes, macrophages, B 
lymphocytes, some T lymphocytes, dendritic reticular cells in germinal centers and 
glomerular podocytes. The number of CR1 antigenic sites per cell is different among 
blood cell types, with 950, 2100, 4800 and 5700 on erythrocytes, B-lymphocytes, 
monocytes and polymorphonuclear leucocytes respectively (Fearon, 1980). Since 
erythrocytes comprise the vast majority of circulating blood cells (5xl0^A itre) in 
comparison with total leucocytes (5x10^/litre), it has been estimated that 90-95% of 
CR1 in the circulation is present on the surface of erythrocytes. This observation led to 
the suggestion that erythrocytes may play an important role in certain immune reactions 
(Siegel glal, 1981).
CR1 bound C3b can be cleaved by factor I yielding a 140kD fragment, C3c, which 
is composed of intact p chain and the two fragments of a  chain, 40kD and 60kD. This 
fragment is released to the fluid-phase while C3dg, 41kD remains attached to the carrier 
surface (Bokisch et al, 1975; Lachmann et al, 1982). Immune complexes which bear 
C3dg do not bind to CR1, and are therefore released from the receptor (Medof et al, 
1982).
The binding and transport of IC in the circulation is another important function that 
can be fulfilled by CR1. In vivo studies have shown that the binding of opsonized IC 
to erythrocyte CR1 is a very rapid process in which maximum binding is achieved 
within 2-4 minutes, after which dissociation occurs (Medof and Oger, 1982). This 
binding is markedly delayed in the presence of Mg++EGTA, indicating the importance 
of intact classical pathway, which is known to induce rapid generation of C3b (Jepsen 
£1 al, 1986). The dissociated complexes can rebind CR1 through the activation of the 
alternative pathway. Dissociation of IC from CR1 is a consequence of I-mediated 
cleavage of C3b, but there is sufficient C3b on the dissociated IC, that can interact with 
B for the generation of alternative pathway C3 convertase (Medof et_ al, 1982).
Following the injection of large preformed complement-treated IC intravenously 
into primates it was shown that rapid binding to erythrocytes occurred. As the
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erythrocytes pass through the liver, the bound IC were removed and degraded 
(Cornacoff £t &L 1983). The role of Fcylll (Kimberly et al, 1989) has been discussed 
above (section 1.6.2). IC formed by the infusion of BSA into pre-immunised primates 
resulted in the formation of IC that did not bind to erythrocytes (Cornacoff al, 1983). 
In vitro studies have shown that BSA IC formed in serum do not bind to CR1 
(Whaley, 1987; Varga et al, 1988). However, when IC are formed with a large antigen 
such as thyroglobulin, the IC remain relatively insoluble after complement activation 
and CR1 binding will occur (Whaley, 1987). However, even in this situation only a 
small portion of IC bind to erythrocytes. In contrast, solubilised immune precipitates 
bind readily to erythrocytes in vitro (Medof and Oger, 1982). This difference in IC 
behavior probably occurs because solubilised IC have more molecules of bound C3b to 
IgG (1:1, Fujita et al, 1981) than IC which have been kept soluble by PIP (2:5, Naama 
Si al, 1985). As erythrocyte CR1 are clustered, multivalent attachment is important in 
promoting adhesion between the receptors and the C3b-coated particles. It is 
reasonable to conclude that erythrocyte transportation of IC, which have been formed in 
the circulation, only occurs when they remain relatively large and insoluble after 
complement activation. Such transportation prevents the deposition of large insoluble 
IC in the microvasculature. In most instances, it is probable that PIP will render IC 
sufficiently small and soluble to circulate without danger of their deposition in the 
microvasculature.
Recently it has been demonstrated that the addition of packed human erythrocytes to 
human or guinea pig serum, resulted in the inhibition of the capability of serum to 
induce solubilisation of immune complexes. CR1 did not appear to be involved in this 
process, as blockade with anti-CRl mAb or the removal of CR1 by trypsinization of 
erythrocytes did not alter the ability of erythrocytes to inhibit solubilisation of IC 
(Dorval & al, 1989).
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1.9. THE ROLE OF COMPLEMENT IN IMMUNE COMPLEX
DISEASES
1.9.1 Introduction
It is agreed that the deposition or the formation of IC in tissues is associated with 
tissue injury and IC diseases. IC mediated tissue injury was classified into three 
processes, termed types I, II and III (Coombes and Gell, 1968). Type I 
hypersensitivity is an immediate hypersensitivity due to antigen binding with cell-bound 
IgE antibody. Type II hypersensitivity reactions are associated with host tissue-bound 
antigens, whereas type III reactions are produced by the binding of the antibodies with 
free-antigens which could be either exogenous in origin or host-derived. Type III 
reactions were considered to be important in the pathogenesis of immune complex 
diseases. However, it has been pointed out (Henson, 1982) that as the mediator 
systems involved in the production of tissue injury in both types II and III 
hypersensitivity reactions are the same, it serves no useful purpose to distinguish 
between them. This point is further emphasized when one considers that certain forms 
of glomerulonephritis, which were previously thought to be produced by the deposition 
of circulating IC, may well be due to antibody reacting with antigen which is part of the 
normal renal glomerular epithelial cell (eg Heymann's nephritis) or non-renal antigens 
which have become bound to normal glomerular structures (eg DNA binding to 
basement membrane collagen). In these situations, examination of the tissues by 
immunofluorescence microscopy would reveal appearances which were 
indistinguishable from those produced by the deposition of circulating IC.
The binding of antibody with exogenous antigens protects the individual because 
the active site of an enzyme or the binding site of a virus particle or bacterial exotoxin 
may be blocked. Possible mechanisms for this include: (1) the active site being the 
epitope recognised by the antibody, (2) steric blockade by antibody binding to an 
epitope adjacent to the active site, (3) a conformational change induced by antigen- 
antibody union may render the active site inaccessible, or (4) aggregation of the antigen
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by antibody may also restrict the expression of the biological activity of the antigen. 
Although the consequence of antibody binding to antigen is for example the 
neutralization of viruses or exotoxins, as most naturally-occurring antigens are 
multivalent, and as antibody molecules possess at least two antigen-binding sites, 
extensive cross-linking may occur leading to the formation of large aggregates of 
reduced solubility. Such aggregates if formed in the tissues would be difficult to 
remove, and if formed in the circulation would tend to precipitate within the blood 
vessels. However, it is not certain whether IC on their own induce tissue injury 
without the participation of Fc-dependent mediator systems (complement activation, Fc 
receptors on platelets, neutrophils, macrophages etc.). Indeed most experimental data 
show that the acute inflammation, which occurs as a consequence of IC deposition or 
formation within tissues, was ameliorated by prior depletion of mediators such as 
complement or neutrophils (Henson and Cochrane, 1974). However, these 
experiments were all short term because of the difficulty in depleting complement and 
neutrophils over prolonged periods of time. Thus, the long term direct effects of the 
presence of insoluble IC in the tissues are unknown.
1.9.2. Experimental models of immune complex tissue injury
Arthus reaction: In 1903 Maurice Arthus showed that daily intracutaneous 
injections of horse serum into rabbits eventually began to produce inflammation at the 
injection site. On the fifth day he noted the transient occurrence of oedema, but as the 
injection continued the inflammatory response became more marked with the 
appearance of erythema, haemorrhage and occasionally necrosis (Arthus, 1903). The 
Arthus reaction has now been investigated in great detail (Cochrane and Janoff, 1973). 
The reaction is a local vasculitis which develops in and around the small blood vessels 
of the skin. When antigen is injected into the skin of actively immunised animals it 
diffuses towards antibody which is present within the vessel wall. The vasculitis is due 
to the formation of IC in the region of the vessel wall with the subsequent activation of
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a number of mediator systems which are responsible for the inflammatory response 
(Cochrane and Janoff, 1973).
The time taken for the Arthus reaction to reach its peak intensity is between 4 and 
10 hours, after which it wanes and has usually disappeared between 24 and 48 hours. 
However if sufficient antigen and antibody are available, haemorrhage and necrosis 
may occur, and the lesions are obvious for longer periods. Sequential 
immunofluorescence and histological studies have shown that following the deposition 
of IC and complement components in the vessel wall, neutrophils accumulate in the 
vessel wall and the perivascular tissues. Intravascular clumping of platelets results, and 
if severe, vascular occlusion and necrosis occurs. Neutrophils predominate in the early 
cellular infiltrate, but by 8 hours mononuclear cells appear, and by 24-48 hours they are 
predominant cell type.
Precipitating antibody is far more effective than non-precipitating antibody in the 
production of Arthus reaction (Cochrane and Weigle, 1958). Early studies showed that 
the Arthus reaction did not occur in animals which had been depleted of complement by 
cobra venom factor (Henson and Cochrane, 1974). Although complement is required, 
the observation that the reaction occurs in C4-deficient guinea pigs (Frank et al, 1973) 
suggests that, in this species at least, the classical pathway is not essential. These 
observations indicate (1) that insoluble complexes are of central importance in the 
production of immune complex-mediated tissue injury, and (2) the complement system 
plays an important role in the pathogenesis of the inflammatory response induced by 
insoluble complexes.
Human diseases which are thought to be examples of Arthus reactions, include:
1) Extrinsic allergic alveolitis, eg farmer's lung and pigeon fancier's lung where 
the antigen is inhaled. 2) Filariasis, where the antigen is present on, and may be 
released from parasites, which are found in the lymphatic vessels. 3) Erythema 
nodosum leprosum, and the Jarisch-Herxheimer reaction occurring in patients with 
leprosy and syphilis, respectively. Where patients who have high titres of antibody 
against the causative micro-organisms are treated with chemotherapy, antigen release
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results in IC formation. 4) Rheumatoid arthritis is thought to be a variant of the Arthus 
reaction. The formation of IC within synovial joints produces an inflammatory 
response. 5) Certain types of glomerulonephritis might be due to the entrapment of 
circulating antigen within the glomerulus. ICs are also formed when antibody binds to 
the tissue-fixed antigen. Although this mechanism operates in an experimental murine 
system, at present there are no known naturally occurring counterparts.
Apart from their formation in situ, IC may be deposited within the tissues from the 
circulation.
Serum sickness: Acute serum sickness is the prototype of the circulating IC disease, 
and this can be produced experimentally by injecting a large dose of a soluble protein 
antigen, such as BS A, intravenously into rabbits. After a period of a few days (usually 
7-8) in which the concentration of BSA in the blood gradually diminish (non-immune 
elimination) the rate of decline accelerates, corresponding to the production of antibody 
(immune elimination). Antigen-antibody complexes are formed in moderate antigen- 
excess, and are deposited in glomeruli, arteries and joints. Systemic 
hypocomplementaemia occurs and immunofluorescence studies reveal deposits of C3 as 
well as immunoglobulin and antigen in the tissue lesions (Germuth, 1953; Dixon et ai, 
1958). Depletion of complement does not influence the renal lesions, but the 
development of arteritic lesions are prevented by prior decomplementation or neutrophil 
depletion (Henson and Cochrane, 1971). Large IC (>19S) are detected in the 
circulation of these rabbits during the period of serum sickness (Cochrane and 
Hawkins, 1968). Pharmacological or haemodynamic manipulations, which promote or 
prevent the entry of circulating complexes to the microcirculation and the tissues, 
amplify or reduce tissue injury (Cochrane, 1971). Thus, in the acute serum sickness 
model, the evidence supports the view that circulating IC formed in antigen-excess 
produce glomerulonephritis. The histological appearances of this nephritis are similar 
to those present in human acute post-infectious glomerulonephritis (Germuth, 1953;
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Dixon ai, 1958).
Chronic renal injury can be produced in rabbits by repeated immunisation with a 
foreign protein antigen (Dixon et &L 1961; Germuth s laL  1967), with a variety of 
different glomerular, histological and immunohistochemichal lesions induced in the 
same strain of rabbits. Electron microscopic studies showed the presence of mesangial, 
subendothelial and subepithelial electron dense deposits. Although these variations 
were dependent upon the antigen dosage schedule and the antibody response of the 
rabbits, they could be produced with many different antigens. Mesangial injury was 
usually associated with the presence of IC which were greater than 500 000 daltons, 
whereas capillary wall deposition was associated with smaller circulating IC (Germuth 
1972). It was suggested that these were models of chronic soluble IC diseases 
and that pathogenic complexes were only formed in antigen-excess. Variations in 
histopathology were explained by differences in the size of the complexes and the 
avidity of the antibody (Germuth e£ M, 1977; Scherzer and Ward, 1978). The results of 
these experiments showed that chronic glomerulonephritis could occur as the result of 
the deposition in the tissues of soluble circulating IC, containing antigens which had no 
affinity to the kidney. It is worth noting that rabbits which developed IC 
glomerulonephritis made precipitating antibodies, and that renal disease occurred only 
in those rabbits in which complexes were formed at equivalence (23 of 28) or in 
antibody-excess (22 of 95) (Dixon et al, 1961), whereas the rabbits permanently in 
antigen-excess did not develop renal disease. As large complexes are formed at 
equivalence, and as these are removed rapidly from the circulation by the liver 
following their injection intravenously (Haakenstad et a[, 1975), it is rational to conclude 
that such complexes can only produce tissue damage in vivo, when their removal by 
the reticuloendothelial system is impaired. It has been proposed that large insoluble 
complexes could be formed within the microcirculation and deposited locally, and thus 
would not be detected systemically. When rabbits or pigs were pre-immunised with 
protein antigens, and small quantities of antigen, insufficient to saturate available
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antibody, were injected directly into the renal artery, acute glomerulonephritis 
developed (Gabbiani g ta l, 1975; Shigemetsu e ta l, 1979; Clark e ta l, 1980) and 
repeated antigen injection gave rise to mesangiocapillary glomerulonephritis (Clark et al,
1980). In contrast, in a carefully performed study, rabbits maintained in permanent 
antigen-excess over prolonged periods never developed glomerulonephritis (Boyns £t 
al, 1968). Thus, circulating large IC formed with precipitating antibodies formed at or 
around equivalence appear to be incriminated in the pathogenesis of some forms of 
experimental glomerulonephritis and vasculitis. There are also experiments which 
show that interstitial lung disease may be produced in rabbits by similar procedures 
(Brentjens et al, 1974). The role of circulating IC in the pathogenesis of membranous 
glomerulonephritis is controversial. In experimental immune complex nephritis, 
subepithelial electron-dense deposits are distinctly unusual. A popular alternative 
hypothesis which has experimental backing, is that antigen gets trapped in the 
glomerulus and the IC are formed in situ (Couser and Salant, 1980). However, there is 
as yet no evidence that this occur in vivo. Although it has been shown that small IC 
formed with low affinity antibody and antigen with low epitope density can localize in 
the sub-epithelial space following intravenous injection (Law et al, 1984), it is not 
known whether the antigen and antibody dissociate in the circulation and re-complex 
within the glomerulus.
Once IC have been deposited or formed within the kidney, they must undergo a 
process of aggregation (termed condensation) to give rise to the electron dense deposits 
which are the hallmark of IC diseases. Following the intravenous injection of 
complexes these electron dense deposits will only occur with precipitating antigen- 
antibody systems (Agodoa £t ai, 1983).
The role of complement in protecting the individual against immune complex 
disease, is related to its ability to render complexes small and soluble (see prevention of 
immune precipitation and solubilisation of IC, section 1.7). Thus, on the one hand 
complement is a mediator of immune complex mediated tissue injury, and on the other it 
protects against immune complex disease.
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1.10. MEASUREMENT OF COMPLEMENT AND COMPLEMENT 
ACTIVATION
The extent of complement activation, in vivo or in vitro may be readily assessed 
by measuring functional activity of individual components in serum. Normal values of 
total complement or of a single component may result from compensatory synthesis or 
hypersynthesis which do occur in certain chronic inflammatory diseases. Also 
decreased complement activity does not distinguish between deficiency or consumption. 
Accordingly, from a clinical point of view, the use of a precise assay for the 
measurement of complement activation is very important for the diagnosis and 
management of patients with different immunopathological diseases which are 
associated with complement activation or deficiency for example, systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), hereditary angioedema and so forth.
Many methods have been developed for the measurement of complement activation 
through the direct determination of the levels of complement activation split products or 
complexes in tissues or biological fluids. These cleavage products include the 
anaphylatoxins (C4a, C3a and C5a), the cleavage products of C4, C3 and B which 
include C4d, a2D (C3dg), Ba and Bb respectively. Also it includes the multimolecular 
complexes Clr:Cls:Cl-INH C3bBbP and C5b-9.
Measurement of C4 activation cleavage products, C4d, has been performed by an 
electroimmunoassay (rocket immunoelectrophoresis) using polyclonal antibodies 
(Folkersen et al, 1985; Petersen et al, 1988). A mouse monoclonal antibody which 
recognizes neoantigenic determinant of C4d has been produced and used for the 
trapping of C4d fragment in an ELISA system where the bound C4 fragment was 
detected with polyclonal anti-C4d (Kolb et al, 1988).
C3 degradation fragments (C3dg and C3c) are the naturally occurring cleavage 
products of iC3b produced by the action of factor I and its cofactor CR1 (Medof £l al, 
1982). Since C3, C3b and iC3b are recognised by C3dg antibodies, they must be 
separated from C3dg prior to assay. Polyethyleneglycol (PEG; ll%w/v) can be used
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to precipitate C3, C3b and iC3b (Perrin et al, 1975). The drawback of this method is 
that incomplete precipitation of and sometimes excessive precipitation of C3dg may 
occur. The non-precipitable C3dg which is soluble in 11% PEG, can be measured by 
radial immunodiffusion (Perrin e ta l , 1975; El-Ghobary and Whaley, 1980), 
electroimmunoassay (Pepys, 1985) or laser nephelometry (Senaldi et al, 1988) using 
antisera to C3dg. A double decker-electroimmunoassay has been suggested in order to 
avoid the problem of PEG precipitation, and included the electrophoresis of EDTA- 
plasma (test samples) through a gel containing anti-C3c, which removes C3, C3b, iC3b 
and C3c, and then into a second gel containing anti-C3d (C3dg). The height of the 
rocket is proportional to the concentration of C3dg (Brandslund et al, 1981). ELISA's 
have also been introduced for the measurement of C3dg, using monoclonal antibodies 
(mAb) that recognize neoantigenic determinants on the molecule. A monoclonal 
antibody that recognizes the C3d determinants (Nielsen et al, 1986) or C3g determinant 
(Mollnes and Lachmann, 1987) and another mAb (bH6) that recognizes the neoantigen 
on the C3b, iC3b and C3c fragments, have also been developed (Garred et al, 1988).
The measurement of factor B cleavage products has been introduced as a means of 
measuring alternative pathway activation. Quantitation of the Ba fragment by radial 
immunodiffusion (Gotze and Miiller-Eberhard, 1976) or laser nephelometry (Senaldi et 
al, 1988) can be performed following PEG precipitation of B and Bb. The problems of 
PEG precipitation have been discussed above. A double-decker electroimmunoassay 
has been suggested, where the first gel contains antiserum recognizing B and Bb, 
whilst the second gel contains antibody recognizing Bb fragment. The size of the 
rocket is proportional to the concentration of Ba (Teissner and Rasmussen, 1988).
Measurement of anaphylatoxins, C3a, C4a and C5a is performed using fluid-phase 
radioimmunoassays after the precipitation of native C3, C4 and C5 with PEG or 
saturated ammonium sulphate (Gorski, 1981; Chenoweth e ta l ,  1981). The 
measurement of anaphylatoxins in clinical specimens (plasma) does not always reflect 
the ongoing complement activation; for instance, plasma levels of C 5a are extremely
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low during complement activation due to the binding of C5a and C5a ^  Arg to their 
receptor on leucocytes (Chenoweth and Hugli, 1978; Van Epps and Chenoweth, 1984), 
while this anaphylatoxin is readily detectable during in vitro activation of serum. 
Recently, a monoclonal antibody to a synthetic octapeptide C3a (69-76) has been 
produced. Since this mAb recognizes a neoantigenic determinant on C3a which is not 
expressed on native C3, it can be used for the measurement of C3a(jesArgin clinical 
samples without the need for precipitating C3 (Burger et aL 1988). Anaphylatoxin 
assay kits are available commercially but are extremely expensive.
The multimolecular complexes include; (C l-IN H ^C lrrC ls complex (Sim et al, 
1979; Ziccardi and Cooper, 1979), C3bBbP complex (Fearon and Austen, 1975) and 
the SC5b-9 complex (Podack et al, 1977). Clr:Cls:Cl-INH complex can be measured 
by electroimmunoassay (Laurell et al, 1979), solid phase radioimmunoassay, where the 
C ls moiety of the complex is trapped on the solid-phase using anti-Cls and the Cl- 
INH is probed with radiolabled anti-Cl-INH (Hack et al, 1981). ELISA procedures 
have been widely used for the detection of C ls:Clr:Cl-IN H  complex applying the 
same principle of the radioimmunoassay already described, where instead of using 
radiolabelled of anti-Cl-INH, the antibody is linked into an enzyme such as alkaline 
phosphatase (Inman and Harpel, 1983; Lockshin et al, 1986) or peroxidase (Nilsson 
and Back, 1985). The C3bBbP complex can also be measured by ELISA by trapping 
the properdin moiety of the complex with anti-properdin and probing with anti-C3 
conjugated with alkaline phosphatase (Mayes et al, 1984) or peroxidase (Asghar gt ai, 
1987). The SC5b-9 complex may be quantified with the use of antibodies that 
recognize the neoantigenic determinants that are generated on the complex. This can be 
performed using a radioimmunoassay (Bhakdi and Muhly, 1983), although several 
ELISA procedures have been introduced for SC5b-9 measurement in biological fluids. 
Gawryl g£&I (1986) has described an ELISA where the C9 moiety of the complex is 
trapped with anti-C9 and the C5 is detected using rabbit anti-human C5 followed by 
peroxidase conjugated goat anti-rabbit IgG.
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The use of ELISA procedures to measure the levels of these multimolecular 
complement activation complexes should circumvent many of the problems encountered 
with the other methods described above. Antisera can be purchased from commercial 
sources, the IgG fraction purified and easily labeled with biotin. Thus, any 
immunology laboratory could introduce these tests.
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1.11. PROPOSED STUDY
As complement activation plays a significant role in the immune complex diseases, 
it is not unreasonable to assume that the level of complement activation should parallel 
the degree of tissue injury. Thus, measurement of one or more activation products in 
plasma could be used to monitor the extent of tissue injury. The purpose of this study 
included:
1) To measure complement activation products in patients with IC diseases after the 
development of avidin-biotin ELISA procedures for Cls:Clr:Cl-inhibitor (Cls:C l- 
INH), C3bBbP (C3:P) and SC5b-9 (C5b-9) complexes.
2) To use these assays to investigate the effect of variations in IC concentration, 
antigen:antibody ratio and the role of complexed antigen on IC-mediated complement 
activation.
3) To investigate the effect of erythrocytes on IC mediated complement activation. 
This study was undertaken as complement activation within the blood occurs in the 
presence of 50%(v/v) erythrocytes, expressing membrane proteins which regulate 
complement activation (eg. CR1 and DAF).
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2.1 B U F F E R S
Phosphate buffered saline (PBS 20x) 
NaCl 320gm
48.4gm
13.6gm
K2HP04
KH2PO4
Dissolved in deionised water to a final volume of 2 litres.
PBS Tween:
20xPBS 50ml
Deionised water 950ml
Tween 20 (Sigma) 500ul
Isotonic veronal-buffered saline (5x VBS1
Solution A: Sodium chloride (85gm) and sodium barbitone, Na5,5-diethylbarbital, 
N.F. N aC g H ji^ O g  (3.75gm) were dissolved in 1 litre of deionised water.
Solution B: Barbitone, Na5,5-diethylebarbituric acid, N.F. C g H ^ ^ C ^
(5.75gm) was dissolved in 600ml deionised water by heating and vigorous stirring.
Solution A was added to solution B and the final volume was adjusted to 2 litres 
with deionised water. The pH was between 7.4-7.6.
Isotonic EDTA (0.086M.L-1 pH 7.4)
Solution A: Disodium ethylenediaminetetracetic acid (EDTA, 0.12M.L'!) Was made 
by dissolving 89.338gm EDTA (BDH) in 1500ml deionised water and the volume was 
adjusted to 2 litres with deionised water. The pH of this solution is 4.5.
Solution B: Sodium hydroxide (300mM.L_1) was made by dissolving 24gm 
NaOH pellets in 1500ml deionised water and the final volume was adjusted to 2 litres 
with deionised water.
Solution B was added to solution A, while stirring, until a pH of 7.4 was achieved. 
The molarity of EDTA in the buffer was calculated according the following formula:
Final molarity of EDTA= Starting volu.me.of EDTA -x0.12
Starting volume EDTA + volume of NaOH used
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The concentration is usually 0.086M.L'1.
EOT A
Solution A: Ethyleneglycol-bis-(B-amino-ethyl-ether) N,N'-tetracetic acid
(9.5 lgm) was added to 125ml deionised water while stirring.
Solution B: Sodium hydroxide (10M.L"*) was made by dissolving 80gm NaOH in 
200ml deionised water.
Solution B was added to solution A, while stirring, until EGTA dissolves. The pH 
was adjusted to 7.4 and the final volume was adjusted to 250ml by addition of 
deionised water.
VBS-F.DTA (0.01 M l.
5xVBS 100ml
Isotonic EDTA (0.086M.L'1) 58ml
The volume was adjusted to 1 litre with deionised water.
Gelatin (10%)
Ten grams gelatin (BDH) were dissolved in 80ml hot water and the final volume 
was adjusted to 100ml by the addition of deionised water. The solution was divided to 
10 ml aliquots and kept at 4°C until use. Each aliquot was melted by placing it in a 
boiling water bath.
CaClo (AOmM.L-h
Calcium chloride (3.286gm) was dissolved in deionised water so that the final 
volume of the solution was 500ml. Calcium ions are required to keep Cl 
macromolecule intact.
MgCh nn0mM.l.-U
Magnesium chloride (MgCl2.6H20, 10.165gm) was dissolved in deionised water 
so that the final volume of the solution was 500ml. Magnesium ions are required for 
the formation of the classical and alternative C3 and C5 convertases (C4b2a, C4b2a3b, 
C3bBbP, (C3b)nBb).
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Isotonic veronal-buffered saline containing gelatin and cations (GVB++1 
5xVBS 200ml
MgCl2 (lOOmM.L'1) 10ml
CaCl2 (30mM.L_1) 5ml
Gelatin (10%) 10ml
Molten gelatin was added to 100ml deionised water before the addition of the other 
reagents. The volume was then adjusted to 1 litre by the addition of deionised water. 
The buffer was stored at 4°C and used within 1 week.
Isotonic veronal-buffered saline containing gelatin without cations (GVB=1 
5xVBS 200ml
Gelatin (10%) 10ml
Molten gelatin was added to 100ml deionised water before the addition of 5xVBS. 
The volume was then adjusted to 1 litre by the addition of deionised water. The buffer 
was stored at 4°C and used within 1 week.
GVB=.EDTA (lOmM.L-1)
EDTA (O.O86111M.L-1) 58ml
GVB= 442ml
Prepared weekly and stored at 4° C.
Phosphate Buffer (D.5M.L~1)
Stock solutions:
A) NaH2P04 (0.5 M L '1)
NaH2P04 60gm
Dissolved in deionised water to a final volume of 1 litre.
B) Na2HP04 (0.5M.L"1)
Na2HP04 71gm
Dissolved in deionised water to a final volume of 1 litre.
Stock solution of 0.5 M.L"1 phosphate buffer was made by the addition of solution 
A to solution B until the required pH was achieved. To make 0.01 M.L‘1 phosphate
79.
buffer, the stock buffer was diluted 1:50 with deionised water.
Phosphate buffer (U5M.L~lpH 8 containing cvsteine O.OIM.L"* and EDTA 0.002M.L~1) 
Cysteine 1.21gm
EDTA 0.672gm
Dissolved in phosphate buffer (0.5M.L-1 pH 8) to a final volume of 1 litre.
Acetate buffer 10.1M.L~1 pH 4.51
Sodium acetate 8.2gm
Sodium acetate was dissolved in 750ml deionised water, and the pH was adjusted 
to 4.5 by the drop-wise addition of glacial acetic acid. The final volume was adjusted to 
1 litre by the addition of deionised water.
Olvcine-HCl ffl.1 M .Ir1 pH 2.8^
Glycine 7.05gm
Deionised water up to 1 litre.
The pH was corrected to 2.8 with concentrated HC1 prior to adjusting the volume to 
1 litre.
2.2. MEASUREMENT OF nH
The pH of solutions was measured using a Pye Unicam pH meter (model 292). 
The pH meter was adjusted, before the pH of any solution was measured, using an 
appropriate reference pH standard. For each measurement the temperature of the 
solution was determined and the pH meter calibrated at that temperature.
2.3. MEASUREMENT OF CONDUCTIVITY
Conductivity was measured at 0°C, using a Radiometer Copenhagen conductivity 
meter (model CD M3).
2.4. MEASUREMENT OF OPTICAL DENSITY
The optical density, at different wave length*, was measured by Schimadzu 
spectrophotometer, model No. UY 120-02.
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2.5. PREPARATION OF DIALYSIS TUBING
Dialysis tubing was prepared by boiling 3 times in EDTA (lmM.L"l) and then 
stored at 4°C in the same solution.
2.6. PREPARATION OF NORMAL HUMAN SERIJM
Venous blood was drawn from normal volunteers, and allowed to clot at room 
temperature, for 1 hour before being transferred to ice for 1 hour. The serum was 
separated by centrifugation at 2000g, for 15 minutes, at 4°C. The recovered serum 
was divided into aliquots and stored at -70° C.
2.7. CONCENTRATION OF PROTEIN SOLUTIONS
2.7.1 Vacuum dialysis
The fluid to be concentrated was placed in dialysis tube which was then suspended 
in a vacuum flask. The vacuum was generated by using an electric vacuum pump. 
Protein concentration was checked spectrophotometrically at OD280> until the required 
concentration was achieved.
2.7.2 Lyophilization (Freeze-drying)
The material to be lyophilized was placed in a suitably sized lyophilization flask, 
and frozen with liquid nitrogen or a mixture of ethanol and dry ice. The frozen material 
was connected to the freeze-dryer until all the moisture had been removed.
2.8. TECHNIQUES USING AGAROSE
2.8.1 Double diffusion (Ouchterlony technique)
Materials and Buffers:
Agarose (BDH)
VBS.EDTA (0.01M.L-1) (section 2.1)
Method
The agarose gel was prepared by melting agarose (lgm) in 100ml isotonic 
VBS.EDTA. The resulting molten agarose was placed in sterile universal containers 
and stored at 4°C until required. Agarose gel was melted in a boiling water bath, and
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9.6ml was poured onto 10x10cm glass plate which had previously been washed, 
swabbed with 70% alcohol, dried and placed on a level surface. After the agarose had 
set the gel was then cut using a template and gel punch.
These plates were used for measuring the titres of rabbit antisera (anti-BSA and 
anti-thyroglobulin). The antisera were titrated using serial doubling dilutions and each 
peripheral well was loaded with a single dilution. The antigen (1 mg/ml) was loaded in 
the central well. The plate was then incubated at room temperature, overnight, in a 
humid chamber.
2.8.2 Immunoelectrophoresis 
Materials and Buffers
Agarose (BDH)
Barbitone buffer (pH8.6):
Barbitone 4.605gm
Sodium barbitone 25.77gm
Sodium azide 2.5gm
Deionised water up to 2.5 litres 
Method
One gram agarose was added to 100ml of hot barbitone buffer, and when dissolved 
3gm of polyethyleneglycol 6000 was added. The resulting solution was divided into 
aliquots, each aliquot being stored in a sterile universal container and stored at 4°C. A 
glass plate (10x10cm) was washed, swabbed with 70% alcohol, dried and placed on a 
horizontal surface. Molten agarose (9.6ml) was poured on the plate and allowed to set, 
after which the sample wells and troughs were cut using a template. The samples were 
loaded and bromophenol blue was placed in one of the wells as indicator. 
Immunoelectrophoresis was performed for two hours (10 Volts/cm) in a standard 
immunoelectrophoresis tank (Shandon). After the bromophenol blue had migrated to 
the anodal end of the troughs, the current was switched off and the antisera were placed
82.
in the appropriate troughs. The plate was then placed in a humified chamber, at room 
temperature overnight, to allow diffusion of the antigen and antibody to occur. The 
plates were then placed in a plastic box and covered with half-strength physiological 
saline (0.075M). The saline was changed three times over a 24 hour period, and then 
washed with deionised water for a further three hours. The gels were stained by 
covering them with the staining solution (section 2.9) for 15 minutes at room 
temperature. Destaining was performed by washing with destain solution (section 2.9) 
for 10 minutes. The plate was then allowed to air-dry at room temperature for one day.
2.9. SODTIJM DODECYL SULPHATE PO L Y A C R Y L A M ID E  G EL 
ELECTROPHORESIS (SDS-PACE1 (Laemmli, 1970)
R eagents
All reagents were of the 'electrophoresis' grade and were obtained from the 
following sources:
N,N,N',N'-Tetramethylethylendiamine (TEMED) (Sigma)
2-Mercaptoethanol (Sigma)
Coomassie brilliant blue (Sigma)
Bromophenol blue (Sigma)
Aciylamide (BDH) 
bis-Acrylamide (BDH)
Sodium dodecyl sulphate (BDH)
Buffers and solutions:
Acrvlamide 30% (w/v)
Acrylamide 30gm
bis-Acrylamide 0.8gm
Deionised water 100ml
Kept at 4°C and was used within 1 month.
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SDS 10% fw/v)
SDS lOgm
Deionised water 100ml
Tris (0.75M.L.-1)
Tris base 90.8gm
Deionised water up to 1 litre.
Tris-HCI fO.75MI.-l r>H6.8l
Tris base 90.8gm
Deionised water up to 1 litre
The pH was corrected to 6.8 with concentrated HC1 prior to adjusting the final 
volume to 1 litre.
Tris-HCI fO.75MI.~l pH8.81
Tris base 90.8gm
Deionised water up to 1 litre
The pH was corrected to 8.8 with concentrated HC1 prior to adjusting the final 
volume to 1 litre.
Glvcine (0.86M.L"1)
Glycine 64.4gm
Deionised water up to 1 litre
Separation gel
Acrylamide 30% (w/v) 10ml
Deionised water 4.8ml
Tris HC1 (0.75M.L'1 pH8.8) 15ml
Ammonium persulphate
TEMED (added just before pouring the gel)
30mg
15pl
Stacking gel
Acrylamide 30% 1.8ml
SDS 10% 0.1ml
Tris HC1 (0.75M.L-1 pH6.8) 3ml
Ammonium persulphate 18mg
Deionised water 13ml
TEMED (added just before pouring the gel) 9p,l
Running buffer
SDS 10% (w/v) 20ml
Tris (0.75M.L-1) 66ml
Glycine (0.86M .I/1) 440ml
Deionised water up to 2 litres.
Sample buffer
SDS 10% (w/v) 30ml
Tris HC1 (0.75M.L"1 pH6.8) 8.5ml
Glycerol 10ml
Deionised water 46.4ml
Mercaptoethanol 5|il
Staining solution
Methanol 5 parts
Acetic acid 1 part
Deionised water 4 parts
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Coomassie brilliant blue 0.1% (w/v final concentration)
Destaining solution
Methanol 1 part 
1 part 
8 parts
Acetic acid
Deionised water
Methods
Two glass plates 20cmx20cm were washed thoroughly, swabbed with 70% alcohol 
and dried. The plates were then separated by 1mm spacers clamped and held vertically. 
The two sides and the bottom of the chamber were sealed by adding 15|il TEMED to 
1.5 ml of running gel and allowing the mixture to run down the edges of the gel cavity. 
The separation gel was then poured in the sealed chamber and a layer of isopropyl 
alcohol was added, in order to ensure that the surface of the gel was perfectly level. 
After polymerization (1 hour at room temperature) the alcohol layer was removed and 
the surface of the gel was washed. The stacking gel was poured over the surface of the 
running gel to fill the surface of the cavity. A comb was placed in the gel to form the 
lanes in which the samples would be loaded. The gel was clamped to the 
electrophoresis tank which had already been filled with electrophoresis buffer. Once 
the stacking gel had set the comb was removed and the samples were loaded. Prior to 
loading the samples were mixed with sample buffer containing mercaptoethanol and 
boiled for three minutes. When the samples were to be electrophoresed under non­
reducing conditions, the mercaptoethanol was omitted from the sample buffer.
Molecular weight standard curve construction
Molecular weight standards (Sigma) contain the following standards: Carbonic 
anhydrase (29kD), ovalbumin (45kD), BSA (66kD), phosphorylase B (97kD), p- 
galactosidase (116kD) and myosin (205kD), were 10|il reduced on the gel together with
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Figure 2.1; Plot of sodium dodecyl sulphate-polyacrylamide gel electrophoresis! 
(SDS-PAGE) standard curve. The logarithm of the molecular weight of each standard; 
protein is plotted against its relative mobility. !
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samples. After staining the relative mobility for each band was measured according to 
the following formula:
P f -  The migration distance of protein_______
The migration distance of the dye front
The standard curve was constructed on a semi-log paper by plotting the logarithm 
of the molecular weight of each standard against its relative mobility (Fig 2.1). The 
relative mobility of each protein band in the test gel was determined and their molecular 
weights determined directly from the standard curve.
2.10. PRODUCTION OF ANTIBODIES IN RABBITS 
Materials
Bovine serum albumin (BSA) (Sigma)
Bovine thyroglobulin (Sigma)
Freund's complete adjuvant (Difco)
Freund's incomplete adjuvant (Difco)
Sterile isotonic saline (Hospital Pharmacy)
Method
The immunogen (BSA, or thyroglobulin) was dissolved in sterile isotonic saline to 
give a solution with a final concentration of lmg/ml. This solution was then emulsified 
with equal volume of Freund's complete adjuvant. Each rabbit was injected 
subcutaneously with 0.5ml of emulsion at each of four sites. Four and six weeks after 
the first injection, booster injections were given. Each animal received 1ml of lmg/ml 
immunogen in Freund’s incomplete adjuvant at four sites. Ten days after the last boost, 
test bleeds (5ml) were taken from the marginal ear vein and tested for antibody content 
against specific antigen by using double diffusion. When reasonably high titres of 
precipitating antibodies were present, 50ml blood was drawn from the marginal ear vein 
of the animals at weekly intervals for 3 weeks.
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The blood was collected in sterile glass universal containers and allowed to clot at 
37°C for 30 minutes, and then transferred to ice for one hour to allow clot retraction to 
occur. The serum was then recovered by centrifugation, 2500g, at 4°C for 15 minutes, 
heat inactivated at 56° C for 1 hour, and then stored in aliquots at -20° C until required.
2.11 PURIFICATION OF IgG ON DIETHYLEAMINOETHYL CELLULOSE 
(DE52) 
Materials and buffers:
DE52 (Whatman)
Saturated ammonium sulphate (S AS) (section 2.1)
VBS (section 2.1)
PBS (section 2.1)
Phosphate buffer (0.01M.L"* pH 7.6) (section 2.1)
Method
The serum globulins were precipitated by placing the serum in an ice bath and 
adding an equal volume of SAS dropwise with continuous stirring. The serum was 
allowed to stand for 1/2 hour in the ice bath and the precipitated globulins were 
separated by centrifugation (2000g for 15 minutes at 2°C). The precipitate was 
dissolved in 5xVBS (half the volume of the original serum) and then dialysed 
extensively against phosphate buffer overnight at 4°C, before being applied to a small 
column of DE52 (1ml swollen gel per lOmg applied protein) which had been 
equilibrated with the same buffer. Following the application of the sample, the column 
was washed with the equilibration buffer and 5ml fractions were collected. The protein 
concentration (OD280) of each fraction was measured and the peak of excluded protein 
(IgG) was pooled (Fig 2.2). The protein concentration of the pool was measured 
(OD280) prior to its division into aliquots for storage at -20° C.
2.12. CONJUGATION OF BSA AND THYROOEOBIH.IN TN CNBR 
ACTIVATED SEPHAROSE-4R
(Pharmacia)
(Sigma)
(Sigma)
(BDH)
990 ml 
10ml
8.4gm
29.22gm
Materials
CNBr activated Sepharose-4B 
BSA
Bovine thyroglobulin 
Sodium azide 
Reagents and Buffers 
0.001M HC1
Deionised water 
0.1MHC1 
Coupling buffer 
NaHC0 3  
NaCl
Dissolved in deionised water and made up to 1 litre final volume.
Blocking Buffer
Tris base 12.114gm
Dissolved in deionised water and pH adjusted to 8 with concentrated HC1 prior to 
adjusting volume to 1 litre with deionised water.
Acetate buffer
Sodium acetate 8.203gm
NaCl 29.22gm
Dissolved deionised water and pH adjusted to 4 with glacial acetic acid prior to 
adjusting final volume to 1 litre with deionised water.
Tris-HCI (0.1M.L“1.pH8). NaCl (0.5M.L-1):
Tris base *2-114gm
NaCl 29.22gm
Dissolved in deionised water and pH adjusted to 8 with concentrated HC1 prior to
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8gm
adjusting volume to 1 litre with deionised water.
Phosphate Buffered saline (pH 7.2i 
NaCl
K2HPO4 1.21gm
KH2PO4 0.34gm
Dissolved in 1 litre of deionised water.
Method
CNBr-activated Sepharose was washed with 0.001M.L-1 HC1 (10 volumes per one 
volume swollen gel). The ligand which had been dissolved in coupling buffer was 
added to the swollen gel (lOmg/ml swollen gel) and mixed end-over-end for 1 hour at 
room temperature. The mixture was centrifuged (lOOOg for 5 minutes at 2°C), the 
supernatant removed and its protein concentration was measured spectrophotometrically 
(OD28o)- The efficiency of binding of ligand to the gel was expressed as percent 
bound ligand and calculated as follows:
%Bound Ligand= Amount of ^ d  xl00
Amount of ligand applied
Usually the percent of binding was over 90%. The remaining active sites on the 
Sepharose beads were blocked by incubating the gel with 0.1 M.L * Tris-HCl pH8 with 
end-over-end mixing for 1 hour at room temperature. The gel was then washed with 
three alternating cycles of acetate buffer (O.IM.L'l pjj4 containing 0.5M.L'! NaCl) 
and Tris-HCl (0.1M.L"1 pH8 containing 0.5M.L-1 NaCl). The gel was resuspended in 
an equal volume of same buffer (Tris-HCl 0.1M.L'1 pH8 containing 0.5M.L"1 NaCl) 
and sodium azide was added to a final concentration of 0.1 % (w/v) and the product 
stored at4°C.
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Figure 2.3: The elution profile of Sepharose-4B-thyroglobulin immunoadsorbent 
column. The unbound protein is excluded in the first peak, and the second peal 
represents the anti-thyroglobulin which eluted with glycine-HCl buffer.
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2,13^.AFFINITY PURIFICATION OF ANTIBODIES fTpO FRACTION) 
Materials
Thyroglobulin-Sepharose 4B or BSA-Sepharose 4B (Section 2.1)
DE52 (Whatman)
Anti-whole rabbit serum (donkey) (S APU)
Anti-rabbit IgG (sheep) (SAPU)
Buffers and reagents
Glycine HC1 (0.1M.L’1 pH2.8) (section 2.1)
Phosphate Buffer (0.01M.L-1 pH 7.6) (section 2.1)
Tris Base IM.L'1
Tris base 12.1gm
Dissolved in deionised water to a final volume of 100ml.
Sodium hydroxide (D.l
NaOH 0.4gm
Dissolved in deionised water to a final volume of 100ml.
Method
Affinity purification of anti-BSA or anti-thyroglobulin was performed by mixing 
equal volume of antiserum with the appropriate antigen-Sepharose 4B complex. After 
end-over-end mixing for 2 hours at room temperature the mixture was poured into a 
small column and washed extensively with PBS until the eluate contained no protein. 
The antibody was eluted by glycine-HCl (0.1M.L-1 pH 2.8) and 5ml fractions were 
collected (Fig 2.3). Rapid neutralization of the fractions was achieved by the addition 
of 150fil Tris (0.1M.L'1) to each tube. The protein concentration was measured 
spectrophotometrically. The fractions containing the peak of eluted protein were pooled 
and dialysed extensively against phosphate buffer (0.01M.L-! pH7.6), before being 
passed over a DE52 column which had been pre-equilibrated with the same buffer. The 
exclusion peak (purified IgG antibody) was dialysed against PBS, and the protein 
concentration was adjusted to 1 mg/ml by vacuum dialysis. The preparation was
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Figure 2.4: Plot of Folin-phenol assay standard curve. The amount of the standard 
protein (BSA) is plotted against its optical density (OD700).
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divided into aliquots and stored at -20° C until required.
The purity of the purified IgG was checked by SDS-PAGE which showed a single 
band (150kD) when run under non-reducing conditions and two bands (50kD and 
25kD) when run under reducing conditions.
2,14. DETERM INATION OF PROTEIN CONCENTRATION BY 
MODIFIED FOLIN-PHENOL ASSAY 
Buffers, reagents and stock solutions
Folin reagent (Sigma)
Solution A: Prepared by dissolving lOgm of sodium carbonate and lOOmg of sodium 
potassium tartrate in 500ml of sodium hydroxide (O.IM.L'l).
Solution B: 0.15% (w/v) aqueous solution of copper sulphate (CUSO4 .5H2 O). 
Solution C: Folin reagent (diluted 1:1 with deionised water).
Solution D: is freshly made by mixing of 50 volumes of solution A with 1 volume of 
solution B. Two millilitres from this solution were added to each of two series of test 
tubes. One series was used for test samples and the other for the reference standard and 
negative control. Ten microlitres of the test sample or the standard, were added to each 
designated tube. Two hundred microlitres of Folin reagent was added to each tube. 
The tubes were vortexed and incubated at room temperature for 30 minutes.
The colour intensity was measured spectrophotometrically at 700nm, using the 
blank tube as a zero reference for all tubes. The standard curve (Fig 2.4) was 
constructed by plotting the OD700 values against the protein concentration of each 
standard, and test sample values were determined from the standard curve and 
multiplied by the dilution factor.
2.15 QUANTITATIVE PRECIPITIN CURVE AND DETERMINATION
OF E Q U I V A L E N C E  POINT FOR ANTI-B&A— AND------ANTE
THYROGEOBIILIN
Method
One hundred microlitres of each of a series of doubling dilutions (in PBS) of BSA
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(starting from 8mg/ml) or thyroglobulin (starting from lOmg/ml) were added to a series 
of microcap centrifuge tubes. An additional tube in each series received lOOpl PBS and 
was used as a negative control. An equal volume (lOOp.1) of the appropriate purified 
antibody (1 mg/ml) was added to each tube and after mixing they were incubated in a 
37° C water bath for 1 hour, and then kept at 4°C overnight. Precipitated immune 
complexes were separated by centrifugation in a Beckman microfuge (lOOOOrpm) for 
10 minutes and the supernatant was aspirated. The pellet was washed three times with 
ice-cold PBS, and then dissolved in lOOql of NaOH (O.IM.L-*). The amount of 
protein in each tube was measured by the Folin phenol assay (Table 2.1). The 
precipitin curve was constructed by plotting the quantity of the precipitate on the 
ordinate against the concentration of antigen in the same tube on the abscissa (Fig 2.5).
In order to validate the equivalence point, the supernatants from the quantitative 
precipitin curve tubes were screened for antigen and antibody by double diffusion 
(section 2.8.1).
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Table 2.1; Quantitative precipitation and equivalence points for BSA anti-BSA and 
thyroglobulin anti-thyroglobulin IC.
Tube No. BSA * (ng) o d 700 PPt (jig) Thyroglobulin (p,g)OD7QQ PPt (M-g)
1 BOO 000 000 1000 0.0001 00
2 400 000 000 500 0.013 12
3 200 000 000 250 0.021 19
4 100 0.0001 000 125 0.099 91
5 50 0.028 26 62.5 0.152 149
6 25 0.075 69 31.25 0.078 72
7 12.5 0.078 71 15.625 0.072 66
8 6.25 0.094 86 7.5 0.038 35
9 3.125 0.062 57 3.9 0.032 30
10 1.56 0.039 36 1.95 0.023 21
11 0.78 0.02 18 0.97 0.012 10
12 0.39 0.011 10
(*) Each concentration of the antigen was mixed with 100|ig of affinity purified antibody
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Figure 2.5; Quantitative precipitin curve for anti-BSA (A) and anti-thyroglobulin (B) 
antibodies. The amount of antigen (BSA or thyroglobulin) is shown on the abscissa 
and the amount of the precipitated IC is shown on the ordinate. The equivalence point is 
that which showed the largest precipitate. The zone of antigen-excess and that of 
antibody-excess are to the right and to the left of the equivalence point respectively.
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2.16 PREPARATION OF IgG FRAGMENTS 
Materials and Buffers
Papain (Sigma)
Pepsin (Sigma)
Acetate buffer (0.1 M.L"1 pH 4.5) (section 2.1)
Phosphate buffer (0.5M.L' 1 cysteine O.OIM.L' 1 EDTA 0.002M.L' 1 pH8.0)
(section 2 .1)
Fab fragment (Papain digestion, Hudson and Hay, 1980)
The IgG concentration was adjusted to 20mg/ml by means of vacuum dialysis, and 
the concentrated material was dialysed overnight against phosphate buffer (0.5 M.L-1 
pH8) containing cysteine (0.01M.L-1) and EDTA (0.002M.L-!). The dialysed material 
was placed in a small bijoux bottle, and papain was added (Img/lOOmg IgG). The 
mixture was incubated at 37° C overnight in a shaking water bath. The mixture was 
then dialysed overnight against 5 litres PBS. Following centrifugation (lOOOg for 5 
minutes at 2°C) to remove any insoluble material, the supernatant was passed over a 
small column of protein-G Sepharose to remove the Fc piece, while the Fab fragments, 
which did not bind to the column were collected in the exclusion peak. The purity of 
Fab fragments was determined by IEP (section 2.8) and SDS-PAGE (section 2.9) 
using 10 % gel, where samples were run in the reduced and non-reduced form.
Preparation of F(ab')2 (pepsin digestion, Hudson and Hay, 1980)
The IgG concentration was adjusted at 20mg/ml, and dialysed against sodium 
acetate buffer (0.1M.L' 1 pH4.5). Pepsin was added (lmg/50mg IgG) and the mixture 
was incubated at 37° C overnight in a shaking water bath. The reaction mixture was 
then dialysed overnight against 5 litres PBS. The dialysed material was centrifuged 
(lOOOg for 5 minutes at 2°C) to remove any insoluble material. The digested IgG was 
passed over a protein-G Sepharose column equilibrated with PBS and the F(ab)2
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fragments which did not bind to the column were collected in the exclusion peak 
(section 2.17). The purity of F(ab)2 was checked by SDS-PAGE (section 2.9) using a 
10% gel and samples were run in the reduced and non-reduced form.
2.17 PROTEIN-G SEPHAROSE CHROMATOGRAPHY 
Materials and Buffers:
Protein-G Sepharose 4 Fast Flow (Pharmacia)
Glycine-HCl (0.1M.L_1.pH2.8) (section 2.1)
PBS (section 2.1)
Method
The required quantity of protein-G Sepharose was reconstituted in PBS and the gel 
was then packed in a small column. The digested IgG was passed through the column 
which was then washed with PBS and the exclusion peak was collected in 1ml fractions. 
The purity of the recovered Fab or F(ab)2 were checked on SDS-PAGE (section 2.9) using 
a 10% gel and samples were run in the reduced and non-reduced form.
The protein-G Sepharose column was recycled by washing with glycine-HCl buffer 
until no further protein was eluted. The column was then washed with PBS for re­
equilibration. The column was then suspended in 20% ethanol, as a preservative as 
directed by the supplier, and kept at 4°C until required.
2.18 BTOTTNYEATION OF IgG (Jackson elai, 1982; Holmskov-Nielsen et al, 
1986; Costa-Castro et al, 1987)
Materials and Buffers
Goat IgG anti-human Cl-INH (ATAB)
Goat IgG anti-human C3 (ATAB)
Goat IgG anti-human C5 (ATAB)
Biotin N-hydroxy-succinimide ester (Sigma)
Dimethyl sulphoxide (DMSO) (BDH)
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Merthiolate (Sigma)
Glycerine (BDH)
Phosphate buffered saline (PBS, pH 7.2) (section 2.1)
Phosphate buffered saline
(adjusted to pH8.5 with 0.5% w/v Na2CC>3) (section 2.1)
M ethod
The protein concentration of IgG antibody was adjusted to 1 mg/ml, and 6ml were 
dialysed against PBS (pH 8.5) overnight at 4°C. Biotin was dissolved in DMSO 
(lmg/ml). Each of the dialysed antibodies were placed in small bijoux bottle and to 
each one 1ml of biotin solution was added and mixed. After incubation at room 
temperature for 4 hours with intermittent gentle shaking, the reaction mixtures were 
dialysed extensively against PBS, pH 7.2, to remove free biotin. Merthiolate and 
glycerine were added to the biotin-conjugated antibodies as preservatives to final 
concentration of 0.05% (w/v) and 5%(v/v) respectively. The conjugates were kept at 
4°C until required.
2.19 MEASUREMENT OF COMPLEMENT COMPONENTS
Complement components C3, C4, factor B and Cl-INH were measured by laser- 
nephelometry, using a Baker Instruments Nephelometer Type 420. Normal ranges 
established in this laboratory were: C4 (199-574|ig/ml), factor B (149-42lfig/ml), C3 
(720-1800|ig/ml) and Cl-INH (160-370qg/ml).
2.20 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
Materials:
Goat IgG anti-human Cls (ATAB)
Goat IgG anti-human Properdin (ATAB)
Sheep IgG anti-human C9 (ICN)
Goat IgG anti-human Cl-INH (ATAB)
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Goat IgG anti-human 03 (ATAB)
Goat IgG anti-human C5 (ATAB) 
Biotin-conjugated goat IgG anti-human 03 
Biotin-conjugated goat IgG anti-human Cl-INH 
Biotin-conjugated goat IgG anti-human 05
(section 2.18) 
(section 2.18) 
(section 2.18)
H2 O2 30%(v /v ) (BDH)
O-phenylenediamine (OPD) (Sigma)
96 well flat bottom microelisa plates (Dynatech)
Avidin-horse radish peroxidase conjugate (Vector)
B uffers:
Coating Buffer ffl.Q5M.L~1 Carbonate-Bicarbonate. pH 9.61
Na2 C03 0.79g
NaHC03 1.46g
Deionised water to 500ml 
Blocking Buffer (PBS. 0.1% Gelatin!
PBS 500ml
Gelatin 0.5g
Substrate Buffer (0.2M.L' 1 phosphate. 0.1M.L"1 citrate buffer pH 5.6)
Solution A: Na2HP0 4  14.196g
Deionised water to 500ml
Solution B: Citric acid 9.61 g
Deionised Water to 500ml
Solution C: Solution A (28ml) was mixed with solution B (22ml). The final 
volume was completed to 100ml with deionised water and OPD (34mg) was added. 
Hydrogen peroxide (30%) was added (40p.l) to the buffer immediately, before use.
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4NH2S<Q4
H2 SO4 (concentrated)
Deionised water was added to a final volume of 1 litre.
108ml
Dilution Buffer:
Isotonic EDTA (0.086M.L-1 pH7.4) 
Gelatin (10% w/v)
Tween 20 0.5ml
116ml
10ml
PBS was added to final volume of 1 litre.
M ethod
Enzyme linked immunosorbent assays (ELISA) were developed to measure the 
multimolecular activation products Clr:Cls:Cl-INH, C3bBbP, and C5b-9. The assays 
were performed by coating the first two rows of each plate with 100|il/well of anti-Cl- 
INH (10|ig/ml), anti-C3 (5jig/ml) or anti-C5 (5|U.g/ml) and the remaining 6 rows were 
coated with anti-Cls (10|lg/ml), anti-properdin (5|ig/ml) and anti-C9 (5|U.g/ml) 
respectively. The first two rows were used for the reference standard curve in each 
assay. Coated plates were kept in a humid chamber at 4°C overnight prior to use. 
Plates were then washed 5 times with PBS-Tween, using an automated ELISA washer 
(Dynatech), 250fxl/well of the blocking buffer was applied for 1 hour and plates 
incubated in humid chamber at room temperature, followed by another 6 washes. 
Reference samples, test samples and internal controls (100p.l/well) were added in 
duplicate. Dilution buffer (100jal/well) was added to two wells as a negative 
(background) control. The plates were incubated for a further hour at room 
temperature followed by a further 6 washes. The biotin conjugated antibodies 
(100|il/well) were applied as follows; biotin anti-Cl-INH for Cls:Cl-INH assay, 
biotin anti-C3 for C3:P assay and biotin anti-C5 for C5b-9 assay and the plates were 
incubated at room temperature for an hour followed by 6 washes. Avidin-horse radish
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peroxidase conjugate was added (100pl/well) and the plates were incubated at room 
temperature for an hour. After a further 6 washes 100^1 substrate was added to each 
well and the plates were then incubated at room temperature until the colour developed. 
Plates were read using a microelisa reader (Dynatech) at wave length of 490nm.
2.20.1 Titration of the coating antibodies
The antibodies used in the three assays for coating the ELISA plates were titrated 
using different concentrations (20|ig/ml, 10|ig/ml, 5p.g/ml and 2.5|ig/ml) with the other 
conditions fixed for each assay.
2.20.2 Titration of biotin-antibody probes
Different dilutions were used of each of biotin anti-Cl-INH (1/250, 1/1000,1/5000 
and 1/25000), biotin anti-C3 (1/250, 1/1000, 1/5000 and 1/25000) and biotin anti-C5 
(1/250, 1/750 and 1/1500). All other conditions were fixed for each assay.
2.20.3 Reference serum standard
Total Cl-INH, C3 and C5 concentrations were measured in a standard pooled 
serum (from 40 individuals, stored in aliquots at -70°C). The pool contained 191|ig/ml 
Cl-INH, HOOp-g/ml C3 and 75^tg/ml C5. Rows A and B of the ELISA plates 
contained the standard curves, which were linear from 0.75 to 24 ng/ml for Cl-INH, 
0.9 to 30 ng/ml for C3 and 1.1 to 38 ng/ml for C5. The optical density readings for the 
samples were read off the standard curve and expressed as ng/ml.
2.20.4 Development of optical density (time course)
The change of the optical density was studied at different intervals (2, 4, 6 and 8 
minutes). For this purpose, four standard curves were set under similar conditions, in 
duplicates, in each ELISA. Each standard curve was assigned for one of the suggested 
colour development intervals.
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2.20.5 Sensitivity of the assays
The sensitivity of the assays was defined as the linear part of the standard curve 
with the upper and the lower ends of the standard curve representing the upper and the 
lower limits of the assay respectively. The standard curves were constructed using 
optimal conditions for each ELISA.
2.20.6 Reproducibility of the assays
Internal controls: For Cls:Cl-INH ELISA, fresh NHS was activated with BSA 
anti-BSA IC at equivalence (50|ig of antibody and 3.125|ig of antigen per lOOpl of 
NHS) for 30 minutes at 37° C. For C3:P and C5b-9 ELIS As, fresh NHS was activated 
by incubation with zymosan (1 mg/ml NHS) at 37°C for 30 minutes. In both activation 
processes, the reaction was stopped by the addition of EDTA (0.086M.L-1) to a final 
concentration of lOmM.L'1. The activated sera were divided into aliquots and stored at - 
70oC.
The interassay variation was defined by calculating the coefficient of variation for 
the internal controls which were assayed in 10 different experiments for each ELISA.
Stability of samples: The stability of Cls:Cl-INH, C3:P and C5b-9 complexes 
was tested by measuring the levels in samples of patient plasma and EDTA-treated IC 
zymosan activated sera (see above) after; a) two cycles of freeze-thawing, b) incubation 
at 20° C and 37° C for 1 ,2  and 4 hours and c) long term storage at -70° C. These 
conditions caused no significant alteration in the levels of any of the three activation 
complexes.
2.20.7 Use of ELISA for the measurement of complement activation in 
patients with different immune complex diseases
Patients: Thirty patients with systemic lupus erythematosus (SLE) (Tan £tnl, 1982) 
and 254 with rheumatoid arthritis (RA) (Ropes et aL 1958) were included in this study. 
Rheumatoid patients were subdivided, on the basis of IgM-RF sero-positivity, into the 
sero-positive (134) and the sero-negative (120) subgroups. Venous blood was
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collected by venesection and divided into two aliquots. One was allowed to clot at 
room temperature and the other anti-coagulated with EDTA (final concentration of 
lOmMJL'1). Serum and plasma were obtained by centrifugation (2000g for 10 minutes 
at -2°C) aliquoted and stored at -70° C within 2 hours of venesection. Synovial fluid 
was collected from knee effusions of 17 RA patients simultaneously with blood 
sampling.
Normal controls: Serum and plasma from thirty laboratory personnel (13 males and 
17 females) were collected and stored as above, and the analysis of these groups was 
used to determine the normal ranges.
2.20.8 Effect of IgM rheumatoid factor (IgM-RF) on the ELISA systems
NHS was activated with IC or zymosan (as described above). Further activation 
was stopped by the addition of EDTA (0.086M.L-1, pH 7.4) to a final concentration of 
lOmM.L'l. IgM-RF (gift from Dr J. Davidson) was then added to the activated serum 
to give a final concentrations of 250, 500, and lOOOfig/ml (normal serum concentration 
of IgM-RF <40|ig/ml). Activated serum levels of Cls:Cl-INH, C3:P and C5b-9 were 
measured by ELISA. Controls included IgM-RF in buffer (same concentrations used 
with activated serum) and activated serum without IgM-RF.
2.21 ELISA FOR THE MEASUREMENT OF RHEUMATOID FACTOR 
IN PATIENTS SERA AND PLASMA
ELISA plates were coated with human IgG (for IgM-RF and IgA-RF) or rabbit IgG 
(for IgG-RF) at a concentration of 5qg/ml in carbonate-bicarbonate buffer (0.005M.L'1, 
pH9.6, 100ql/well). Coated plates were kept in humid chamber at 4°C overnight prior 
to use. Plates were then washed four times with PBS-Tween (0.005%v/v) and blocked 
with 0.1% BSA in PBS (2O0|il/well) for 1 hour at room temperature. The excess 
blocking buffer was removed by a further four washings with PBS-Tween and 
following the application of samples and standards (lOOpl/well), the plates were
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incubated for 2 hours at room temperature. In the IgG-RF ELISA, the standards and 
samples were processed by treatment with pepsin. This was performed by mixing the 
sample (5|il) with 250^1 of pepsin solution (10|!g pepsin/ml of 0.1M.L-1 acetate buffer 
pH 4.4) and the mixture was incubated at 37° C overnight. The pepsin was then 
inactivated by the addition of 250pl of disodium hydrogen phosphate solution 
(0.563M.L'!). One hundred microlitres/well was taken from the resulting solution for 
the assay of IgG-RF. The plates were washed again four times and the bound RF was 
probed using anti-|! chain (Dakopatts), anti-a chain (Dakopatts) or anti-human IgG 
(Cappel) F(ab)2 fragment conjugated to horse-radish peroxidase for the IgM-RF, IgA- 
RF and IgG-RF assays respectively. All conjugates were used at a dilution of 1/1000 
and the plate incubated for 1 hour at room temperature. After four washes the bound 
enzyme was detected using the standard developing reaction (section 2 .20).
2.22. STATISTICS
Non-parametric statistical tests (Spearman rank correlation test and Wilcoxon 
matched pairs test) were used for data analysis.
2.23 TITRATION OF OPTIMAL SENSITIZING DOSE OF RABBIT 
ANTI-SHEEP ERYTHROCYTES 
Materials and buffers
Polyethylene 96 well round bottomed microtitre plate (Dynatech)
Rabbit anti-sheep erythrocytes antiserum (Haemolytic serum) (Serotec)
PBS (section 2 .1)
Method
Rabbit haemolytic serum was heat-inactivated by incubation at 56° C for 30 
minutes. Fifty microlitres PBS were added to a series of wells and the haemolytic 
serum was titrated by doubling dilutions. For each dilution 50pl of sheep erythrocytes
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(Ix l09/ml) was added to each well and after shaking, the plate was incubated at room 
temperature for 1 hour. The lowest antibody dilution which did not give agglutination 
was chosen as the optimal sensitizing dose. It was usually a 1/500 dilution of the 
antiserum.
2.24 PR EPA R ATION QF ANTIBODY SENSITIZED SHEEP  
ERYTHROCYTES (EAs)
Materials
Sheep erythrocytes (Gibco)
Rabbit anti-sheep erythrocyte antiserum (Haemolytic serum) (Serotec)
PBS (section 2.1)
GVB++ (section 2.1)
GVB=EDTA (section 2.1)
Method
Sheep erythrocytes were washed three times with GVB=EDTA, taking care to 
remove the buffy coat. Between washes the cells were centrifuged (2000g for lOmin at 
4°C). After washing the cells were resuspended in GVB=EDTA and the cell 
concentration was determined by lysing 100|il of E in 2.9ml water and measuring the 
optical density at 541nm (lxlO9 E/ml at OD541 = 0.385). The cell count was adjusted 
to lx l0 9/ml by the addition of GVB-EDTA containing the optimal dilution of 
sensitizing antibody and incubated in a shaking water bath at 37°C for 30 minutes. The 
cells were then washed in GVB++ and the concentration adjusted to 5xl08/ml in 
GVB++ kept at 4°C for use within 4 days.
2.25 DETERMINATION OF THE OPTIMAL DOSE OF IC FQR 
DEPLETION OE HUMAN COMPLEMENT
Materials
EA (lx l08/ml GVB++) (section 2.21)
100
80
60
40
20
0
1
Serum Dilution
Figure 2.6: Haemolytic assay for the titration of the efficiency of different doses of 
IC, formed at equivalence, on the depletion of NHS complement. Four IgG antibody 
concentrations were used (per ml NHS): 1000pg («— *), 500jng (*—*), 250pg 
(□—□), 125jxg (■—■) and 62.5p.g (*—*). Untreated NHS was used as a control
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GVB++ (section 2.1)
NHS (section 2 .6)
Method
The ability of immune complexes to activate the complement system in human 
serum was assessed by examining the residual haemolytic activity of serum. Different 
concentrations of IC (100, 50, 25 and 12.5|LLg anti-thyroglobulin in 25p.l GVB++) were 
added to a series of four tubes containing 100|il serum. These tubes were incubated at 
37°C for 30 minutes, after which time they were centrifuged (lOOOOrpm for 5 minutes 
in a Beckman microfuge). The supernatant serum was then serially diluted (1/9, 1/18, 
1/36, 1/72 and 1/144) in GVB++ and IOOjllI of each dilution was added to a series of 
test tubes. One hundred microlitres (lOOjil) of EA (1x10^) were added to each tube and 
the mixtures were incubated in a shaking water bath at 37°C for 30 minutes. Control 
tubes included 100% lysis and a cell blank (lOOpl EA + lOOpl GVB++). After the 
addition of 2ml saline/tubes (2ml deionised water for the 100% lysis control) and 
centrifugation (2000rpm for 5 minutes at 2°C) the degree of lysis was determined 
spectrophotometrically (OD414). The percent lysis was measured using the formula:
y  lysis -  QD414 (Sample) - OD414 (Cell Blank)______
OD414 (100% lysis) -OD414 (Cell Blank)
The optimal dose of IC (Fig 2.6) that depleted more than 90% of NHS complement 
was selected (500^ig IgG antibody/ml NHS) as the maximum IC dose to be used in all 
the experiments performed throughout this study.
2.26 ACTIVATION OF NORMAL HUMAN SERUM BY IMMUNE 
COMPLEXES (IC)
Materials
BSA (Sigma)
Thyroglobulin (Sigma)
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IgG-fraction of affinity purified antibodies 
(anti-BSA and anti-thyroglobulin) (lmg/ml) 
Normal human serum (NHS)
MgCl2 (0.1M.L"1)
EGTA (0.1M.L-1)
EDTA (0.086M.L'1)
PBS
(section 2.13) 
(section 2 .6) 
(section 2 .1) 
(section 2 .1) 
(section 2 .1) 
(section 2 .1)
The IC were prepared from two different antigens (BSA and thyroglobulin). Each 
antigen was studied at five antigen antibody ratios (16-times and 4-times antibody- 
excess, equivalence, 4-times and 16-times antigen-excess). Dose response curves for 
each antigen:antibody ratio were performed using four antibody doses (500, 250, 125 
and 62.5|ig IgG antibody/ml NHS). Kinetic experiments were performed using a 
single dose of BSA and thyroglobulin IC (250jLXg IgG antibody/ml NHS) for each of 
the five antigen:antibody ratios.
Dose response and kinetic experiments for IC formed with both antigens were 
performed using nascent and preformed IC (see below).
2.26.1 Activation by nascent IC (dose response)
The antibodies (starting concentration lmg/ml in PBS) and the antigens (BSA or 
thyroglobulin) were doubly diluted in PBS, in a separate series of microcap tubes 
which were then warmed in a water bath at 37° C.
Normal human serum (100|il) was dispensed into two series, of four test tubes 
each, and placed in a water bath (37° C). EGTA (0.1M.L'1) was added to the tubes of 
one series to give a final concentration of 0.01 M.L  ^ in NHS followed by MgC^ 
(0.1M.L"1) to give a final concentration of 0.0025M.L'1. An equivalent volume of 
PBS was added to the tubes of the other series which had not received Mg++EGTA. 
The appropriate concentrations of antigen (BSA or thyroglobulin) were then added 
(10|il/100|il NHS) to the duplicate sets of tubes, the appropriate concentration of pre­
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warmed antibody was added in a constant volume of 50|il to give final concentration of 
500, 250, 125 and 62.5}ig IgG antibody/ml NHS. IC were formed at 16-times 
antibody-excess, 4-times antibody-excess, equivalence, 4-times antigen-excess and 16- 
times antigen-excess. Controls in this experiment included: NHS containing the highest 
IC dose (for each antigenrantibody ratio) with EDTA (final concentration of 0.01M.L’1), 
NHS/EDTA, NHS/Mg++EGTA, NHS without IC, NHS in ice, NHS with highest 
does of antibody (500|ig IgG antibody/ml NHS), NHS with the highest dose of 
antigen. After mixing their contents, the tubes were placed in a shaking water bath 
(37° C) for half an hour. The reaction was stopped by the addition of an equal volume 
of ice-cold PBS containing EDTA (0.02M.L-*). After mixing the tubes were 
centrifuged (lOOOOrpm for 5 minutes at room temperature) using a Beckman microfuge 
and the supernatants were collected and the concentration of complement activation 
products were measured.
2.26.2 Activation by preformed IC (dose response)
Antibody (400jil at lmg/ml in PBS) was added to a series of five microcap tubes 
and the required concentration of antigen (BSA or thyroglobulin) in 40[il was added to 
give the following antigen:antibody ratios: 16-times and 4-times antibody-excess, 
equivalence, 4-times and 16-times antigen-excess. The contents were mixed and the 
tubes incubated in water bath (37° C) for 30 minutes before being transferred to an ice 
bath a further 30 minutes. At the end of this incubation period the tube contents were 
mixed thoroughly and IC at each antigen-antibody ratio were doubly diluted (3 times) in 
PBS, and 60|il of each dilution containing 50, 25, 12.5 and 625\ig of antibody were 
added to lOOpl of NHS at 37° C. The contents were mixed and incubated for 30 
minutes in a shaking water bath at 37° C. The reaction was stopped by the addition of 
an equal volume of ice-cold PBS containing EDTA (0.02M.L"1) to each tube and after 
mixing the tubes were centrifuged (10000 rpm for 5 minutes at room temperature) using 
a Beckman microfuge. The supernatants were collected for assaying for complement
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activation products. The controls were identical to those used for the experiments on 
complement activation by nascent IC.
2.26.3 Kinetics of complement activation by IC
i
Nascent and preformed IC were studied at different antigen-antibody ratios but the 
concentration of antibody in the IC was kept constant at 250|ig IgG/ml NHS. For the 
studies of complement activation by nascent thyroglobulin anti-thyroglobulin IC, 
antigen:antibody ratios of 16-times and 4-times antibody-excess, equivalence, 4-times 
and 16-times antigen-excess were used, and all experiments were performed at three 
temperatures (37° C, 30° C, 20° C). For all other experiments IC were studied at only 
three different antigen-antibody ratios (4-times antibody-excess, equivalence, 4-times 
antigen-excess) and incubations were performed only at 37° C.
Nascent IC: Normal human serum (NHS, 1ml) was dispensed into two series of 
tubes (5 tubes each) and EGTA (0.1M.L’1) was added to one series to give a final NHS 
concentration of 0.01 M.L' 1 followed by MgCl2 (final concentration of 0.005M.L'1). 
The tubes were placed in a shaking water bath. The pre-warmed antigen was added, 
mixed, followed by the addition of the pre-warmed antibody (250fig IgG antibody/ml 
NHS ^ finally the tubes were mixed well. The time of the addition of the antibody was 
considered to be time zero. Samples (175|il) were removed at designated time points 
and transferred into ice-cold PBS containing EDTA (0.02M.L-1). The tubes were 
centrifuged (lOOOOrpm for 5 minutes at room temperature) using a Beckman microfuge, 
and the supernatants were collected and assayed for complement activation products.
Preformed IC: IC were prepared as above and NHS was dispensed into two series 
of tubes (5 tubes each). EGTA and Mg++ were added to one set of tubes to give a final 
concentrations of 0.01M.L' 1 and 0.0025M.L'1 respectively. The tubes were placed in 
a shaking water bath at 37°C. The preformed IC at different antigemantibody ratios
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were added to NHS to give 250|ag IgG antibody/ml NHS. The time of the addition of 
preformed IC was considered as the time zero, and samples (175|iil) were removed 
from the reaction mixture at designated time points and transferred to tubes containing 
ice-cold PBS and EDTA (0.02M.L-1). The tubes were then centrifuged (lOOOQrpm for 
5 minutes at room temperature) using a Beckman microfuge, and the supernatant 
collected and assayed for complement activation products.
2.27. ACTIVATION OF COMPLEMENT IN THE PRESENCE OF 
HUMAN ERYTHROCYTES
These studies were undertaken to study the effect of erythrocytes on complement 
activation in NHS, as complement activation occurring in whole blood occurs in the 
presence of 50%(v/v) erythrocytes (approximately) and as erythrocytes express at least 
two membrane proteins which regulate complement activation (DAF and CR1).
These experiments were performed at four IC concentrations (500, 250, 125 and 
62.5|ig IgG antibody/ml NHS) and at five antigen:antibody ratios (16-times and 4- 
times antibody-excess, equivalence, 4-times and 16-times antigen-excess), in the 
presence or absence of an equal volume of packed autologus erythrocytes. Activation 
of complement in the presence of human erythrocytes was studied using the same 
procedures as described in section 2.24. The exception being in the addition of an 
equal volume of packed human erythrocytes to the NHS. At the end of the experiments 
the erythrocytes were removed by centrifugation and the supernatants were assayed for 
complement activation products.
2.28. PREPARATION OF HUMAN ERYTHROCYTES
Blood was withdrawn from normal volunteers and anti-coagulated with EDTA 
(lOmM.L-1). The plasma and buffy coat were removed after centrifugation at 2000g 
for 10 minutes at 4°C. The erythrocytes were washed 5 times with GVB_EDTA, 
taking care to remove residual buffy coats after each centrifugation. A 50% suspension 
of erythrocytes in GVB++ was prepared. The cells were used at the same day of
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preparation. For the complement activation experiments, in which human erythrocytes 
were included, autologus NHS was used.
2.29. TRYPSINIZATION OF HUMAN ERYTHROCYTES 
Materials and Buffers
Trypsin (Sigma)
Isotonic VBS (lx) section 2.1
GVB++ section 2.1
Human erythrocytes section 2.26
Method
In an attempt to investigate the role of CR1, erythrocytes were trypsinised (Lay and 
Nussenzweig, 1968; Dorval M il, 1989) prior their addition to the complement 
activation mixture.
Purified human erythrocytes were centrifuged (2000g for 5 minutes at 4°C) 
resuspended in an equal volume of VBS. and placed in a glass tube and warmed to 
37°C. Trypsin (2.5ml at 2mg/ml in VBS) was added to 5ml of 50% erythrocyte 
suspension. The mixture was incubated at 37°C for 1 hour in a shaking water bath. 
Trypsin was removed by washing the cells 5 times with GVB++ and centrifuging the 
cells (2000g x 5mins at 4°C) between each wash. The efficiency of trypsinization was 
determined using an immune adherence assay. In a preliminary experiment it was 
shown that trypsinised erythrocytes did not activate complement.
2.30. IMMUNE ADHERENCE ASSAY 
Materials and buffers
Microtitre plate (96 well) (Dynatech)
Immune adherence buffer (LAB) (Isotonic VBS (lx) containing 1% BSA and
3.2% dextrose)
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EAC43b (lx l0 8/ml IAB) (Section 2.27)
Human erythrocytes (Ehum lx l09/ml IAB)
Method
Fifty microlitres IAB were added to every well of a microtitre plate and 50|il of 
control or trypsinised Ehum (lx l09/ml IAB) were dispensed into the wells in row one. 
The cells were doubly diluted across six wells. The indicator cells, EAC43b (lxlO8), 
were added (50|il) to all wells, the cells mixed and the plates incubated for 1 hour at 
room temperature. The pattern of agglutination was then read. Controls included 
control and trypsinised Ehum alone and EAC43b alone. Agglutination was observed 
with control Ehum but not with trypsinised Ehum.
2.31. BLOCKING OF ERYTHROCYTE CRT AND TITRATION OF 
OPTIMAL BLOCKING CONCENTRATION OF ANTI-CRT FAB
FRAGMENTS 
Materials
Anti-CRl (Fab fragment) section 2.16
Normal human erythrocytes (Ehum) section 2.26
GVB++ Section 2.1
Method
In a further attempt to investigate the role of CR1, erythrocytes were pre-incubated 
with Fab anti-CRl or normal rabbit IgG Fab which had been pre-absorbed against 
NHS-Sepharose (half an hour at room temperature), prior to their incubation with 
erythrocytes.
Two hundred microlitres of Ehum (lx l09/ml GVB++) were placed in each of six 
microcap tubes. Anti-CRl Fab was doubly diluted (0.6mg/ml down to 0.0187mg/ml) 
and 200|il was added to each tube containing the cells. The normal rabbit IgG Fab was 
added to a second series of tubes. The tube contents were mixed end-over-end at room
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temperature for 1 hour. The unbound Fab fragments were removed by washing the 
cells two times with GVB++. CR1 blockade was determined using the immune 
adherence assay (section 2.8). The lowest dilution of Fab anti-CRl which blocked 
immune adherence completely was 0.0374mg/ml. Normal rabbit IgG Fab did not 
inhibit immune adherence. In a preliminary experiment it was shown that Fab treated 
erythrocytes did not activate complement.
2.32. PREPARATION OF C3-DEPLETED SERUM (R3)
Zymosan was mixed with freshly drawn NHS to give final concentrations of
0.5mg/ml and 1 mg/ml. The zymosan-serum mixture was incubated in a shaking water 
bath at 37° C for 1 hour, after which the mixture was centrifuged (2000g for 10 minutes 
at 4°C) and the zymosan treated serum (R3-reagent) recovered and divided into aliquots 
and stored at -70° C.
Titration of R3-reagent
Titration of the R3-reagent was performed by haemolytic assay. The R3 
preparations were serially diluted with GVB++ from 1/10 to 1/320. One hundred 
microlitres of each dilution was transferred to a duplicate series of test tubes to which 
100 |il of EAs (1x10s cells/ml) were added. Controls included NHS diluted in the 
same manner of R3, cell blank and 100% lysis. The tubes were incubated in a shaking 
water bath at 37° C, for 1 hour and the reaction was stopped by addition of 2ml isotonic 
saline (except the 100% lysis to which 2ml deionised water were added). All tubes 
were centrifuged at 2000g for 5 minutes at 4°C. The extent of haemolysis was 
determined spectrophotometrically at OD414 (Fig 2.7). The optimal dilution of R3 
selected was the lowest dilution which produced less than 5% haemolysis.
2.33. PREPARATION OF EAC43R INTERMEDIATE
Materials and buffers
pa section 2.21
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R3-reagent section 2.30
Suramin (Antrypol, lOmg/ml) (Bayer)
GVB++ section 2 1
GVB-EDTA section 2.1
DGVB44- section 2.1
NHS section 2.6
Method
Nine millilitres of EA adjusted at 1x10^ cells/ml in GVB++ were pre-warmed and 
mixed with 1ml of pre-warmed R3-reagent, with continuous shaking for 75 seconds, 
after which suramin was added to a final concentration of 1 mg/ml. After a further 2 
minutes incubation at 37° C, the EAC43b were diluted in an equal volume of ice-cold 
GVB=EDTA, centrifuged (2000g for 5 minutes at 4°C) then washed three times in 
GVB=EDTA and finally resuspended in 5ml GVB=EDTA and incubated at 37° C for 2 
hours in a shaking water bath in order to decay C2a. The EAC43b were washed with 
DGVB++and standardized at 1x10** /ml DGVB++, stored at 4°C and used within 4 
days.
2.34. ASSAYS FOR SOLUBILISATION AND PREV EN TIO N  OF 
IMMUNE PRECIPITATION
Radiolabeling of BSA and thvroglobulin with 125I: The procedure was performed, 
as described by McConahey and Dixon (1966). Briefly, the protein solution (lmg/ml 
PBS) was placed in a bijoux containing one millicurie (mCi) of carrier-free 125I, lOOpl 
of fresh solution of chloramine T (lmg/ml) was added and after incubation at room 
temperature for four minutes, the reaction was stopped by the addition of lQOpl of 
(2mg/ml) sodium metabisulphite. Protein-bound ^ 1  was separated from free “^-^ 1 by 
passing the solution through a 25xlcm column of Sephadex G25 Superfine 
(Pharmacia) pre-equilibrated with PBS, and one ml fractions were collected. The
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radioactivity of each fraction was measured by counting 5 |il from each fraction using a 
Packard gamma counter (model 300C). The radioactivity was represented by two 
peaks. The first peak contained the protein-bound ^ 1 ,  as determined by precipitation 
with 10% trichloracetic acid, and the second one represented the protein free ^25 j The 
protein concentration of the first peak was measured spectrophotometrically at OD2gQ 
and determined as cpm/|ig of protein.
The prevention of immune precipitation and solubilisation assays were performed to 
determine the solubility of nascent and preformed BS A anti-BS AIC and thyroglobulin 
anti-thyroglobulin IC at the concentrations used in complement activation experiments. 
This was performed as an attempt to investigate relation of IC solubility with the 
concentration of C3:P complex produced by these complexes.
Prevention of immune precipitation assay was performed by mixing 5|il antigen 
(125j_ggA or *251_thyroglobulin), lOpl antibody and 50pl NHS and the volume was 
completed to 1 15|l l 1 with GVB++ where the concentrations of IC at each antigen- 
antibody ratios were proportional to that used in complement activation experiments. 
The reaction mixture, excluding the antibody, was prepared on ice and then incubated at 
37° C, and the pre-warmed antibody was added at time zero. Incubation continued for 
30 minutes when 50jnl sample was taken from each tube into 1ml ice-cold PBS, in a 
microcap tube, and the IC precipitate removed by centrifugation (Bechman microfuge).
Controls included: (A) precipitable radioactivity by antibody in the absence of 
serum (GVB++), (B) total radioactivity which is represented by the antigen input alone, 
for each antigen-antibody ratio, in buffer and (C) TCA precipitable counts: 50pl antigen 
(BSA or thyroglobulin, 5mg/ml) plus 5pl I-antigen plus 60|il 20% TCA.
The percentage of soluble IC was calculated according to the following formula:
% solnhle= cpm in supernatant (seruml - cpm in supernatant (buffer) XJ00  
total cpm/tube - cpm in buffer supernatant
In case of solubilisation, all the experimental conditions were similar to that of the
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PIP assay, with the exception that the IC were preformed prior to their addition to the 
pre-warmed serum.
2.35. RADIOIMMUNOASSAY FOR THE MEASUREMENT OF C3 a. 
C4a AND. C5a 
Materials and buffers
All reagents were obtained from Amersham International pic, and include the 
following:
1. Precipitating reagent
2. Assay buffer
3. Tracer (^^IC3a des-Arg, ^^IC4a des-Argor ^^IC5a des-Arg)
4. Rabbit anti-C3a des-Arg anti-C4ades-Argor anti-C5ades-Arg (First antibody)
5. Standards containing different concentrations of C3a des-Arg C4a des-Arg and 
C5a des-Arg (Table 2.2).
6. Goat anti-rabbit antiserum (second antibody).
Microcap centrifuge tubes
Conical bottom assay tubes (70x12mm)
Method
Because of the expense of commercially available anaphylatoxin immunoassay kits, 
concentrations of C4a, C3a and C5a were only measured in certain studies of 
complement activation.
The principle of all the assays was the same and include the following steps;
.Sample preparation:
The sample (15JJ-1) and the precipitating buffer (75p.l) were mixed in microcap 
tubes. After 30 minutes at room temperature the tubes were centrifuged for 5 minutes 
in a Beckman microfuge (lOOOOrpm for 5 minutes). The supernatants which were free
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of native C4, C3 or C5, were aspirated for assay.
Assay procedure
Each sample was assayed in duplicate and each assay included the following series 
of controls; total radioactivity (TC), non-specific binding (NSB), blank (Bo) and the 
five standards containing known concentrations of C4a, C3a or C5a (Table 2.2).
Fifty microlitres of assay buffer were pipetted into all assay tubes, the content of 
which were then vortex mixed. The standards and samples were pipetted (50ju.l)into the 
appropriate tubes, after which the assay tracer (50jj1) was added. The TC tubes were 
then covered with clingfilm and set aside for counting. The antiserum (rabbit anti-C4a, 
C3a or C5a des Arg) was pipetted (50|il) into all the tubes except NSB to which 50|il 
isotonic saline was added. The tube contents were then vortex mixed, covered with 
cling-film and incubated at room temperature for 3 hours. The second antibody (goat 
anti-rabbit IgG) was added into all tubes except TC tubes, and the contents were re­
mixed and incubated at room temperature for 30 minutes. At the end of this incubation 
period 2ml isotonic saline was added to all tubes except TC tubes. The tubes were 
centrifuged (2500g for 15 minutes at 4°C) and the supernatant was carefully aspirated. 
The radioactivity present in each assay tube was counted using a Packard automatic 
gammacounter (Model 300C).
Calculation of results
The average counts per minutes (cpm) for each set of replicate tubes was calculated 
and the average NSB cpm was subtracted from all the tubes except TC. The percentage 
Bo/TC was determined using the following formula:
%Bo/TC= Boq>m -NSBcpm x lQ0  
TCcpm
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The percent B/Bo for standards and samples was calculated using the following 
formula:
Standard or/ Sample cpm - NSB cpm x^qq 
Bo cpm - NSB cpm
The standard curve was constructed by plotting the percent B/Bo as a function of 
the log C3a des-Argor C5a des-Arg (Fig 2.8) concentration on a log-logit graph paper, 
while for C4a des-Arg assay the log concentration of C4a was constructed against the 
%B/Bo of those standards (according to the instruction of the manufacturer). The 
concentration of anaphylatoxins, in nanograms, per tube were determined directly from 
the standard curve, and the total concentrations of original samples was calculated by 
multiplying by the dilution factor.
117.
Table 2.2. Concentrations of C4a des-Arg, C3a des-Arg and C5a des-Arg in the 
standard curves of the radioimmunoassays used for the determination of C4a, C3a and 
C5a respectively.
Standard C4a C3a C5a
(ng/50|il) (ng/50|il) (ng/50pJ)
A 25 65 10
B 10 30 4
C 5 12 1.6
D 2.5 5 0.64
E 1 2 0.25
oa/aas
5 0 -
10 100
C5a(ng /50ju1)
Figure 2.8: Plot of the standard curve of the radioimmunoassay used for the
determination of C5a. The concentrations of C5a are plotted on the abscissa (log scale) 
against their B/Bo% which is shown on the ordinate (logit scale).
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Id *  D E V ELO PM EN T OF ELISA PROCEDURES FOR THE
MEASUREMENT OF Cls:Cl-INH. C3:P AND C5h-9 COMPLEXES 
3.1.1. Titration of the coating antibodies
Titration of coating antibodies revealed that antibody concentrations of 10p.g/ml, 
5|ig/ml and 5p.g/ml for Cls:Cl-INH, C3:P and C5b-9 assays respectively gave good 
standard curves in terms of sensitivity range, and in terms of the amount of antibody 
required (Fig 3.1.1).
3.1.2. Titration of biotin-conjugated antibody probes
The optimal biotin-conjugated antibody probe dilution which gave the widest range 
of sensitivity and best linear fit was found to be with 1/ldOO, 1/1000 and 1/750 for 
Cls:Cl-INH, C3:P and C5b-9 assays respectively (Fig 3.1.2).
3.1.3. Sensitivity of the assays
The sensitivity limits of the assays were 24-0.75, 29.5-0.92 and 30-0.9 ng/ml for 
Cl-INH (in the Cls:Cl-INH assay), C3 (in the C3:P assay) and C5 (in the C5b-9 
assay) respectively (Fig 3.1.3). The optical density readings for the samples were read 
off the standard curve and expressed as ng/ml.
3.1.4. Development of OD
The time course of OD^^q development showed that the OD^qq increased with time 
for each of the standard curves of the three ELIS As (Fig 3.1.4).
3.1.5. Reproducibility of the assays
In the three ELISAs all samples were assayed in duplicate. When the difference 
between the duplicate determinations was greater than 5% of the mean, the sample was 
retested.
The interassay coefficient of variations of the internal controls, which were tested 
on ten consecutive experiments, were ±10%, ±3% and ±5% for the Cls.Cl-INH, C3.P
Fipure.3.1.1 (A. B and C): Titration of coating antibodies for (A) Cls:Cl-INH 
assay, (B) C3:P assay and (C) C5b-9 assay. The concentrations used are 20gg/ml 
(□—□), 10|ig/ml (•—•), 5 pg/ml (*—a) and 2.5|ig/ml (*—a). The concentration of tie 
antigen was plotted on the abscissa, and the optical density (OD490) on the ordinate.
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Figure 3.1.2 (A. B and C): Titration of biotin-second antibody conjugates for (A) 
C ls:Cl-INH assay, (B) C3:P assay and (C) C5b-9 assay. The conjugate dilutions for 
biotin-anti-Cl-INH were 1/250 (■—■), 1/1000 ( M ), 1/5000 (* -* )  and 1/25000 
(a—*). The dilutions for biotin-anti-C3 were 1/250 (■— ■ ), 1/1000 (*—*), 1/5000 
(a—*) and 1/25000 (*—*). For the biotin-anti-C5 the dilutions were 1/250 (*—■), 
1/750 ( ° )  and 1/1500 (*—a). The concentration of the antigen was plotted, on the 
abscissa, against the optical density (OD490) on the ordinate.
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Figure 3.1.3 (A. B and O : The sensitivity limits of the (A) Cls:Cl-INH assay, 
(B) C3:P assay and (C) C5b-9 assay. The concentration of the antigen was plotted,on 
the abscissa, against the optical density (OD490) on the ordinate.
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Figure 3.1.4 (A. B and C): Kinetics of OD4 9 0  development in (A) Cls:Cl-INH 
assay, (B) C3:P assay and (C) C5b-9 assay. The colour development was stopped at 2 
minutes (*—<*), 4 minutes (*—•), 6 minutes (n—□) and 8 minutes (■—■). The 
concentration of the antigen was plotted, on the abscissa against the optical density 
(OD490) on the ordinate.
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and C5b-9 assays respectively.
3.1.6. Stability of samples
Incubation of the multimolecular complexes Cls:Cl-INH, C3:P and C5b-9 at 20°C 
and 37° C for 1, 2 and 4 hours and storage at -70° C for one month did not alter the 
levels of any of the three multimolecular complexes.
3.2. MEASUREMENT OF COMPLEMENT ACTIVATION COMPLEXES 
IN PATIENTS AND NORMAL INDIVIDUALS
3.2.1. Levels of complement activation complexes
Level of Cls:Cl-INH, C3:P and C5b-9 were measured in normal individuals, SLE 
and RA patients (Table 3.1). The mean level of complement activation complexes in 
sero-negative RA patients (mean ± SE of mean) were Cls:Cl-INH (80.8ng/ml ± 25), 
C3:P (44.4ng/ml ± 2.6) and C5b-9 (18ng/ml ± 0.7); in sero-positive RA patients the 
levels were Cls:Cl-INH (271ng/ml ± 51.9), C3:P (90.2ng/ml ± 8.6) and C5b-9 
(70ng/ml ± 19.7) and in SLE patients were Cls:Cl-INH (77.8ng/ml ± 8.5), C3:P 
(56ng/ml ± 7.9) and C5b-9 (27ng/ml ± 2.4) (Table 3.1).
3.2.2. Comparison of the levels of complement activation complexes in 
serum and plasma
Comparison of the levels of the complement activation complexes Cls:Cl-INH, 
C3:P and C5b-9 in normal controls sera and plasma showed no significant difference. 
However, the RA patients had significantly higher serum levels of C3:P (mean 
88ng/ml, median 58ng/ml) compared to plasma (mean 68ng/ml, median 45ng/ml, 
p<0.001 by Wilcoxon pairs test). No significant difference was observed between 
serum and plasma levels of Cls:Cl-INH or C5b-9 in RA patients. However, for the 
remainder of the study measurements of complement activation products were 
performed on samples of EDTA-plasma.
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3.2.3. Comparison of the levels of the complement activation complexes 
in normals and SLE and RA patients
In both RA and SLE patients plasma levels of all three activation products were 
higher than those in normals (p<0.0001 for all three, Table 3.1, Fig 3.2.1).
In normal individuals there was a significant correlation (Spearman rank test) 
between Cls:Cl-INH and C3:P and between C3:P and C5b-9 but not between Cls:Cl- 
INH and C5b-9 (Table 3.2). In the RA patients plasma levels of all activation products 
correlated with each other, while in SLE patients levels of Cls:Cl-INH and C3:P 
correlated with those of C5b-9 (Table 3.2).
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Figure 3.2.1: Levels of the multimolecular complement activation complexes in 
plasma of normals, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) 
patients. Solid lines represent the mean of each group.
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Table 3tl, Plasma levels of Cls:Cl-INH, C3:P and C5b-9 (ng/ml) in normals and 
patients with SLE and RA.
G roup C ls :C l-IN H C3:P C5b-9
N orm als mean 16 13 5
median 15 12 5
range 12-40 5-40 3-14
SLE mean 77.8 56 27
median 62 36 25
range 30-265 26-200 9-71
% in normal range 7% 53% 13%
p<0.0001 p<0.0001 p<0.0001*
RA mean 182 68.2 45
(total group) median 68 45 21
range 27-4600 19-710 5-1950
% in normal range 7% 43% 24%
p<0.0001 p<0.0001 p<0.0001*
RA mean 271 90.2 70
(IgM-RF median 102 58 27
positive) range 44-4600 21-710 6-1950
% in normal range 0% 26% 12%
p<0.0001 p<0.0001 p<0.0001*
RA mean 80.8 44.4 18
(IgM-RF median 53 34 17
negative) range 31-2816 20-258 6-51
% in normal range 14% 52% 34%
p<0.0001 p<0.0001 p<0.0001*
(*) Wilcoxon pairs test
TflfrJ.c 3t2.,-L Correlations of the three complement activation complexes in plasma 
samples of normal individuals (n=30) and SLE (n=30) and RA (n=254) by Spearman 
rank correlation.
GROUP C ls:C l-IN H  C ls:C l-IN H  C3:P
versus C3:P versus C5b-9 versus C5b-9
Normals r=0.39 r=-0.14 r=-0.038
p<0.01 NS* p<0.01
RA r=0.44 r=0.49 r=0.62
p<0.0001 p<0.0001 p<0.0001
SLE r=0.16 r=0.5 r=0.75
NS* p<0.001 p<0.0001
(*) not significant
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Table 3.3: Correlations between plasma levels of complement activation complexes 
and the rheumatoid factor isotypes in sero-positive RA patients (Spearman rank 
correlations).
RF Isotype C Is :C l-IN H C3:P C5b-9
IgM-RF p<0.0001 p<0.01 p<0.001
IgG-RF p<0.0001 p<0.001 p<0.0001
IgA-RF p<0.0001 p<0.01 p<0.001
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3.2.4. Correlation of rheumatoid factors with complement activation 
complexes
Division of the RA patients on the basis of IgM-RF sero-positivity, showed that the 
levels of all three activation complexes were significantly higher in the sero-positive 
than in sero-negative (P<0.0001 for all three complement activation complexes, 
Wilcoxon pairs test), compared to the normal controls (Table 3.1).
In those patients who were sero-positive, levels of Cls:Cl-INH, C3:P and C5b-9 
correlated with IgM-RF (p<0.0001, p<0.01 and p<0.001 respectively), IgG-RF 
(p<0.0001, p< 0.001 and p<0.0001 respectively) and IgA-RF (p<0.0001, p< 0.01 and 
p<0.001 respectively) (Table 3.3).
3.2.5. Correlation of the complement activation complexes with ESR
In the total RA group ESR levels correlated with Cls:Cl-INH (r= 0.21, p<0.001) 
and with C5b-9 (r= 0.18, p<0.005). These correlations persisted when the sero­
positive RA group was studied (r=0.306, p<0.001 and r=0.18, p<0.01 respectively), 
but no correlation with ESR was observed in the sero-negative group (Table 3.4).
3.2.6. Levels of complement activation complexes in paired plasma and 
and synovial fluids:
Synovial fluid levels of Cls:Cl-INH, C3:P and C5b-9 were not significantly 
different from those in paired plasma. The synovial fluid level of Cls:Cl-INH and 
C5b-9 correlated with their respective plasma levels (r=0.75, p<0.005 and r= 0.5, 
p<0.0001 respectively, Wlcoxon pairs test, Fig 3.2.2). However, C3:P levels in 
synovial fluid did not correlate with those in plasma (p>0.1).
3.2.7. IgG versus F(ab ' )2 fragment of anti-Cl-INH, anti-P and anti-C9 
as coating antibodies
ELISA plates were coated with whole IgG or the F(ab)2 fragments of the
appropriate trapping antibodies and the levels of Cls:Cl-INH, C3:P and C5b-9 were 
measured in 65 samples. Results were analysed by Wilcoxon pair test and Spearman
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rank correlation. There was no significant difference in the observed mean or rank of 
Cls:Cl-INH, C3:P or C5b-9 levels, when samples were measured using IgG or 
F(ab')2 as coating antibody.
3.2.8. Effect of IgM-RF on the levels of complement activation 
complexes in ELISA
Increasing concentrations of purified IgM-RF (250, 500, and 1000|ig/ml) had no
effect on the levels of formed Cls:Cl-INH, C3:P and C5b-9 measured in EDTA treated
unactivated and activated NHS (Fig 3.2.3)
3.2.9. Correlation between levels of complement activation complexes 
and complement components
Analysis of the correlation between the levels of C3, C4, factor B and Cl-INH as 
measured by nephelometry and levels of Cls:Cl-INH, C3:P and C5b-9, by Spearman 
rank test showed no correlation in SLE patients (Table 3.5). In RA patients Cl-INH 
and factor B correlated with Cls:Cl-INH (r= 0.32, p<0.0001 and r=0.18, p<0.005 
respectively), Cl-INH and factor B correlated with C3:P (r=0.21, p<0.001 and 
r=0.13, p<0.01 respectively) and Cl-INH correlated with C5b-9 (r=0.25, p<0.0001). 
No correlations were observed with C3 or C4 (Table 3.6).
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Table 3.4 Spearman rank correlations of the complement activation 
complexes with ESR in different RA patients.
CAC*
RA Group/Subgroup
RA (All) RA (IgM-RF
sero +ve)
RA (IgM-R 
sero -
C ls :C l- IN H 0.2061 0.3096 -0.0077
(257) (134) (HO)
0.001 0.001 0.5
C3:P 0.1157 0.1469 -0.0433
(223) (135) (107)
0.1 0.1 0.5
C5b-9 0.1826 0.1875 0.0649
(257) (135) (109)
0.005 0.01 0.5
(Number order: Correlation coefficient, variable number, significance)
(*) Complement activation complexes
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Table 3.5 Spearman rank correlations of the complement activation 
complexes with level of complement components in SLE patients.
CAC*
Complement Components 
Cl-IN H  C4 C3 B
C ls:C l-IN H -0.0232 -0.1515 -0.1875 -0.2254
(30) (30) (30) (30)
0.5 0.5 0.1 0.1
C3:P -0.1385 -0.1472 0.0747 -0.1801
(30) (30) (30) (30)
0.5 0.5 0.5 0.1
C5b-9 0.0398 -0.1922 0.0228 -0.1401
(30) (30) (30) (30)
0.5 0.1 0.5 0.5
(Number order: Correlation coefficient, variable number, significance)
(*) Complement activation complexes
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Table 3.6 Spearm an rank  correlations of the complement activation 
complexes with levels of complement components in RA patients.
CAC*
Complement Components 
C l-IN H  C4 C3 B
C ls :C l- IN H 0.3513 -0.0957 0.0855 0.0813
(267) (267) (269) (269)
0.0001 0.1 0.1 0.005
C3:P 0.2079 -0.0536 0.0246 0.1296
(246) (246) (248) (248)
0.001 0.1 0.5 0.1
C5b-9 0.2477 -0.0803 -0.0197 0.0915
(267) (267) (269) (269)
0.001 0.1 0.5 0.1
(Number order: Correlation coefficient, variable number, significance)
(*) Complement activation complexes
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Figure 3.2.3: Effect of IgM-rheumatoid factor on Cls:Cl-INH, C3:P and C5b-9 ELISA 
systems. IgM-RF was added into EDTA-containing IC-activated (•—•), and zymosan- 
activated (a—*) NHS and to buffer (•---•). The level of the multimolecular complement 
activation complexes (ng/ml) were plotted against the RF concentration (pg/ml).
130.
3,3t C O M P L E M E N T  a c t i v a t i o n  b y  i m m u n e  c o m p t f .x f s
3.3.1. Nascent thyroglobubin anti-thyroglobulin IC
a) Effect of IC concentration
The extent of Cl activation, as assessed by the serum level of the Cls:Cl-INH 
complex and C4a, was dependent upon the concentration of IC for all antigen-antibody 
ratios (Fig 3.3.1 A).
The amount of C3 turnover, as assessed by C3a generation was dependent on 
the concentration of IC for all antigen-antibody ratios, with the exception of IC formed 
at 16 times antigen-excess where the highest concentration of IC (500|ig antibody/ml) 
resulted in less C3a generation than was observed at the second highest concentration of 
IC (250pg IgG antibody/ml NHS) (Fig 3.3.1 B right panel). In contrast when turnover 
of C3 was assessed by levels of C3:P complex, although there was evidence of dose 
dependent effect* at antigen-antibody ratios of 16-times antibody-excess, and four and 
16-times antigen-excess, the level of C3:P decreased at the highest IC concentrations 
(Fig 3.3.1 B right panel). In order to explain this finding, the possibility that the C3:P 
assay could detect both the fluid-phase C3b and properdin (± Bb) complex and C3:P 
bound to soluble IC was considered. Thyroglobulin containing IC are relatively 
insoluble and at higher concentrations, a greater proportion would be insoluble. If 
some of the C3:P complex is bound to IC then these would also be precipitated at these 
higher IC concentrations. This point is discussed later (section 3.3.8).
C5 activation as assessed by the formation of C5b-9 complex formation and C5a 
generation was related to IC concentration at antigen-antibody ratios of 4-times and 16- 
times antibody-excess, but did not show any clear dose dependent effect when IC were 
formed at equivalence or in antigen-excess (Fig 3.3.TC).
b) Effect of antigen-antibodv ratio
Cl activation as measured by Cls:Cl-INH generation, occurred most efficiently 
when IC were formed in antibody-excess (particularly at 4-times antibody-excess) and
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at equivalence (Fig 3.3.2 A left panel), while little activation occurred in antigen-excess. 
These results were confirmed by the results of C4a assays, although there was a 
consistent, but unexplained increase in C4a when IC were formed at 16-times antigen- 
excess (Fig 3.2 2 A right panel).
Activation of C3 as shown by C3a formation was again efficient in antibody-excess 
and at equivalence with little C3a generated when IC were formed in antigen-excess 
(Fig 3.3.2 B right panel).
At the two lowest IC concentrations studied, C3:P levels were greatest at 4-times 
antibody-excess and at equivalence and was lower when IC were formed in 16-times 
antibody-excess and in antigen-excess (Fig 3.3.2 B left panel). At the higher 
concentrations of IC, less C3:P was detected at 4-times antibody-excess and at 
equivalence than at the other antigen-antibody ratios (Fig 3.3.2 B left panel). The 
possibility that this lower concentration of C3:P at 4-times antibody-excess and 
equivalence is due to precipitation of IC-bound C3:P is considered later (Section 
3.3.8).
The effect of antigen-antibody ratio on C5 activation as assessed by formation of 
C5a was the same as that seen for Cl activation and C3a generation, with most 
activation occurring when IC were formed at 4-times antibody-excess and least 
activation occurring in antigen-excess (Fig 3.3.2 C). In contrast, the greatest level of 
the C5b-9 complex was produced at 16-times antibody-excess, with very little being 
generated when IC formed at equivalence or in antigen-excess (Fig 3.3.2. C).
c) Role of classical and alternative pathways
When IC were formed in Mg++EGTA-treated serum, no evidence of Cl- 
activation, as assessed by measuring Cls:Cl-INH and C4a levels, was detected.
At all antigen-antibody ratios less C3a was produced in Mg EGTA-treated serum 
than in NHS, but as in NHS, in Mg++EGTA the greatest formation of C3a occurred in 
antibody-excess and at equivalence (Fig 3.3.3 A right panel).
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With lower concentrations of IC (62,5pg IgG/ml and 125qg IgG/ml) the greatest 
amounts of C3:P complex were formed at 4-times antibody-excess and at equivalence, 
but the amount of these complexes which was formed in Mg++EGTA was less than that 
formed in NHS (Fig 3.3.3 A left panel). When the highest concentration of IC was 
studied in Mg++EGTA treated serum there was no clear effect of antigen-antibody ratio 
on C3:P formation (Fig 3.3.4Aleft panel). In this case the amount of C3:P present was 
the same as that formed when IC were formed at equivalence or 4-times antibody- 
excess in normal serum.
C5a generation in the presence of Mg++EGTA was reduced when the IC were 
formed in 16-times antibody-excess, 4-times antibody-excess and equivalence, while in 
IC formed at antigen-excess the C5a generation was similar to that in the presence of 
normal serum (Fig 3.3.4 B right panel). The dose-response studies showed a reduction 
in C5a generation at the higher concentrations of IC (250 and 500|ig IgG antibody/ml 
NHS) (Fig 3.3.3 B right panel).
C5b-9 formation was only reduced very slightly in Mg++EGTA treated serum (Fig 
3.3.3 B, 3.3.4 B left panels).
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Figure 3.3.1 (A. B and C): Effect of of nascent thyroglobulin anti-thyroglobulin IC 
concentration on complement activation. Five antigen-antibody ratios were used, 16-times 
antibody excess (*—a), 4-times antibody excess (*—a), equivalence (■— ■), 4-times 
antigen excess (♦— *) and 16-times antigen excess («— o). (A) Cl activation as assessed by 
generation of Cls:Cl-INH (left panel) and C4a (right panel),(B) C3 activation as assessed by 
C3:P formation (left panel) and C3a generation (right panel) and (C) C5 activation as 
assessed by assembly of C5b-9 (left panel) and C5a (right panel). Bars represent the 
standard error of the mean of three determinations. Anaphylatoxin measurements are the 
mean of duplicate determinations. Concentration of Cls:Cl-INH expressed as ng/ml Cl-INH, 
C3:P as ng/ml C3 and C5b-9 as ng/ml C5.
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Figure 3.3.2 (A. B and C): Effect of antigen-antibody ratio of nascent thyroglobulin 
anti-thyroglobulin IC on complement activation. Four differet IC concentrations were used,
62.5 (♦ -+ ) , 125 ( a—a), 250 (■—«) and 500^tg ( •—•) IgG antibody/ml NHS. (A) Cl 
activation as assessed by generation of Cls:Cl-INH (left panel) and C4a (right panel), (B) 
C3 activation as assessed by C3:P formation (left panel) and C3a generation (right panel) 
and (C) C5 activation as assessed by assembly of C5b-9 (left panel) and C5a (nght panel). 
Bars represent the standard error of the mean of three determinations. Anaphylatoxin 
measurements are the mean of duplicate determinations. Concentration of C ls.C l INH 
expressed as ng/ml Cl-INH, C3:P as ng/ml C3 and C5b-9 as ng/ml C5.
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Figure 3.3.3 (A and B): Role of the classical and alternative pathways on activation of 
C3 and C5 by nascent thyroglobulin anti-thyroglobulin IC at equivalence (dose response 
curves) in the absence (•—•) or the presence (O—O) of MgEGTA. (A) Generation of 
C3:P (left panel) and C3a (right panel). (B) Generation of C5b-9 (left panel) and C5a 
(right panel). Bars represent the standard error of the mean of three determinations. 
Anaphylatoxin measurements are the mean of duplicate determinations. Concentration of 
C3:P expressed as ng/ml C3 and C5b-9 as ng/ml C5.
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Figure 3.3.4 (A and Bti Role of the classical and the alternative pathways on C3 
and C5 activation by nascent thyroglobulin anti-thyroglobulin IC at equivalence (Effect of 
antigen-antibody ratios) at IC dose of 500|ig IgG antibody/ml.in the absence (•—•) or 
the presence (O—O) of MgEGTA. (A) Generation of C3:P (left panel) and C3a (right 
panel). (B) Generation of C5b-9 (left panel) and C5a (right panel). Bars represent the 
standard error of the mean of three determinations. Anaphylatoxin measurements are the 
mean of duplicate determinations. Concentration of C3:P expressed as ng/ml C3 and 
C5b-9 as ng/ml C5.
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3.3.2 Preformed thyroglobulin anti-thyroglobulin IC
a) Effect of IC concentration
Activation of Cl, as assessed by Cls.’Cl-INH and C4a levels was dependent upon 
the concentration of IC for all antigen-antibody ratios (Fig 3.2 5 A).
The amount of C3 turnover, as assessed by C3a generation, was also dependent 
upon the concentration of IC added to the serum (Fig 3.3.5 B right panel). However 
the concentration of C3:P complex was related to the concentration of IC only at the 
extremes of antigen or antibody-excess (16-times antibody-excess and 16-times 
antigen-excess) (Fig 3.3.5 B left panel).
Levels of C5a increased with IC concentration at all antigen-antibody ratios (Fig
3.3.5 C right panel). When IC formed at 16-times and 4-times antibody-excess were 
incubated with serum, the amount of C5b-9 generation was proportional to the 
concentration of IC. There was no clear dose-response relation at the other antigen- 
antibody ratios (Fig 3.3.5 C left panel).
b) Effect of antigen-antibodv ratio
Cl activation, as assessed by Cls:Cl-INH and C4a concentrations, was dependent 
upon antigen-antibody ratio. IC formed at 4-times antibody-excess were the most 
effective activators of Cl while those formed at 4-times antigen-excess and 16-times 
antigen-excess were the least effective, when assessed by Cls:Cl-INH formation (Fig
3.3.6 A left panel). The overall picture was similar when C4a was measured, although, 
in this assay IC formed in 16-times antibody-excess appeared to be about as effective as 
those formed in 4-times antigen-excess and 16-times antigen-excess (Fig 3.3.6 A right 
panel).
C3 activation, as assessed by C3a generation was also dependent upon antigen- 
antibody ratio. IC formed at 4-times antibody-excess and at equivalence were the most
effective (Fig 3.3.6 B right panel).
At the lowest concentration of IC, the generation of C3:P was most efficient with
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IC formed at equivalence or 4-times antibody-excess, but this pattern was lost as the 
concentration of IC was increased (Fig 3.3.6 B left panel). At the two highest IC 
concentrations, the highest levels of C3‘P were produced at the extremes of antibody 
(16-times) and antigen-excess (16-times). This is similar to the pattern observed with 
nascent IC.
C5a generation was most efficient with IC formed at 4-times antibody-excess 
whereas IC formed in antigen-excess were least effective (Fig 3.3.6 C right panel). 
When C5 activation was measured by C5b-9 production, IC formed at 16-times 
antibody-excess were most effective, with the efficiency of activation decreasing as the 
proportion of antigen in the IC increased (Fig 3.3.6 C left panel).
c) Role of classical and alternative pathways
Cl activation did not occur in Mg++EGTA-treated serum.
C3a generation was reduced by approximately 50% at all antigen-antibody ratios in 
the presence of Mg++EGTA (Figs. 3.3.7 B; 3.3.8 B right panels). Similarly, in 
Mg^EGTA-treated serum, levels of the C3:P complex were reduced by 50% for IC 
formed in antigen-excess. In antibody-excess the reduction was less pronounced and 
no reduction was seen at equivalence (Figs. 3.3.7 A; 3.3.8 A left panels).
C5a generation by IC formed at 4-times antibody-excess, 4-times antigen-excess 
and at equivalence was reduced by 30-40% by Mg++EGTA (Figs. 3.3.7 B; 3.3.8 B 
right panels). A reduction of about 25% was found at the higher concentrations of IC 
formed at 4-times antibody-excess, but no reduction was seen at the lower 
concentrations and at this ratio or for any of the ratios seen at 16-times antibody-excess. 
There was little difference or only a small reduction in the amounts of C5b-9 generated 
by IC in antibody-excess in Mg++EGTA-treated serum (Figs. 3.3.7 B; 3.3.8 B left 
panels). IC formed at equivalence or in antigen-excess produced as much C5b-9 in the 
presence of Mg++EGTA as they did in NHS.
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Figure 3.3.5 (A. B and O : Effect of IC concentration of preformed thyroglobulin 
anti-thyroglobulin IC on complement activation at five antigen-antibody ratios, 16-times 
antibody excess (*—*), 4-times antibody excess (*—*), equivalence (■— ■ ), 4-times 
antigen excess («— *) and 16-times antigen excess (o— o). (A) Cl activation as assessed 
by generation of Cls:Cl-INH (left panel) and C4a (right panel),(B) C3 activation as 
assessed by C3:P formation (left panel) and C3a generation (right panel) and (C) C5 
activation as assessed by assembly of C5b-9 (left panel) and C5a (right panel). Bars 
represent the standard error of the mean of three determinations. Anaphylatoxin 
measurements are the mean of duplicate determinations. Concentration of Cls.Cl-INH 
expressed as ng/ml Cl-INH, C3:P as ng/ml C3 and C5b-9 as ng/ml C5.
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Figure 3.3.6 (A. B and C): Effect of antigen-antibody ratio of preformed 
thyroglobulin anti-thyroglobulin IC on complement activation. Four different IC 
concentrations were used, 62.5 (♦— *), 125 ( D °), 250 (■ ■) and 500p.g IgG 
antibody/ml NHS ( • —•). (A) Cl activation as assessed by generation of Cls:Cl-INH 
(left panel) and C4a (right panel)r(B) C3 activation as assessed by C3:P formation (left 
panel) and C3a generation (right panel) and (C) C5 activation as assessed by assembly of 
C5b-9 (left panel) and C5a (right panel). Bars represent the standard error of the mean of 
three determinations. Anaphylatoxin measurements are the mean of duplicate 
determinations. Concentration of Cls:Cl-INH expressed as ng/ml Cl-INH, C3.P as 
ng/ml C3 and C5b-9 as ng/ml C5.
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Figure 3.3.7 (A and B): Role of the classical and the alternative pathways on 
activation of C3 and C5 by preformed thyroglobulin anti-thyroglobulin IC at 4-times 
antibody-excess (effect of IC concentration) in the absence (•—•) or the presence 
(O—O) of Mg++EGTA. (A) Generation of C3:P (left panel) and C3a (right panel). (B) 
Generation of C5b-9 (left panel) and C5a (right panel). Bars represent the standard error 
of the mean of three determinations. Anaphylatoxin measurements are the mean of 
duplicate determinations. Concentration of C3:P expressed as ng/ml C3 and C5b-9 as 
ng/ml C5.
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Figure 3.3.8 (A and B): Role of the classical and the alternative pathways on 
activation of C3 and C5 by preformed thyroglobulin anti-thyroglobulin IC at five antigen- 
antibody ratios (effect of antigen-antibody ratios), at IC dose of 500(ig IgG antibody/ml 
NHS, in the absence (•—•) or the presence (O—O) of Mg++EGTA. (A) Generation of 
C3:P (left panel) and C3a (right panel). (B) Generation of C5b-9 (left panel) and C5a 
(right panel). Bars represent the standard error of the mean of three determinations. 
Anaphylatoxin measurements are the mean of duplicate determinations. Concentration of 
Cls:Cl-INH expressed as ng/ml Cl-INH, C3:P as ng/ml C3 and C5b-9 as ng/ml C5.
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3.3.3. Comparison of complement activation by nascent and preformed 
thyroglobulin IC
As a generalization, IC formed in serum produced more Cl activation than 
preformed IC (Fig 3.3.9). At the extremes of antigen and antibody-excess there was 
either little difference or slightly less Cl activation with preformed IC.
C3a generation was higher with preformed IC than with nascent IC (Fig 3.3.9 B). 
The studies of C3:P complex formation showed that in antigen-excess more generation 
occurred with preformed IC.
Preformed IC at all antigen-antibody ratios produced more C5a than IC which were 
formed in the presence of serum. C5b-9 generation was greater with preformed IC in 
antibody-excess or at equivalence than with IC formed in serum at the same antigen- 
antibody ratio (Fig 3.3.9 C).
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Figure 3.3.9 (A. B and CV. Comparison of complement activation by nascent 
(a—*) and preformed (■— ■) thyroglobulin anti-thyroglobulin IC at 16-times antibody 
excess (A and C) and at equivalence (B). A) Cl activation as assessed by the generation 
of Cls:Cl-INH complex (left panel) and C4a generation (right panel),B) C3 activation as 
assessed by the generation of C3:P complex (left panel) and C3a generation (right panel) 
and C) C5 activation as assessed by the generation of C5b-9 complex (left panel) and 
C5a generation (right panel). Bars represent standard error of the mean 
determinations. Anaphylatoxin measurements are the mean of duplicate determinations. 
Concentration of Cls:Cl-INH expressed as ng/ml Cl-INH, C3:P as ng/ml C3 and C5b- 
9 as ng/ml C5.
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Comparison Q_f C4a and C ls:C l-IN H  as measures o f  Cl a ctiv a tio n
There was a good correlation between levels of C4a and Cls:Cl-INH at all antigen- 
antibody ratios for IC formed in the presence of serum and for preformed IC (Fig 
3.3.10 A). When IC were formed in serum at antigen-excess there appeared to be 
disproportionately more C4a formed than Cls:Cl-INH.
Comparison of C3a and C3:P as measures of C3 convertase activity
There was correlation between the generation of C3:P and C3a at extreme antigen 
and antibody ratios in both nascent and preformed IC. In contrast, with IC formed at 
equivalence or at four times antibody-excess there was no correlation (Fig 3.3.10 B).
Comparison of C5a and C5b-9 as measures of C5 convertase activity
There was a good correlation between the concentration of C5a and C5b-9 at all 
antigen-antibody ratios for IC formed in the presence of serum and for preformed IC 
(Fig 3.3.10C).
When the number of C5a (12kD) molecules generated during complement activation 
by thyroglobulin anti-thyroglobulin IC was compared with the number of C5b 
molecules (178kD) which had been incorporated to the C5b-9 complex, it was found 
that the C5a:C5b ratio was 166±8. This suggests that only a very small proportion of 
C5b molecules are incorporated to the C5b-9 complex when complement is activated by 
IC containing soluble protein antigen.
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Figure 3.3.10 ( A .  B and C): Relationship between the generation of
multimolecular complement activation complexes and anaphylatoxin generation by 
thyroglobulin anti-thyroglobulin IC at five antigen antibody ratios, 16-times antibody 
excess (*—*), 4-times antibody excess a), equivalence (■ ■), 4 times antigen
excess («— ♦) and 16-times antigen excess (*—*). A) Cls:Cl-INH v. C4a by nascent 
IC (left panel) and preformed IC (right panel), B) C3:P v. C3a by nascent IC (left panel) 
and preformed IC (right panel) and C) C5b-9 v. C5a by nascent IC (left panel) and
preformed IC (right panel).
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3.3.4. Nascent BSA anti-BSA IC
a) Effect of IC concentration
IC formed in serum at five different antigen-antibody ratios produced dose 
dependent C l activation as assessed by the serum level of the Cls:Cl-INH complex 
(Fig 3.3.11 A left panel).
Activation of C3, as shown by the generation of the C3:P complex was found to be 
dose-dependent except when higher concentration of ICs were formed at equivalence or 
in antibody-excess (Fig 3.3.11 B left panel). Studies of the cause of this decreased 
concentration of the C3:P complex at the highest IC concentration will be presented in 
section 3.3.7.
Activation of C5, as measured by the generation of the C5b-9 complex was dose- 
dependent when IC were formed in antibody-excess or at equivalence, but when IC 
were formed in antigen-excess the amount of C5b-9 formed was maximal with an 
antibody concentration of 12 5pg IgG /ml (Fig 3.3.11 C left panel).
b) Effect of antigen-antibodv ratio
Cl activation occurred most efficiently with IC formed at equivalence, followed by 
those formed at 4-times antibody-excess (Fig 3.3.11 A right panel). IC formed at 16- 
times antibody-excess or in antigen-excess produced far-less Cl activation.
At the two lowest IC concentrations, C3 activation was greatest at equivalence, with 
far less activation occurring when IC were formed in either antigen or antibody-excess 
(Fig 3.3.11 B). However, when the two highest concentrations of IC were used, the 
concentration of C3:P at equivalence was reduced markedly (Fig 3.3.11 B).
C5 activation was greatest in antibody-excess (Fig 3.3.11 C right panel).
c) Role of the classical and al tern a rive pathways
Cl activation did not occur in serum treated with Mg++EGTA. C3 activation was 
markedly reduced at all antigen-antibody ratios when classical pathway activation had
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been blocked by Mg++EGTA (Fig 3.3.12 A, B). In contrast C5b-9 generation was 
almost identical in NHS and in Mg++EGTA-treated serum at all antigen-antibody 
ratios.(Fig 3.3.12 A, B).
3.3.5. Preform ed BSA anti-BSA IC
Effect of IC concentration
The extent of C l activation was dependent on IC concentration at all antigen- 
antibody ratios (Fig 3.3.13 A left panel).
In contrast the amount of C3:P complex formed did not show any clear relationship 
to the concentration of IC (Fig 3.3.13 B left panel).
A dose-dependent increase in the formation of the C5b-9 complex was observed 
with IC formed in antibody-excess and equivalence (Fig 3.3.13 C left panel), but the 
effect of IC concentration was not so obvious with IC formed at 4 and 16-times 
antigen-excess (Fig 3.3.13 C left panel).
b) Effect of antigen-antibodv ratio
Activation of Cl was pronounced with IC formed at equivalence, but was much 
less marked when IC were formed in either antigen or antibody-excess (Fig 3.3.13 A 
right panel).
The concentration of the C3:P complex at different antigen-antibody ratios was 
dependent upon the IC concentration. At the lowest concentration (62.5|ig 
antibody/ml) C3:P formation was greatest at equivalence and least at 16-times antigen- 
excess (Fig 3.3.13 B right panel). At higher IC concentrations less C3:P was detected 
at equivalence than when IC were formed in either antigen or antibody-excess (Fig
3.3.13 B right panel).
C5b-9 generation was greatest in antibody-excess and least in antigen-excess (Fig
3.3.13 .C right panel).
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c) Role of classical and alternative pathways
Cl activation did not occur in Mg++EGTA-treated serum.
In most cases, the concentrations of C3:P complex in Mg++EGT A-treated serum 
were lower than those in NHS (Fig 3.3.14 A and B). At the three lower IC 
concentrations, the level of C5b-9 generated in Mg"*”*"EGTA-treated serum were almost 
the same as those produced in NHS (Fig 3.3.14 A and B). At the higher concentration, 
the C5b-9 concentration was slightly lower in Mg++ EGT A-treated serum.
3.3.6. Comparison of complement activation by nascent and preformed 
BSA anti-BSA IC
Nascent IC at all antigen-antibody ratios (Fig 3.3.11 A) produced more Cl 
activation than preformed IC (Fig 3.3.13 A).
Production of the C3:P complex was also greater with nascent IC (Fig 3.3. 11 B 
and 3.3.13 B), but C5b-9 generation was greater with preformed IC (Fig 3.3.11 C and
3.3.13 C).
There was little difference in the effect of Mg++EGTA on the generation of 
C5b-9 by nascent or preformed IC.
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Figure 3.3.11 (A. B and O : Complement activation by nascent BSA anti-BSA IC. 
(A) Cl activation as assessed by Cls:Cl-INH generation, (B) C3 activation as assessed 
by C3:P complex formation and (C) C5 activation as assessed by the formation of C5b-9 
complex. Left panel represents the effect of IC concentration for the five antigen- 
antibody ratios; 16-times antibody-excess (*—*), 4-times antibody-excess 
equivalence (■— ■ ), 4-times antigen-excess (♦ ♦) and 16-times antigen-excess (o o). 
The right hand panels represent the effect of antigen-antibody ratio at four IC 
concentrations: 62.5 («—♦), 125 ( w ) ,  250 (— ■) and 500qg IgG antibody/ml 
NHS (•— •). Concentration of Cls:Cl-INH expressed as ng/ml Cl-INH, C3:P as 
ng/ml C3 and C5b-9 as ng/ml C5. Each point represents the mean of duplicate
determinations.
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Figure 3.3.12 (A and B): Complement activation by nascent BSA anti-BSA IC in the absence 
(•—•) or the presence (O—O) of Mg++EGTA to investigate the role of the classical ancHWe 
alternative pathways. A) Effect of IC concentration: C3:P generation (left) and C5b-9 formation 
(right) by IC at 16-times antibody-excess. B) Effect of antigen-antyibody ratio: C3:P generation 
(left) and C5b-9 formation (right) at an IC concentration of 500 |ig IgG antibody/ml NB5 
Concentration of C3:P expressed as ng/ml C3 and C5b-9 as ng/ml C5. Each point represents-fVt 
mean of duplicate determinations.
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Figure 3.3.13 (A. R and C): Complement activation by preformed BSA anti-BSA 
IC. (A) Cl activation as assessed by Cls:Cl-INH generation (B) C3 activation as 
assessed by C3:P complex formation and (C) C5 activation as assessed by the formation 
of C5b-9 complex. Left hand panel represent the effect of IC concentrations for IC at 
five antigen-antibody ratios; 16-times antibody-excess (*— ), 4-times antibody-excess 
), equivalence ( — ), 4-times antigen-excess ( ~ )  and 16-times antigen-excess 
(— »). The right panels show the effect of antigen-antibody ratio at four IC doses. 
62.5 ( ~ ) ,  125 ( - a ) ,  250 ( * - )  and 500pg IgG antibody/ml NHS ( ~  . 
Concentration of Cls:Cl-INH expressed as ng/ml Cl-INH. C3:P as ng/ml C3 and C5b- 
9 as ng/ml C5. Each point represents the mean of duplicate determinations.
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Figure 3.3,14 (A and BE Complement activation by preformed BSA anti-BSA IC 
in the absence ( •—•) or the presence (O—O) of Mg++EGTA to study the roles of the 
classical and the alternative pathways. A) Effect of IC concentration: C3:P generation 
(left) and C5b-9 formation (right) by IC at 16-times antibody-excess. B) Effect of 
antigen-antibody ratio: C3:P generation (left) and C5b-9 formation (right) at an IC 
concentration of 500 jig IgG antibody/ml NHS. Concentration of Cls:Cl-INH 
expressed as ng/ml Cl-INH, C3:P as ng/ml C3 and C5b-9 as ng/ml C5. Each point 
represents the mean of duplicate determinations.
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3.3.7 Comparison of complement activation by thyroglobulin anti- 
thyroglobulin IC and BSA anti-BSA IC
Cl activation occurred more efficiently with thyroglobulin anti-thyroglobulin IC 
formed in 4-times antibody-excess whereas in the BSA anti-BSA system IC formed at 
equivalence were most effective. For both types of IC, Cl activation was greater with 
nascent IC than with preformed IC (Fig 3.3.2, 5 A and 3.3.11, 13 A).
Generation of the C3:P complex was clearly most effective with nascent BSA anti- 
BSA IC at equivalence at the three lower IC concentrations. In contrast with nascent 
thyroglobulin anti-thyroglobulin IC there were two distinct differences: 1) At the two 
lower IC concentrations IC formed at 4-times antibody-excess stimulated the production 
of almost as much C3:P as IC formed at equivalence, 2) At higher IC concentration less 
C3:P was formed at 4-times antibody-excess and at equivalence than at other antigen- 
antibody ratios (Fig 3.3.2 B and 3.3.11 B).
The patterns of C3:P generation were similar when both types of IC were 
preformed at all antigen-antibody ratios. However, greater levels of C3:P were 
produced with thyroglobulin anti-thyroglobulin IC (Fig: 3.3.5 B and 3.3.13 B).
C5b-9 complex formation was greater when both types of IC were formed in 
antibody-excess, and with preformed IC rather than with nascent IC. Thyroglobulin 
anti-thyroglobulin IC produced more C5b-9 than BSA anti-BSA IC (Fig 3.3.2, 5 C and 
3.3.11, 13 C). C5b-9 formation was not significantly reduced when either type of IC 
was formed in Mg++EGTA (Fig 3.2.4 B, 3.3.8 B.and 3.3.12 B, 3.3.14 B right 
panel.).
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3.3.8. Investigation into the reduced C3:P concentrations
Concentrations of C3:P were reduced when nascent thyroglobulin anti- 
thyroglobulin IC were formed at equivalence and when nascent BSA anti-BSA IC were 
formed at equivalence or at 4-times antigen or 4-times antibody-excess.
a) Measurement of C3:P levels was undertaken before and after centrifugation 
(Beckman Microfuge lOOOOrpm for 5 minutes) at room temperature, in order to 
investigate the possibility that at least some of the C3:P was bound to IC, and if these 
IC were insoluble, bound C3:P complexes would co-sediment and not be detected in 
the assay. However, the levels of C3:P were the same in centrifuged and non­
centrifuged samples (Fig 3.3.15).
b) This problem was investigated further by measuring the solubility of nascent 
thyroglobulin anti-thyroglobulin IC and BSA anti-BSA IC after incubation in serum for 
30 minutes at 37° C. The results of the experiment showed that nascent thyroglobulin 
anti-thyroglobulin IC were extremely insoluble at equivalence or at 4-times antigen or 
4-times antibody-excess (Fig 3.3.16 A, B left panel) whereas C3:P levels were only 
markedly reduced at equivalence. In contrast all nascent BSA anti-BSA IC, with the 
exception of a small proportion of those formed in 16-times antibody-excess, remained 
soluble (Fig 3.3.16 A, B right panel), while C3:P levels were markedly reduced when 
IC were formed at equivalence or in 4-times antigen or 4-times antibody-excess.
Likewise the pattern of solubilisation of preformed thyroglobulin anti-thyroglobulin 
and BSA anti-BSA IC (Fig 3.3.17 A, B) were not related to the pattern of C3:P 
formation with either types of preformed IC.
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Figure: 3.3.15 (A and BE Relationship between C3:P levels and insolubility of IC, 
as detected by ELISA, GjiP was generated during complement activation by (A) nascent 
thyroglobulin anti-thyroglobulin IC and (B) nascent BSA anti-BSA IC at five antigen- 
antibody ratios at an IC dose of 500|ig IgG antibody/ml NHS in centrifuged ( •  •) and 
uncentrifuged (■— ■) samples. Concentration of C3:P expressed as ng/ml C3. Each 
point represents the mean of duplicate determinations.
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Figure 3.3.16 (A and B): Solubility of nascent thyroglobulin anti-thyroglobulin IC 
(left) and nascent BSA anti-BSA IC (right) A) Effect of IC concentration at five antigen- 
antibody ratios, 16-times antibody excess (*—*), 4-times antibody excess (a ^), 
equivalence (■— ■ ), 4-times antigen excess («— *) and 16-times antigen excess («— *) 
and B) Effect of antigen antibody ratio on the solubility of nascent thyroglobulin anti- 
thyroglobulin IC (left) and nascent BSA anti-BSA IC (right) at four IC dose: 62.5 
(♦—♦), 125 ( c m ), 250 (■—■) and 500jJ.g (•—•) IgG antibody/ml NHS.
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Figure 3.3.17 (A and BE Solubility of preformed thyroglobulin anti-thyroglobulin 
IC (left) and preformed BSA anti-BSA IC (right) A) Effect of IC concentration at five 
antigen-antibody ratios: 16-times antibody excess (*—*), 4-times antibody excess 
(*—*), equivalence (■— ■ ), 4-times antigen excess («— ♦) and 16-times antigen excess 
(o— o) and B) Effect of antigen antibody ratio on the solubility of nascent thyroglobulin 
anti-thyroglobulin IC (left) and nascent BSA anti-BSA IC (right) in four IC doses 62.5 
(♦— *), 125 ( a—□), 250 (■—■) and 500qg (•—•) IgG antibody/ml NHS.
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3.4. KINETICS OF COMPLEMENT ACTIVATION BY Tr 
3.4.1 Nascent thyroglobulin anti-thyroglobulin IC
ai Cl activation
In the experiments performed at 37°C, increased levels of the Cls:Cl-INH 
complex were detected within one minute of the addition of antigen and antibody to 
serum (Fig 3.4.1 A left panel). For IC formed at 4-times antibody-excess the level of 
Cls.'Cl-INH complex increased to reach a plateau after 15 minutes, whereas the plateau 
was reached somewhat earlier with IC formed at all other antigen-antibody ratios. In 
the case of IC formed at 16-times antibody-excess the level of Cls:Cl-INH was 
maximal within 2.5 minutes, suggesting that at extremes of antibody-excess, Cl 
activation is completed extremely rapidly. C4a generation was studied at only 3 
antigen-antibody ratios (Fig 3.4.1 A right panel.). After an extremely rapid increase in 
C4a levels, the maximal rate of increase and highest levels were achieved between 10 
and 15 minutes. Disproportionately more C4a than Cls:Cl-INH complex was 
generated at 4-times antigen-excess.
Comparison of the results of the two assays of Cl activation showed that C4a 
levels tended to rise earlier than those of Cls:Cl-INH (Fig 3.4.1. A).
When Cl activation was studied at the three different temperatures it was shown 
that the rate and extent of formation of the Cls:Cl-INH complex were lower at 30°C 
and 20°C (Fig 3.4.2 A). Indeed very little Cl activation occurred at 20°C.
b) C3 activation
In the experiments performed at 37° C, levels of C3:P complex increased from time 
0, with all IC except for those formed at 16-times antigen-excess, and reached a peak 
after 15 minutes (Fig 3.4.1 B left panel.). For IC formed at 16-times antigen-excess 
there appeared to be a lag period of 5 minutes before the C3:P level increased. At 30 
minutes C3:P concentrations were similar for IC formed at all antigen-antibody ratios.
In contrast, there was a marked dependence on antigen-antibody ratios with the 
initial rate of C3a generation and the final concentration was greater for IC formed at
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equivalence and 4-times antibody-excess than for those formed at 4-times antigen- 
excess (Fig 3.4.1 B right panel). When IC were formed in antibody-excess or in 
antigen-excess, the peak concentration of C3a was produced within 7.5 minutes 
whereas when IC were formed at equivalence, the peak level was not reached until after 
15 minutes (Fig 3.4.1 B right panel).
C3.P complex formation in response to the formation of IC in serum, was found to 
be temperature dependent. In contrast to the experiments described above, in this 
experiment when IC were incubated at 37°C, there appeared to be two phases of C3:P 
complex formation (Fig 3.4.2 B left panel). For all antigen-antibody ratios there was 
phase with a slow rate of formation which was followed by a second phase when C3:P 
complex levels increased rapidly. When IC were formed at 16-times antigen-excess 
there was a clear lag phase of 7.5 minutes before levels of the C3:P complex began to 
rise. When IC were incubated at 30°C, the initial-phase of slowly increasing C3:P 
levels was prolonged and the final concentration of the C3:P complex was reduced. 
When the experiments were performed at 20° C little, or no C3:P complex was formed 
(Fig 3.4.2 B left panel).
c) C5 activation
There was a lag-period of 7.5 minutes before levels of the C5b-9 complex were 
detected (Fig 3.4.l.C left panel). When IC were formed at equivalence or in antigen- 
excess, the concentration of the C5b-9 complex reached their maximum after 15 
minutes whereas when IC were formed in antibody-excess the level continued to rise 
throughout the 30 minutes incubation period (Fig 3.4.1. C left panel).
In contrast to C5b-9 formation, C5a levels increased immediately after the 
formation of IC (Fig 3.4.1. C right panel), and levels were maximal within 10 minutes 
at all antigen-antibody ratios studied. Although the peak level of C5a was higher for IC 
formed at 4-times antibody-excess than those formed at equivalence, the difference 
between the levels was far less than the difference in C5b-9 complex levels formed at
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these two antigen-antibody ratios. IC formed at 4-times antigen-excess resulted in the 
generation of far lower levels of C5a than with IC formed at the other two antigen- 
antibody ratios. Levels of C5b-9 complex were reduced when IC were formed at 30°C 
and the lag-phase tended to be longer than when IC were formed at 37°C (Fig 3.4.2 C 
left panel). When the incubation temperature was reduced to 20°C, levels of C5b-9 
were even lower and in antigen-excess virtually no C5b-9 complexes were formed.
d) Role of classical and alternative pathways
Cls:Cl-INH complexes and C4a were not formed in Mg44EGTA-treated serum.
A pronounced lag-phase prior to the formation of the C3:P complex occurred when 
IC at all 5 antigen-antibody ratios were formed in serum containing Mg44EGTA. 
Furthermore the rate of formation and the final concentration of the C3:P complex were 
reduced under these conditions. When IC were formed in Mg4"1" EGT A-treated serum at 
30° C or 20° C, very little C3:P complex was formed (Fig 3.4.2 B left).
The rate and extent of C3a generation was also reduced when IC were formed in 
Mg44 EGT A-treated serum. The reduction was most marked for IC formed at 
equivalence (Fig 3.4.2 B right panel).
The lag-phase for C5b-9 complex formation was the same in normal serum as in 
Mg44 EGTA-treated serum (Fig 3.4.2 C left). However, the level of C5b-9 was 
slightly higher in normal serum than in Mg44 EGT A-treated serum. In contrast, the 
lag-phase was not apparent when C5a generation was studied in antibody-excess or at 
equivalence (Fig 3.4.2 C right panel), while in antigen-excess there was a lag-phase.
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Figure 3.4.1 (A. B and C): Kinetics of complement activation by nascent
thyroglobulin anti-thyroglobulin IC: (A) Cl activation as assessed by Cls:Cl-INH complex 
(left) and C4a (right), (B) C3 activation as assessed by C3:P complex (left) and C3a (right) 
and (C) C5 activation as assessed by C5b-9 complex (left) and C5a (right) at five antigen- 
antibody ratios at 37°C, 16-times antibody-excess (*—*), 4-times antibody-excess (*— &), 
equivalence (■— ■), 4-times antigen-excess (♦— *) and 16-times antigen-excess (o— ^). 
Concentration of IC used was 250|ig IgG antibody/ml serum . Each point represents the 
mean of duplicate determinations.
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Figure 3.4.2TA. B and C): Effect of incubation temperature on complement activation 
by nascent thyroglobulin anti-thyroglobulin IC at 4-times antibody-excess, in the absence 
(solid symbols) or the presence (empty symbols) of Mg++EGTA (A) Cl activation as 
assessed by Cls:Cl-INH, (B) C3 activation as assessed by C3:P complex and C3a and (C) 
C5 activation as assessed by C5b-9 and C5a. The incubation temperatures were 37°C 
(a—a), 30°C («— *) and 20°C .(#—•). Each point represents the mean of duplicate 
determinations.
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3.4.2. Preformed thyroglobulin anti-thyroglobulin IC
a) C l activation
Levels of the Cls:Cl-INH complex rose rapidly when preformed IC formed at 4- 
times antibody-excess and at equivalence were incubated in serum (Fig 3.4.3 A left 
panel). For IC formed at equivalence the peak level was reached after 2.5 minutes 
whereas for IC formed at 4-times antibody-excess the rate of increase slowed after 0.5 
minutes to reach a maximum at 10 minutes. In contrast to the rapid increase in Cls.C l- 
INH levels seen with IC formed in antibody-excess or at equivalence, a much slower 
rise in Cls:Cl-IN H  levels was seen with IC formed at 4-times antigen-excess. 
Maximum levels were reached after 7.5 minutes (Fig 3.4.3 A left panel).
Levels of C4a also rose rapidly and maximal levels were achieved between 5 and 10 
minutes. The generation of C4a was proportionally similar to that of Cls:Cl-INH 
complex (Fig 3.4.3 A right panel).
b) C3 activation
Serum levels of the C3:P complex increased rapidly when preformed IC were 
incubated with serum. When IC were formed at equivalence the highest level of the 
C3:P complex was reached within 2.5 minutes, whereas when IC were formed at either 
4-times antibody-excess or 4-times antigen-excess, the rate of increase slowed after 1 
minute to reach their maximum levels between 7.5 and 10 minutes (Fig 3.4.3 B left 
panel).
Serum levels of C3a rose rapidly on exposure to IC, with maximum levels being 
achieved by 5 minutes for IC formed at equivalence or 4-times antibody-excess (Fig 
3.4.3 B right panel). In contrast, when IC were formed at 4-times antigen-excess, the 
rate of increase was slower and the maximum concentration was much lower than those 
formed with IC formed at the two other antigen-antibody ratios (Fig 3.4.3 B right 
panel).
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c) C5 activation :
Within 30 seconds of the onset of the incubation, levels of C5b-9 increased rapidly 
for IC formed at 4-times antibody-excess and at equivalence. This phase was followed 
by a second phase in which the level of C5b-9 complex increased more slowly (up to 
10 minutes for IC formed at 4-times antibody-excess and up to 7.5 minutes for IC 
formed at equivalence). Levels of C5b-9 were much lower when IC formed at 4-times 
antigen-excess were incubated in serum. In this case the levels increased slowly from 
time 0. The rate of increase was so small that it is difficult to say whether a significant 
increase in C5b-9 occurred between 15 and 30 minutes.(Fig 3.4.3 C left panel).
When IC formed at 4-times antibody-excess were studied, the C5a levels reached 
its peak after 10 minutes, whereas when IC were formed at equivalence the level of C5a 
continued to rise throughout the 30 minutes incubation period (Fig 3.4.3 C right panel). 
With IC formed at 4-times antigen-excess, very little C5a was formed and the rate of 
increase was extremely low (Fig 3.4.3 C right panel).
d) Role of classical and alternative pathways:
Formation of Cls:Cl-INH complex and C4a did not occur in Mg++EGTA-treated 
serum.
Formation of C3:P complex was delayed when IC were incubated with 
Mg'1-1" EGT A-treated serum. When the IC were formed at 4-times antigen-excess, the 
concentration of C3:P complex was much lower in Mg++EGT A-treated serum than in 
NHS (Fig 3.4.4 A left). The rate of formation of C3a was markedly lower in 
Mg** EGT A-treated serum than in normal serum, particularly when IC were formed at 
4-times antibody-excess and at equivalence (Fig 3.4.4 A right). Far less C3a was 
formed when IC were formed at 4-times antigen-excess, making it difficult to conclude 
that the rate of formation of C3a was lower in Mg++EGT A-treated serum.
For IC formed at 4-times antibody-excess or at equivalence, the rate of formation of 
the C5b-9 complex occurred in two phases, an initial rapid phase followed by a slower 
secondary phase. In Mg++EGTA these rates were similar to those in normal serum
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(Fig 3.4.4 B left panel), although the amount of C5b-9 formed during both phases was 
lower. When IC were formed at 4-times antigen-excess, very little C5b-9 complex was 
formed, and Mg++EGTA did not appear to influence its rate of formation or the amount 
formed. The rate of C5a generation was lower in the presence of Mg++EGTA at all 
three antigen-antibody ratios. In 4-times antibody-excess and equivalence the C5a 
levels continued to rise throughout the 30 minutes incubation period (Fig 3.4.4 B right 
panel) whereas when IC were formed in 4-times antigen-excess very little C5a was 
formed.
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F i e u r e  3 .4 .3  (A.  B and C): Kinetics of complement activation by preformed
thyroglobulin anti-thyroglobulin IC at three antigen-antibody ratios, (A) Cl activation as 
assessed by Cls:Cl-INH complex (left) and C4a (right), (B) C3 activation as assessed by 
the generation of C3:P complex (left) and C3a (right) and (C) C5 activation as assessed by 
the generation of C5b-9 complex (left) and C5a (right), at 37°C: 4-times antibody-excess 
(A—A), equivalence (■—■) and 4-times antigen-excess (•*— ♦). Concentration of IC used 
was 250p.g IgG antibody/ml serum. Each point represents the mean of duplicate 
determinations.
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Figure 3.4.4 (A and B); Role of classical and alternative pathways on the kinetics of 
complement activation by preformed thyroglobulin anti-thyroglobulin IC at an antigen- 
antibody ratio of 4-times-antibody-excess. (A) C3 activation as assessed by the generation 
of C3:P complex (left panel) and C3a (right) and (B) C5 activation as assessed by the 
generation of C5b-9 complex (left panel) and C5a (right). The incubation temperature was 
37°C and the experiment was performed in the absence (•—•) or the presence (O—O) of 
Mg++EGTA. Each point represents the mean of duplicate determinations.
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3.4.3. Comparison of kinetics of complement activation by nascent and 
preformed thyroglobulin anti-thyroglobulin IC
a) Cl activation
The rate of formation of Cls:Cl-INH complex was slower when nascent IC 
formed in 4-times antibody-excess were studied. However the level of Cls:Cl-INH 
complex reached a plateau after 2.5 minutes with preformed IC whereas the level 
increased for 15 minutes to a far higher level with nascent IC (Fig 3.4.5 A left panel).
b) C3 activation
The initial rate of formation of the C3:P complex was faster for preformed IC than 
for nascent IC, although the final concentration of C3:P complex was higher for nascent 
IC (Fig 3.4.5 B left panel). In the presence of Mg++EGTA the same pattern was seen 
although there was a distinct lag-phase of 1 minute for preformed IC and 7.5 minutes 
for nascent IC (Fig 3.4.5 B left panel).
The initial rates of formation of C3a with preformed IC were faster than those with 
nascent IC at 4-times antibody-excess and at equivalence, whereas when IC were 
formed at 4-times antigen-excess, the initial rate of C3a production for nascent and 
preformed IC was similar (Fig 3.4.5 B right panel). In the presence of EGTA both the 
rate and extent of C3a production were reduced. The rate and extent of C3a formation 
for IC in antibody-excess or antigen-excess was the same in normal and Mg++EGTA- 
treated serum (Fig 3.4.5 B right panel). In contrast, when IC were formed at 
equivalence, Mg++EGTA appeared to produce a somewhat greater reduction on C3a 
formation by nascent IC (Fig 3.4.5 B right panel).
c) C5 activation
C5b-9 formation occurred almost immediately for preformed IC formed at 
equivalence or in antibody-excess. Whereas a significant delay was observed with 
nascent IC. In the presence of Mg++EGTA, C5b-9 formation by preformed IC was
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reduced, whereas little effect was observed on C5b-9 formation by nascent IC (Fig
3.4.5 C left panel).
C5a was formed more rapidly and to a greater extent when preformed IC at 4-times 
antibody-excess and at equivalence were incubated with serum. Mg++EGTA reduced 
the rate of C5a production by both types of IC (Fig 3.4.5 C right panel). At 4-times 
antigen-excess neither preformed nor nascent IC stimulated the production of much C5a 
and Mg++EGTA had no effect on this.
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Figure 3.4.5 (A. B and C): Comparison of kinetics of complement activation between 
nascent thyroglobulin anti-thyroglobulin IC (<*—*) and preformed thyroglobulin anti- 
thyroglobulin IC (■— ■) at an antigen-antibody ratio of 4-times antibody-excess in the 
presence (empty symbols) or the absence (solid symbols) of Mg^EGTA (A) Cl activation 
as assessed by the generation of Cls:Cl-INH complex (left panel) and C4a (right panel),
(B) C3 activation as assessed by the generation of C3:P complex (left panel) and C3a (right 
panel) and (C) C5 activation as assessed by the generation of C5b-9 complex (left panel) 
and C5a (right panel). Incubation temperature 37°C. Concentration of IC was 250p.g IgG 
antibody/ml serum. Each point represents the mean of duplicate determinations.
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3.4.4. Nascent BSA anti-BSA IC
a) Cl activation
Increased levels of Cls:Cl-INH complex were detected within 1 minute of 
formation of the IC (Fig 3.4.6 A). When IC were formed at 4-times antibody-excess 
levels of Cls:Cl-INH complex continued to rise rapidly over the 30 minutes whereas 
when IC were formed at equivalence or 4-times antigen-excess, the rate of increase fell 
markedly after 2.5 minutes.
b) C3 activation
The rates of C3:P generation were virtually identical at all three antigen-antibody 
ratios studied (Fig 3.4.6 B left panel). There was no lag-phase prior to the appearance 
of the C3:P complex and the maximum levels were achieved after 15 minutes. In 
contrast, antigen-antibody ratio had a pronounced influence on the rate and extent of 
formation of C3a. For IC formed at equivalence or 4-times antibody-excess, there was 
an initial phase during which C3a levels increased slowly, followed by a second phase 
in which levels increased more rapidly. For IC formed at equivalence this second phase 
of C3a generation was faster and peak level was higher and was reached by 7.5 minutes 
(Fig 3.4.6 B right panel). The peak C3a level was reached after 15 minutes when IC 
were formed at 4-times antibody-excess. When 1C were formed at 4-times antigen- 
excess little C3a was formed and the rate of formation was low.
c) C5 activation
Very little C5b-9 complex was formed when nascent BSA anti-BSA IC were 
incubated with serum (Fig 3.4.6 C). The level generated during incubation with IC 
formed at 4-times antibody-excess and at equivalence was maximal within 0.5-1 
minutes, whereas the rate of increase was lower for IC formed at 4-times antigen- 
excess, where the maximum level was achieved after 15 minutes.
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d) The role of the classical and alternative pathways
Cls:Cl-INH complexes were not formed in Mg++EGTA-treated serum.
At all three antigen-antibody ratios studied, the rate of increase and the peak level of 
the C3:P complex was reduced in Mg++EGTA-treated serum (Fig 3.4.7 A).
C5b-9 formation was not altered when IC prepared at 4-times antigen-excess or at 
equivalence were formed in Mg++EGTA-treated serum (Fig 3.4.7 B). However, when 
IC prepared at 4-times antibody-excess both the rate of the formation and the final 
concentration of C5b-9 complex were reduced by Mg++EGTA.
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Figure 3.4.6 fA. B and C): Kinetics of Complement activation by nascent BSA anti- 
BSA IC, (A) Cl activation as assessed by Cls:Cl-INH complex, (B) C3 activation as 
assessed by C3:P complex (left) and C3a (right) and (C) C5 activation as assessed by C5b- 
9 complex. Three antigen-antibody ratios were used, 4-times antibody-excess (*— &), 
equivalence (■— ■) and 4-times antigen-excess («— ♦). The concentration of IC was 
250|ig IgG antibody/ml serum. Incubation temperature was 37°C. Each point represents 
the mean of duplicate determinations.
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Figure 3.4.7 (A and B): Role of classical and alternative pathways on the kinetics of 
complement activation by nascent BSA anti-BSA IC formed at equivalence. (A) C3 
activation as assessed by the generation of C3:P complex and (B) C5 activation as assessed 
by the generation of C5b-9 complex. The incubation temperature was 37°C and the 
experiment was performed in the absence (•—•) or the presence (O—O) of Mg++EGTA. 
The concentration of IC used was 250fig IgG antibody/ml serum. Each point represents the 
mean of duplicate determinations.
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3.4.5 Preform ed BSA anti-BSA IC
a) Cl activation
Very low levels of Cls:Cl-INH complex were formed at all three antigen-antibody 
ratios studied. The lowest levels were produced by IC formed at 4-times antibody- 
excess. A small increase occurred within 1 minute for IC formed at 4-times antibody- 
excess or at equivalence (Fig 3.4.8 A). There also appeared to be a 5 minutes period 
while levels of Cls:Cl-INH increased slowly when using IC formed at 4-times 
antigen-excess.
b) C3 activation
IC formed at 4-times antigen-excess produced the fastest rate of increase in levels of 
the C3:P complex and the plateau level was reached by 5 minutes. In contrast, the rate 
of increase for IC formed at equivalence and 4-times antibody-excess were somewhat 
slower and peak levels occurred after 15 minutes (Fig 3.4.8 B left panel). The rate of 
increase of C3a was greater with IC formed at equivalence (Fig 3.4.8 B right panel). 
The maximum levels of C3a were reached after 15 minutes for IC formed at 4-times 
antibody-excess and at equivalence, and after 5 minutes for IC formed at 4-times 
antigen-excess.
c) C5 activation
When IC were formed at 4-times antibody-excess the level of C5b-9 complex 
increased rapidly. The rate of increase was slightly less for IC formed at equivalence. 
The peak levels were reached after 15 minutes for IC at 4-times antibody-excess and at 
equivalence (Fig 3.4.8 C). The rate and extent of formation of C5b-9 were both much 
lower when IC were formed at 4-times antigen-excess.
d) Role of the classical and alternative pathways
The Cls:Cl-INH complex was not formed in Mg++EGTA-treated serum.
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When IC were prepared at 4-times antibody-excess, the initial rate of production of 
C3:P complex was probably identical in normal and Mg++EGTA-treated serum. 
However, the peak level, which was lower in the presence of Mg++EGTA, was 
reached within 5 minutes, whereas in normal serum it was reached after 15 minutes 
(Fig 3.4.9 A). When IC were formed at equivalence or at 4-times antigen-excess, the 
rate of C3:P complex formation was reduced by Mg++EGTA. The final concentration 
of C3:P complex for IC prepared at equivalence was the same in normal and 
Mg^EGTA-treated serum. However, Mg++EGTA reduced the concentration of C3:P 
formed in response to IC prepared at 4-times antigen-excess.
The initial rate of formation and final concentration of the C5b-9 complex were 
reduced in the presence of Mg++EGTA at all antigen-antibody ratios (Fig 3.4.9 B).
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3.4.6. Com parison of complement activation by preform ed and nascent 
BSA anti-BSA IC
a) Cl activation
The rate and extent of production of the Cls:Cl-INH complex were greater for 
nascent than for preformed IC (Fig 3.4.6 A, Fig 3.4.8 A). C4a levels were not 
measured for BSA IC.
b) C3 activation
The rate and extent of formation of the C3:P complex were greater for nascent than 
for preformed IC (Fig 3.4.10 B left panel). On the contrary, the rate and extent of C3a 
formation were greater for preformed than for nascent IC (Fig 3.4.10 B right panel).
c) C5 activation
After a short initial increase (0.5 minutes) in the level of C5b-9 with both types of 
IC, the level did not increase further with nascent IC, whereas with preformed IC the 
concentration increased slowly up to 15 minutes (Fig 3.4.10 C).
150-
50-
0 5 10 15 20 25 30
TIME(mins)
3000-1
100i
50-
1000 - o
25-
0 5 10 15 20 25 30 15 20
Ti meCmins)(B)
200 i
100  -
50-
0 5 10 15 20 25 30
TIME(mins) ( C )
Figure 3.4.10 (A. B and CV: Comparison of kinetics of complement activation 
between nascent BSA anti-BSA IC ( *—*) and preformed BSA anti-BSA IC (■—■ ) at an 
antigen:antibody ratio of 4-times antibody-excess, (A) Cl activation as assessed by the 
generation of Cls:Cl-INH complex, (B) C3 activation as assessed by C3:P complex and 
C3a formation and (C) C5 activation as assessed by C5b-9. The incubation temperature 
was 37°C. The concentration of IC was 250|ig IgG antibody/ml serum. Each point 
represents the mean of duplicate determinations.
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3.4.7. C om parison of k inetics of com plem ent activation  by 
thyroglobulin anti-thyroglobulin IC and BSA anti-BSA IC:
a) Cl activation
i) Nascent IC: The rate of formation of the Cls:Cl-INH complex was higher 
for BSA anti-BSA prepared at 4-times antibody-excess, equivalence and 4-times 
antigen-excess than thyroglobulin: anti-thyroglobulin IC (Fig 3.4.1 A, Fig 3.4.6 A).
ii) Preformed IC: In contrast to the situation with nascent IC, the rate and extent 
of Cls:Cl-INH formation were higher with thyroglobulin anti-thyroglobulin IC than 
BSA anti-BSA IC (Fig 3.4.3 A, Fig 3.4.8 A).
b) C3 activation
i) Nascent IC: The rate and extent of formation of the C3:P complex were 
higher with BSA anti-BSA IC than with thyroglobulin anti-thyroglobulin IC (Fig 3.4.1 
B, Fig 3.4.6 B). There were no obvious effectfof differences in antigen-antibody ratio 
for either type of IC.
C3a production occurred rapidly following the formation of thyroglobulin anti- 
thyroglobulin IC whereas there appeared to be an initial slow increase which was 
followed by a second phase of faster accumulation when BSA anti-BSA IC were 
studied (Fig 3.4.6 B). For both types of IC, those formed at 4-times antigen-excess 
resulted in the production of less C3a than IC formed at the other two antigen-antibody 
ratios. BSA anti-BSA IC formed at equivalence resulted in the production of more C3a 
than those formed at 4-times antibody-excess. This difference was not observed when 
thyroglobulin anti-thyroglobulin IC were studied.
ii) Preformed IC: The rates of formation of the C3:P complex were similar for 
thyroglobulin anti-thyroglobulin IC and BSA anti-BSA IC formed at all three antigen- 
antibody ratios. However the final C3:P levels were higher when BSA anti-BSA IC
were used (Fig 3.4.3 B, Fig 3.4.8 B).
The initial rate of C3a generation was higher for thyroglobulin anti-thyroglobulin IC
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formed at 4-times antibody-excess and at equivalence, than for BSA anti-BSA IC (Fig
3.4.4 B, Fig 3.4.8 B). In contrast, the initial production rate of C3a was higher for 
BSA anti-BSA formed at 4-times antigen-excess than for thyroglobulin anti- 
thyroglobulin IC.
cl C5 activation
i) Nascent IC: C5b-9 generation occurred after a lag-phase of 7.5 minutes for 
thyroglobulin anti-thyroglobulin IC. After the lag-phase the rate of increase of C5b-9 
was greater for IC formed at 4-times antibody-excess and lowest for those formed at 4- 
times antigen-excess (Fig 3.4.1 C, Fig 3.4.6 C). When IC were formed in antibody- 
excess the level of C5b-9 continued to rise until the end of the experiment, whereas 
when IC were formed at equivalence or in antigen-excess the maximum level was 
reached after 15 minutes. In contrast, although little C5b-9 formation was stimulated 
by BSA anti-BSA IC, the levels were maximal within 5-7.5 minutes for IC formed at 
4-times antibody-excess and at equivalence and after 15 minutes by those formed at 4- 
times antigen-excess.
ii) Preformed IC: Both types of IC formed at 4-times antibody-excess or at 
equivalence produced an initial rapid increase in levels of the C5b-9 complex. In both 
cases C5b-9 formation was slightly faster with IC formed at 4-times antibody-excess. 
When IC were prepared at 4-times antigen-excess the rate of production of C5b-9 was 
reduced markedly. The amount of C5b-9 complex formed with thyroglobulin anti- 
thyroglobulin IC prepared at 4-times antibody-excess was far greater than that formed 
when IC were prepared at equivalence. This effect of antigen-antibody,ratio was not 
seen with BSA anti-BSA IC (Fig 3.4.J C, Fig 3.4.8 C).
d) Role of classical and alternative pathways
i) Nascent IC: Although the rate of generation of C3:P complex was reduced by 
Mg++EGTA for both types of IC, a distinct lag-phase occurred prior to the appearance 
of the C3:P complex in response to thyroglobulin anti-thyroglobulin IC which was not
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seen with BSA anti-BSA IC (Fig 3.4.2 B, Fig 3.4.7 A).
The rate of production and the amount of C5b-9 complex produced in response to 
either type of complexes was not markedly affected by Mg++EGTA (Fig 3.4.2 C, Fig 
3.4.7 B).
ii) Preformed IC: The rate of C3:P complex formation by both types of IC was 
reduced in the presence of M g^EGTA (Fig 3.4.4 A, Fig 3.4.9 A).
For both types of IC, the initial rate of C5b-9 complex formation was not reduced, 
but the slower secondary phase and the final levels were reduced by Mg++EGTA (Fig
3.4.4 B, Fig 3.4.9 B).
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3.5. Effect of ervthrocvtes on IC-mediated complement activation
3.5.1.Nascent thyroglobulin anti-thyroglobulin IC
a) Effect of IC concentration
Cl activation, as assessed by the concentration of Cls:Cl-INH, was increased in 
the presence of erythrocytes, at all IC concentration (Fig 3.5.1 A). Levels of C4a were 
not measured.
C3 activation, as assessed by the concentration of C3:P, was generally less in the 
presence of erythrocytes (Fig 3.5.1 B). Levels of C3a were not measured.
Formation of the C5b-9 appeared to be increased slightly when complement 
activation occurred in the presence of erythrocytes, particularly when IC were formed at 
equivalence or in antibody-excess (Fig 3.5.1 C). Levels of C5a were not measured.
b) Effect of antigen-antibodv ratio
Cl activation was greater when IC were formed at 4-times antibody-excess and 
least when IC were formed in antigen-excess. At all the antigen-antibody ratios 
studied, greater levels of Cls:Cl-INH were produced when complement activation 
occurred in the presence of erythrocytes (Fig 3.5.1 A right panel).
At the lowest IC concentration (62.5|ig IgG antibody/ml NHS), serum levels of 
C3:P were greater for IC formed at equivalence, in the absence of erythrocytes. When 
erythrocytes were present, levels of C3:P were reduced except when complement 
activation was stimulated by IC formed at 16-times antigen-excess. In contrast, at the 
highest concentration of IC (500pg IgG antibody/ml NHS), C3:P levels were highest at 
the extremes of antigen and antibody-excess and lowest when IC were formed at 
equivalence or at 4-times antibody-excess. When complement activation occurred in the 
presence of erythrocytes, C3:P levels were reduced (Fig 3.5.1 B right panel).
Generation of C5b-9 was greater when IC were formed at 16-times antibody-excess 
and least when IC were formed at 16-times antigen-excess. In the presence of 
erythrocytes, C5b-9 levels were increased slightly (Fig 3.5.1 C right panel).
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c) Effect of trvpsinization of ervthrocvtes
As the presence of erythrocytes reduced the concentration of C3:P complex formed 
during IC-mediated complement activation, the possibility that C3:P complexes were 
bound to erythrocyte CR1 or that C3b degradation to iC3b had occurred with CR1 
acting as a cofactor to factor I was considered. In a preliminary attempt to investigate 
this problem, the effect of trypsinized erythrocytes on complement activation was 
compared with the effect of normal erythrocytes. It has been shown previously that 
trypsin destroys CR1 (Lay and Nussenzweig, 1968; Dorval et al, 1989). In a 
preliminary study it was shown that neither normal nor trypsinized erythrocytes 
activated complement when incubated with autologous serum at 37° C.
In the experiments described in this study a single concentration of nascent 
thyroglobulin anti-thyroglobulin IC (500|ig IgG antibody/ml NHS) at five different 
antigen-antibody ratios (16-times and 4-times antibody-excess, equivalence, 4-times 
and 16-times antigen-excess) were formed in serum in the absence or the presence of 
autologus normal or trypsinized erythrocytes.
The amount of C3:P formed was reduced when normal erythrocytes were present, 
whereas when trypsinized erythrocytes were used, the level of C3:P was not less than 
that produced in the absence of erythrocytes (Fig 3.5.2 B).
Indeed, when complement activation was produced at 16-times antigen-excess more 
C3:P was formed in the presence of trypsinized erythrocytes.
The concentrations of Cls:Cl-INH and C5b-9 complexes produced in the presence 
of normal erythrocytes were similar to that produced in the presence of trypsinized 
erythrocytes (Fig 3.5.2 A, Fig 3.5.2 C).
d) Effect of CR1 blockade
In a further attempt to investigate the role of CR1, erythrocytes were pre-incubated 
with Fab anti-CRl or normal rabbit IgG Fab which had been pre-absorbed against 
NHS-Sepharose, prior to their incubation with erythrocytes. In a preliminary
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experiment it was shown that Fab treated erythrocytes did not activate complement.
Cls:Cl-INH formation was increased in all five antigen-antibody ratios when 
complement activation occurred in the presence of erythrocytes, and the effect of 
erythrocytes was not altered when they had been pre-incubated with Fab anti-CRl or 
normal rabbit Fab (Fig 3.5.3 A).
The concentration of C3:P was reduced when complement activation occurred in the 
presence of normal erythrocytes. After the erythrocytes had been pre-incubated with 
Fab anti-CRl, the erythrocyte mediated reduction of C3:P levels was not observed. 
Normal rabbit Fab did not abrogate the effect of erythrocytes (Fig 3.5.3 B).
The slight increase in C5b-9 levels observed when complement activation occurred 
in the presence of erythrocytes was not altered when the erythrocytes had been pre- 
incubated with Fab anti-CRl or normal rabbit Fab (Fig 3.5.3 C).
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Figure 3.5.1 (A. B and C): Complement activation by nascent thyroglobulin anti- 
thyroglobulin IC in the presence of human erythrocytes. Left panel: effect of IC 
concentration at 16-times antibody-excess (*—*), 4-times antibody-excess (*—a) and 
16-times antigen-excess (<— o) in the presence (- - - ) or the absence (— ) of 
erythrocytes. Right panel: Effect of antigen-antibody ratio, on complement activation, in 
the presence ( •—•) or absence (■—■) of erythrocytes. (A) Cl activation as assessed by 
the generation of Cls:Cl-INH complex, (B) C3 activation as assessed by C3:P complex 
and (C) C5 activation as assessed by C5b-9 complex. Concentration of IC was 500jig 
IgG antibody/ml serum. Each point represents the mean of duplicate determinations.
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Figwre 3.5.2 (A, B and G);. Effect of trypsinised human erythrocytes on 
complement activation by nascent thyroglobulin anti-thyroglobulin IC, formed at five 
antigen-antibody ratios, at an IC concentration of 500|ig IgG antibody/ml NHS, in the 
absence (■— ■) or the presence of normal human erythrocytes (•—•) or trypsinised 
human erythrocytes ( a —a ). (A) Cl activation as assessed by the generation of Cls:Cl- 
INH, (B ) C3 activation as assessed by the generation of C3:P and (C) C5 activation as 
assessed by the generation of C5b-9. Each point represents the mean of duplicate 
determinations.
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Figure 3.5.3 IA. B and C): Effect of erythrocyte CR1 blockade on complement 
activation by nascent thyroglobulin anti-thyroglobulin IC at different antigen-antibody 
ratios, at an IC concentration of 500jng IgG antibody /ml NHS, in the absence (■— ■ ), 
the presence ( •—•) of normal human erythrocytes or treated human erythrocytes with 
anti-CRl Fab fragment (*—+) and with normal rabbit Fab (*—*). Each point 
represents the mean of duplicate determinations.
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3.5.2. Preformed thyroglobulin anti-thyroglobulin IC
Levels of Cls:Cl-INH and C5b-9 were only increased slightly when complement 
activation (produced by IC containing 500pg IgG antibody/ml) occurred in the presence 
of erythrocytes (Fig 3.5.4 A, Fig 3 5.4 C). The changer in Cls:Cl-INH and C5b-9 
levels were not affected by trypsinization or pre-incubation of erythrocytes with Fab 
anti-CRl. In contrast, trypsinized erythrocytes and Fab anti-CRl treated erythrocytes 
abrogated the effect of erythrocytes on C3:P levels,
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Figure 3.5.4 (A. B and C): Effect of erythrocyte CR1 blockade on complement 
activation by preformed thyroglobulin anti-thyroglobulin IC at five antigen-antibody 
ratios and an IC concentration of 500|ig IgG antibody/ml NHS, in the absence (■—■ ) or 
the presence of normal human erythrocytes ( •—•), human erythrocytes treated with anti- 
CRl Fab (*—«) or with normal rabbit Fab (*—*) (A) Cl activation as assessed by the 
generation of Cls:Cl-INH, (B) C3 activation as assessed by C3:P and (C) C5 activation 
as assessed by the generation of C5b-9. Each point represents the mean of duplicate 
determinations.
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3.5.3. Activation of complement by nascent BSA anti-BSA IC in the 
presence and absence of erythrocytes
a) Effect of antigen-antibodv ratio
Levels of Cls:Cl-INH were higher when complement activation by IC (500fig IgG 
antibody/ml) at all five antigen-antibody ratios occurred in the presence of trypsinized or 
normal erythrocytes. Trypsinized erythrocytes behave in an identical manner to normal 
erythrocytes (Fig 3.5.5. A).
The concentration of C3:P complex was reduced when IC were formed in the 
presence of normal erythrocytes but when trypsinized erythrocytes were used there was 
little difference to that formed in the absence of erythrocytes (Fig 3.5.5 B).
The level of C5b-9 complex was increased when IC were formed at 16-times 
antibody-excess in the presence of erythrocytes (Fig 3.5.5 C). Trypsinized 
erythrocytes had the same effect as normal erythrocytes.
b) Effect of CR1 blockade
The increased levels of Cls:Cl-INH and C5b-9 which were found when 
complement activation occurred in the presence of normal erythrocytes were not 
observed when Fab anti-CRl treated erythrocytes were used (Fig 3.5.6 A, Fig 3.5.6 C).
C3:P level were lower when erythrocytes were present during complement 
activation, but this effect was not observed when they had been pre-incubated with Fab 
anti-CRl. Normal rabbit Fab had no effect on the erythrocytes ability to reduce C3:P 
(Fig 3.5.6 B).
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Figure 3.5.5 (A. B and O : Effect of human erythrocytes on complement activation 
by nascent BSA anti-BSA IC at different antigen-antibody ratios, at an IC dose of 500|ig 
IgG antibody/ml NHS, in the absence (■—■) or the presence of normal human 
erythrocytes ( • —•) or trypsinised human erthrocytes (*—a). (A) Cl activation as 
assessed by the generation of Cls:Cl-INH, (B) C3 activation as assessed by the 
generation of C3:P and (C) C5 activation as assessed by the generation of C5b-9. Each 
point represents the mean of duplicate determinations.
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3.5.4. Effect of erythrocytes on the kinetics of complement activation by 
IC
In these experiments nascent and preformed IC were studied at three antigen- 
antibody ratios (4-times antibody-excess, equivalence, 4-times antigen-excess), at a 
concentration of 250jig IgG antibody/ml NHS.
Nascent thyroglobulin anti-thyroglobulin IC
a) Cl activation
Cls:Cl-INH complexes were detectable within one minute of incubation. Peak 
levels were higher in an incubation mixture containing erythrocytes. For IC formed at 
4-times antibody-excess, the initial rates of Cls:Cl-INH formation were similar, but 
after 5 minutes the rate of increase decreased in the reaction mixture which did not 
contain erythrocytes. The peak level was achieved between 10-15 minutes and 15-30 
minutes in the absence and presence of erythrocytes respectively. When IC were 
formed at equivalence the initial rates of formation of Cls:Cl-INH were similar in both 
reaction mixtures for the first 5 minutes, then as before, there was a reduction in the rate 
of increase in the absence of erythrocytes and a plateau was reached by 10 minutes (Fig
3.5 7 A left panel). When erythrocytes were present the rate of increase in ClsrCl- 
INH concentration continued to increase until it reached a plateau level at 10 minutes. 
For IC formed at 4-times antigen-excess, very little Cls:Cl-INH was formed, 
particularly in the absence of erythrocytes.
The initial rate of the production of C4a was rapid over the first minute, after which 
time the rate of production decreased and reached a plateau by 15 minutes. The rate and 
extent of C4a formation were not altered by the presence of erythrocytes (Fig 3.4 7 A 
left panel). As in the studies of Cls:Cl-INH formation, C4a production was greater 
when IC were formed in antibody-excess or at equivalence and lower when they were 
formed in antigen-excess.
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Figure 3.5.6 (A. B and C); Effect of CR1 blockade on complement activation by 
nascent BSA anti-BSA IC at different antigen-antibody ratios, at an IC dose of 500jig 
IgG antibody/ml NHS in the absence (■—■ ) or the presence of normal human 
erythrocytes ( •—•) or treated human erythrocytes with anti-CRl Fab fragment (*—a) or 
with normal rabbit Fab fragment (A—a). A) Cl activation as assessed by the generation 
of the Cls:Cl-INH complex, B) C3 activation as assessed by the generation of the C3:P 
complex and C) C5 activation as assessed by the generation of C5b-9 complex. Each 
point represents the mean of duplicate determinations.
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b) C3 activation
The initial rate of increase in the level of C3:P was greater when IC were formed in 
antibody-excess and lower when they were formed in antigen-excess. For IC formed at 
4-times antibody-excess, the initial rate fell after 2.5 minutes, whereas the change in 
rate occurred later for IC formed at equivalence (5 minutes) or at 4-times antigen-excess 
(5-10 minutes). The peak C3:P level was similar at all three antigen-antibody ratios. In 
the presence of erythrocytes the initial rate of increase of C3:P and the final 
concentration of C3:P were reduced (Fig 3.5.7 B left panel). The effect of erythrocytes 
was most marked when IC were formed in antigen-excess, and least for IC formed in 
antibody-excess.
The rates of formation of C3a were rapid for IC formed in antibody-excess or at 
equivalence, but lower for IC formed in antigen-excess. The final concentration of C3a 
was slightly higher for IC formed in antibody-excess. In contrast, the level of C3a was 
much lower when IC were formed in antigen-excess. This is in contrast to the level of 
C3:P in these reaction mixtures. The presence of erythrocytes did not affect the rate or 
extent of C3a formation (Fig 3.5.7 B right panel).
c) C5 activation
C5 activation, as assessed by measuring the C5b-9 levels, occurred rapidly and was 
maximal within 7.5-10 minutes when IC were formed in antibody-excess. The rate and 
extent of C5b-9 formation were lower for IC formed at equivalence, and were minimal 
when IC were formed in antigen-excess. More C5b-9 was formed in the presence of 
erythrocytes (Fig 3.5.7 C left panel), and it appeared that the initial rate of C5b-9 
formation was also greater when erythrocytes were present at best when IC were
formed in antibody-excess.
The initial rate of increase of C5a was faster than that for C5b-9, particularly when 
IC were formed in antibody-excess and at equivalence. Although C5a levels were 
lower when IC were formed at equivalence than in antibody-excess, the reduction was
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not as pronounced as the reduction in levels of C5b-9.
From the data it was difficult to determine whether the erythrocytes affected the rate 
and extent of C5a accumulation (Fig 3.5.7 C right panel).
d) Role of classical and alternative pathways
When complement activation occurred in the presence of Mg++EGTA, there was a 
lag-phase of 2.5-5 minutes before C3:P levels began to increase. The rate of increase 
and the final concentration of C3:P and C3a were reduced in Mg++EGTA-treated 
serum. Although levels of C3:P were lower when erythrocytes were present in the 
reaction mixture, C3a levels were almost identical in the presence and absence of 
erythrocytes.-
The rate and extent of C5b-9 formation at all three antigen-antibody ratios were 
similar or slightly reduced in Mg++EGTA-treated serum. The effect of erythrocytes 
was not affected by Mg+^EGTA (Fig 3.5.7 C).
Preformed thyroglobulin anti-thyroglobulin IC
a) C l activation
Very little formation of C ls:C l-IN H  occurred at any antigen-antibody ratios, 
although there was slightly more produced with IC formed at equivalence. The initial 
rate of formation w as extremely rapid with IC formed at equivalence or in antibody- 
excess and was little slower for IC formed in antigen-excess. Slightly more C lsrC l- 
INH was formed when erythrocytes were present (Fig 3.5.8 A).
C4a formation occurred rapidly for the first 30 seconds and then slowed until the 
plateau level was achieved (5 minutes for IC formed at equivalence or in antigen-excess 
and 7.5 minutes for IC formed in antibody-excess). When IC at equivalence were 
studied, C4a was formed slightly more quickly when erythrocytes were present. 
However, the increase was quite small and was not seen at the other antigen-antibody 
ratios (Fig 3.5.8 A).
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b) C3 activation
In the absence of erythrocytes, the initial rate of increase in the level of C3:P was 
rapid at all three antigen-antibody ratios. The rate slowed after one minute for IC 
formed at equivalence or in antibody-excess, and after 2.5 minutes for IC formed in 
antigen-excess. A plateau level of C3:P was reached within 5-10 minutes at all antigen- 
antibody ratios. The maximum level was greatest for IC in antigen-excess. When 
erythrocytes were present the maximum level of C3:P was lower than that seen in their 
absence, and there was an obvious decrease in C3:P levels after 30 minutes incubation. 
This decrease was particularly marked for IC in antigen-excess (Fig 3.5.8 B left panel).
C3a production was extremely rapid, whether erythrocytes were present or not. 
Plateau levels were achieved by 5 minutes for IC in antibody-excess and 2.5 minutes 
for IC at equivalence (Fig 3.5.8 B right panel).
C3a levels were higher when IC at equivalence were used. In contrast, when IC 
were formed in antigen- excess far less C3a was formed, and the rate of production was 
lower than that occurring in response to IC at equivalence or in antibody-excess. 
Erythrocytes probably did not affect the rate of C3a production.
c) C5 activation
For IC formed at equivalence or in antibody-excess, the initial rate of C5b-9 
formation was the same in the presence or absence of erythrocytes. However, the 
second phase of formation was greater when erythrocytes were present (Fig 3.5.8 C 
left panel). More C5b-9 was formed when IC were formed in antibody-excess than at 
equivalence. IC in antigen-excess stimulated little C5b-9 formation, and the presence of 
erythrocytes did not affect this.
A similar effect of the antigen-antibody ratio was observed on the kinetics of C5a 
production (Fig 3.5.8 C right panel). The greatest amount of C5a was produced with 
IC in antibody-excess and the lowest with IC in antigen-excess. At all antigen-antibody 
ratios, the rate and extent of C5a production were unaltered by the presence of 
erythrocytes.
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d) Role of the classical and alternative pathways
i) C3 activation
In Mg++EGTA there was a distinct lag-phase before C3:P levels began to increase 
slowly at all three antigen-antibody ratios. For IC in antibody-excess or at equivalence 
the plateau level was reached at 7.5 and 10 minutes whereas for IC in antigen-excess it 
was reached between 10 and 15 minutes. The maximum levels of C3:P were similar in 
normal serum and Mg++EGTA-treated serum for IC formed in antibody-excess and at 
equivalence (Fig 3.5.8 B left panel). The level of C3:P formed in antigen-excess was 
reduced in the presence of Mg++EGTA. Levels of C3:P were slightly reduced when 
erythrocytes were present, but the rate of C3:P increase was unaltered.
The rate of formation of C3a was reduced in Mg++EGTA and a definite lag-phase 
occurred with IC formed in antibody-excess, although this was less obvious for IC at 
equivalence (Fig 3.5.8 B right panel). The final level of C3a was the same in normal 
serum and in Mg++EGTA-treated serum at all three antigen-antibody ratios. 
Erythrocytes did not affect the rate or extent of formation of C3a in Mg++EGTA-treated 
serum.
ii) C5 activation
The rate and extent of C5b-9 formation were reduced in Mg++EGTA-treated serum. 
In the presence of erythrocytes the final C5b-9 formation was increased when 
complement activation was produced by IC formed at antibody-excess or at equivalence 
(Fig 3.5.8 C left panel). However, erythrocytes did not affect C5b-9 levels when IC in 
antigen-excess were used.
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Figure 3.5.7. (A. B and C); Kinetics of complement activation by nascent 
thyroglobulin anti-thyroglobulin IC (250jlg IgG antibody/ml NHS) at equivalence in the 
presence ( •—•) or the absence (■— ■ ) of human erythrocytes. (A) Cl activation as 
assessed by the generation of Cls:Cl-INH complex (left) and C4a (right), (B) C3 
activation as assessed by the generation of C3:P complex (left) and C3a (right) and (C) 
C5 activation as assessed by the generation of C5b-9 complex (left) and C5a (right). 
The experiment was performed in the presence (empty symbols) or the absence (solid 
symbols) of Mg++EGTA, C4a and C5a levels were not measured in the Mg++EGTA 
experiments Each point represents the mean of duplicate determinations.
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experiments. Each point represents the mean of duplicate determinations.
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3.5.6 Comparison of nascent and preformed thyroglobulin anti- 
thyroglobulin IC
al Cl activation
Although the initial rate of increase in Cls:Cl-INH level was slower with nascent 
IC, they produced a larger final concentration than preformed IC. In the presence of 
erythrocytes Cls:Cl-INH levels were increased markedly with nascent IC, whereas 
with preformed IC the erythrocyte effect was less pronounced (Fig 3.5.7 A left panel, 
Fig 3.5.8 A left panel).
The rate of C4a production was similar for nascent and preformed IC. The peak 
levels of C4a were higher when nascent IC were used, particularly at equivalence or in 
antigen-excess. Erythrocytes did not affect C4a production with either type of IC (Fig
3.5.7 A right panel, Fig 3.5.8 A right panel).
b) C3 activation
When erythrocytes were present C3:P levels were reduced with both types of IC. 
The peak levels of C3:P were lower and were reached earlier when preformed IC were 
used. The largest reduction was seen when nascent IC were formed in antigen-excess.
C3a generation increased more rapidly when preformed IC were used, although the 
peak levels were higher with nascent IC. Erythrocytes did not affect the rate or extent 
of C3a generation for either type of IC (Fig 3.5.7 B right panel, Fig 3.5.8 B right 
panel).
c) C5 activation
Greater amounts of C5b-9 were formed by preformed IC (Fig 3.5.8 C left panel). 
When erythrocytes were present with preformed IC in antibody-excess or at 
equivalence, more C5b-9 was formed than with nascent IC. The initial rate of 
production and final concentrations of C5a were higher for preformed IC formed in 
antibody-excess or at equivalence than for nascent IC.
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Kinetics of complement activation by nascent BSA anti-BSA IC
a) Cl activation
Serum levels of Cls:Cl-INH increased rapidly at all three antigen-antibody ratios. 
The initial rate of increase was greatest for IC formed at equivalence (Fig 3.5.9 A). In 
the presence of erythrocytes the rate of increase remained higher for longer at all three 
antigen-antibody ratios.
b) C3 activation
C3:P levels increased rapidly over the first 2.5 minutes at all three antigen-antibody 
ratios (Fig 3.5.9 B left panel). The presence of erythrocytes did not affect the initial 
rate of increase in C3:P, although the plateau level was generally achieved earlier and 
was lower than was seen in the absence of erythrocytes.
C3a levels increased more slowly than C3:P levels and the presence of erythrocytes 
did not alter the rate of increase or the final concentration. The rate of increase and the 
final concentration were lowest for IC formed in antigen-excess and greater for IC 
formed at equivalence (Fig 3.5.9 B right).
c) C5 activation
Little C5b-9 formation occurred, and rate and extent of formation were not affected 
by the presence of erythrocytes. The initial rate of formation was higher for IC formed 
in antibody-excess or at equivalence than for IC formed in antigen-excess (Fig 3.5.9 
C).
d) Role of the classical and alternative pathways
In the presence of M g^EGTA the rate of increase of C3:P was markedly reduced, 
although the final concentration was only reduced with IC in antigen-excess. When 
complement activation occurred in the presence of erythrocytes, the final concentration 
of C3:P was reduced with IC in antibody-excess and in antigen-excess but not with IC
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at equivalence (Fig 3.5.9 C).
The rate of formation of C5b-9 was reduced in Mg++EGTA-treated serum, but the 
final level for C5b-9 was unchanged. Erythrocytes had no effect on the rate of 
formation or the final concentration of C5b-9 (Fig 3.5.9 C).
Preformed BSA anti-BSA IC
a) Cl activation
In the absence of erythrocytes, the rate of increase and the final concentration of 
Cls:Cl-INH were low. Both were increased slightly when complement activation 
occurred in the presence of erythrocytes, but their effect was mainly seen when 
complement activation was produced by IC at equivalence (Fig 3.5.10 A).
b) C3 activation
The rate of increase in C3:P was rapid, particularly with IC in antigen-excess. In 
the presence of erythrocytes, the rate of increase slowed earlier and the final 
concentration was reduced (Fig 3.5.10 B left panel).
The rate of of increase of C3a was slower than C3:P. For IC formed in antibody- 
excess or at equivalence the plateau level was not achieved until 15 minutes had 
elapsed, whereas with IC in antigen-excess, the plateau was reached within 5 minutes. 
Erythrocytes did not affect the rate or extent of C3a formation (Fig 3.5.10 B right 
panel).
c) C5 activation
For IC formed in antibody-excess or in antigen-excess the rates of formation of 
C5b-9 were lower than for IC formed at equivalence. The rate of C5b-9 formation was 
increased when erythrocytes were present in the reaction mixtures containing IC at 
equivalence (Fig 3.5.10 C), and to a lesser extent in antibody-excess, but not with IC in 
antigen-excess.
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d) The role of the classical and alternative pathways
The rate of increase in C3:P was reduced in Mg++EGTA-treated serum, particularly 
with IC formed at equivalence or in antigen-excess. The final concentration of C3:P 
was reduced with IC formed in antibody-excess or in antigen-excess, but not with IC at 
equivalence (Fig 3.5.10 B left panel). In the presence of erythrocytes the rate of 
increase and the final concentration of C3:P were reduced.
The rate of production and the final concentration of C5b-9 were reduced in 
Mg++ EGTA-treated serum. When complement activation occurred in the presence of 
erythrocytes, increased C5b-9 formation was only seen with IC in antibody-excess (Fig 
3.5.10 C).
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anti-BSA IC (250jig IgG antibody/ml NHS) at equivalence in the presence ( •—•) or the 
absence (■— ■) of human erythrocytes: (A) Cl activation as assessed by the generation 
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absence (solid symbols) of Mg++EGTA. Each point represents the mean of duplicate 
determinations.
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Com parison of nascent and preformed BSA anti-BSA IC
a) Cl activation
The rate and the extent of increase of Cls:Cl-INH were greater with nascent than 
with preformed IC (Fig 3.5.9 A, Fig 3.5.10 A). Erythrocytes had a more pronounced 
effect on the rate and extent of the increase of Cls:Cl-INH with nascent IC.
b) C3 activation
The rate of increase of C3:P over the first 2.5 minutes was higher with nascent IC, 
with the possible exception of preformed IC formed in antigen-excess (Fig 3.5.9 B left 
panel, Fig 3.5.10 B left panel). Erythrocytes appeared to slow the rate of increase in 
C3:P to a greater extent with preformed IC.
The rate and the extent of C3a production were greater with preformed IC (Fig
3.5.9 B right panel, Fig 3.5.10 B right panel). Erythrocytes had no effect on C3a 
formation with either types of IC.
c) C5 activation
The rate and extent of C5b-9 formation were higher with preformed IC. 
Erythrocytes increased the rate and extent of C5b-9 formation only with preformed IC 
(Fig 3.5.9 C, Fig 3.5.10 C).
d) Role of classical and alternative pathways
The rate of increase in C3:P formation with the nascent and preformed IC were 
reduced in Mg^EGTA-treated serum (Fig 3.5.9 B left panel, Fig 3.5.10 B left panel). 
The effect of erythrocytes was more marked with preformed IC.
In Mg++EGTA the rate of formation of C5b-9 was reduced, for both preformed 
and nascent IC, but the extent of formation was reduced only for preformed IC (Fig
3.5.9 C, Fig 3.5.10 C). Erythrocytes in normal serum only increased C5b-9 formation 
for preformed IC at equivalence or in antibody-excess, and in Mg EGTA-treated 
serum was only observed with IC in antibody-excess.
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The measurement of the degree of complement activation is an important constituent 
of monitoring the activity of diseases such as rheumatoid arthritis (Inman and Harpel,
1983) and systemic lupus erythematosus (Lockshin et ai, 1986; Horigome el ai, 1987). 
Currently the degree of complement activation has been assessed by measurement of the 
antigenic levels of components and residual haemolytic activity by the classical and 
alternative haemolytic assays (CH50 and APH50). These results however, may be of 
limited value since some patients have normal or elevated levels due to hypersynthesis 
of complement components which compensates for the increased catabolism caused by 
complement activation (Ruddy et aL 1975). In addition, there are technical problems 
associated with the measurement of complement components, these are namely: 1) 
Antigenic levels may not correspond with functional activity. For instance, C4 is the 
product of two genetic loci, C4A and C4B (O'Neill et ai, 1978). Null alleles are 
common in the normal population (Awdeh et ai, 1979), accordingly a finding of a low 
total C4 in these people is not necessarily as a result of C4 activation (Holme et ai, 
1988). 2) Measurement of complement activation by haemolytic assays only shows 
the residual functional activity of the classical (CH50) or the alternative (APH50) 
pathway and does not necessarily indicate ongoing complement activation. These 
methods also cannot distinguish between genuine deficiency of a complement 
component and activation of the serum resulting in reduced complement levels. 3) 
Certain methods are accompanied with specific problems, for example, since C3dg 
shares antigenic epitopes with C3, C3b and iC3b they must be separated from C3dg 
prior to its measurement. Polyethyleneglycol (PEG; 1 l%w/v) can be used to precipitate 
C3, C3b and iC3b (Perrin et ai, 1975) but precipitation of these components may be 
either incomplete or sometimes excessive C3dg precipitation may occur. Measurement 
of anaphylatoxins is believed to be a good indicator of activation in patients with IC 
diseases (Belmont et ai, 1986), however, levels in clinical specimens (plasma) do not 
always reflect the ongoing complement activation. For instance, plasma levels of C5a 
are extremely low during complement activation due to the binding of C5a and C5a^ cs. .^g
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to their receptors on leucocytes (Chenoweth and Hugli, 1978; Van Epps and 
Chenoweth, 1984), although this anaphylatoxin is readily detectable during in vitro 
activation of serum. Furthermore, the methods for the measurement of cleavage 
products of C4 (C4d), C3 (C3dg) and factor B (Ba) involve technical procedures which 
either limit their value in clinical service laboratories or their use to certain specialist 
centres. For instance, electro-immunoassays (Laurell et aL 1979; Brandslund et ai, 
1981) and radial immunodiffusion (Perrin £l&i, 1975; El-Ghobary and Whaley, 1980) 
are of limited value as only a few samples can be assayed in each procedure and 
immunoprecipitation may take more than 24 hours, which may be an unacceptable delay 
in a clinical service laboratory. Radioimmunoassays (Flack et ai, 1981), although very 
sensitive, have the inherent potential health hazards which occur with the use of 
radioisotopes. ELIS As have been described based on the use of monoclonal antibodies 
against the neoantigenic determinants expressed on the activation products such as C3 
activation products iC3b and C3d (Aguado et&I, 1985; Mollnes, 1985), and C3dg 
(Mollnes andLachmann, 1987), Similarly, monoclonal antibodies have been
described for the neoantigens expressed on the membrane attack complex (Mollnes and 
Harboe, 1987; Falk et ai, 1988). However these monoclonal antibodies are not 
available from commercial sources.
These problems have led to the development of ELIS As which detect soluble 
complement activation complexes (Cls:Cl-INH, C3:P and C5b-9) in biological fluids, 
using polyclonal antibodies. Detection of Cls:Cl-INH indicates classical pathway 
activation (Laurell et ai, 1976; Inman and Harpel, 1983; Hack et ai, 1984) and C5b-9 
complexes the assembly of the membrane attack complex (Gawryl e ie l, 1986). 
Although the presence of the C3:P complex has been thought to measure alternative 
pathway activation (Asghar et ai, 1987; Langlois and Gawryl, 1988), this has not been 
formally proven.
Clr:Cls:Cl-INH complex is generated when Cl-inhibitor binds to the active site of 
C lr and Cls in the activated Cl macromolecule, leading to their dissociation from IC- 
bound Clq. The resulting complex contains two molecules of Cl-inhibitor and one
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molecule each of C lr and Cls (Sim et al, 1979; Ziccardi and Cooper, 1979). Since the 
formation of this complex is independent of calcium ions, it remains stable even in the 
presence of EDTA which may be used to stop any further complement activation.
The C3:P complex has been detected using anti-human properdin and anti-human 
C3. This ELISA should detect a C3bBbP complex, since under physiological 
conditions, B binds C3b but not iC3b (Ross et al, 1983) and under the same 
conditions, properdin will not bind to C3b in the absence of bound Bb (Mayes etui, 
1984; AsgheretaL 1987; Farries etal, 1988a).
The assembly of the membrane attack complex is initiated by the enzymatic cleavage 
of C5 molecules by the classical pathway (Goldlust et al, 1973) and/or the alternative 
pathway (Schreiber et al, 1978) C5 convertases. This step is followed by the non- 
enzymatic assembly of the late complement components (C6-9). The formation of the 
hydrophilic SC5b-9 complex results from the binding of the regulatory protein, S 
protein, to the hydrophobic binding site of C5b67 complex. It is composed of one 
molecule of each of C5b, C6, C7, C8, three molecules of C9 and three molecules of S 
protein (Podacket ai, 1977).
The ELISA systems which I have developed to measure the Cls:Cl-INH, C3:P 
and C5b-9 complexes are based on trapping respectively the Cls, properdin and C9 
components of these complexes, using the IgG fraction of the appropriate goat 
antiserum. The bound complexes are then detected with biotin-conjugated goat IgG 
anti-human Cl-INH, anti-human C3 and anti-human C5 for the three assays 
respectively. Each trapping antibody was selected as it recognised the component 
which was present in serum at the lowest molar concentration in order to allow 
maximum binding of the complex to the ELISA plate wells and minimising competition 
from the free component in the serum. Anti-Clr cannot be used to detect the 
Clr:C ls:(C l-IN H )2 complex as C lr loses most of its antigenic determinants when 
complexed to Cl-INH (Laurell et ai, 1976). The trapping of C9 and probing for C5 
moieties in the C5b-9 complex was used for the measurement of C5b-9 complex but
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Horigome et al (1987) showed that trapping of C7 instead of C9 and probing with anti- 
C5 gave similar results. In these assays, the use of coating and probing antibodies 
from the same animal species reduces the possibility of a high background which 
normally results from interactions between IgG fractions of different species. The 
biotin-avidin system has previously been shown to amplify the sensitivity of 
immunoassays (Guesdon et al, 1979; Sutton et ai, 1985) and give rapid colour 
development. This technique was used throughout this study, and although developing 
rapidly, the colour intensity showed a linear relationship with time (Fig 3.1.4) as 
reported previously (Costa-Castro et al, 1987). Colour development has been reported 
to take a few hours (Nakane and Kawaoi, 1974; Nilsson and Back, 1985), however, in 
the ELIS As described in this study, colour development occurred within 15 minutes 
(Fig 3.1.4). Apart from its increased sensitivity, the most important advantage derived 
from using the avidin-biotin system is the greater recovery of conjugated antibodies 
after the conjugation procedure, which reduced the cost of materials. This method of 
signal amplification has not been used in previously published work in this field.
Commercially available antisera were found to be satisfactory (at low 
concentrations, Fig 3.1.1) for all three ELISA procedures.
Using the procedures described, all these assays were reproducible with intra-assay 
and interassay variations of less than 10%.
The standard curves used in the ELISA described in this study were referred to 
pooled standard serum from 40 normal volunteers. This type of reference curve is 
easier for use in routine laboratories, as purification of complement activation 
complexes for the standard curve requires specialized equipment and expertise. The 
standard curves were constructed by coating some wells with anti-human Cl-INH, C3 
or C5 for the Cls:Cl-INH, C3:P and C5b-9 assays respectively. The concentrations of 
these complexes were then expressed as the amount of Cl-INH, C3 and C5 (ng/ml) 
respectively. The biotin-conjugated antibodies which probe for antigenic epitopes of 
Cl-INH, C3 and C5 are expected to show a similar proportional binding to those
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determinants expressed on the native components (standard curve) as well as those on 
the complexed components (the samples) depending on the concentration of the 
antigenic epitopes. This procedure has been used for the calculation of concentration of 
the C3:P complex (Mayes £* al, 1984; Asghar si al, 1987).
Comparison of the sensitivity of Cls:Cl-lNH and C5b-9 assays with those of other 
workers is difficult, as different standard curves were used. For instance, in case of the 
Cls:Cl-INH ELISA the standard curve was either referred to purified Cls:Cl-INH 
complex (Nilsson and Back, 1985), or by expressing the amounts of Cls into either 
equivalent Cls:Cl-INH complex (jig/ml) (Inman and Harpel, 1983) or as nanomole 
Cls:Cl-INH per ml (Lockshin et al, 1986). In case of the C5b-9 assay, the reference 
standard curves were either performed by using purified membrane attack complex 
(Gawryl £t al, 1986) or expressed as an arbitrary units per ml (Mollnes and Paus, 
1986; Horigome et ai, 1987). The standard curves of Cls:Cl-INH and C5b-9 assays, 
described in this study, were expressed in terms of complexed Cl-INH and C5 (ng/ml) 
respectively. The C3:P ELISA described in this study was more sensitive (lower limit 
0.45ng C3/ml; OD=0.25, Fig 3.1.3.B) than that described by Mayes £t al (1984) 
(lower limit was lOng C3/ml, OD=0.1).
The three ELISAs were used to measure the levels of complement activation in 
normals and patients with RA and SLE. The relationship between individual activation 
complexes and chronic rheumatic diseases has been studied by several groups (Nilsson 
and Back, 1985; Lockshin et ai, 1986; Mayes et ai, 1984; Morgan £t al, 1988). 
However to date no other group has measured the levels of the three complexes in the 
same sample. The data presented here, examine the three activation complexes Cls:Cl- 
INH, C3:P and C5b-9 in serum and plasma of normal individuals and patients with RA 
and SLE and synovial fluid of patients with RA.
Levels of Cls:Cl-INH, C3:P and C5b-9 were similar in the serum and plasma of 
normal individuals, however, in the RA patients a significant difference was observed 
between serum and plasma levels of C3:P (pcO.OOl). Increased levels of activation 
products in serum with respect to plasma have been reported previously (Mollnes et al,
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1985; Nilsson and Back, 1985; Lockshin et al, 1986) and it is thought to occur as a 
result of complement activation via activation of the clotting system and/or in vitro 
complement activation due to the presence of such substances as immune complexes or 
bacterial endotoxins. The use of EDTA-plasma overcomes the potential problems of in 
vitro complement activation. Thus statistical analysis was confined to this group.
Significantly elevated levels of all three complement activation complexes were 
found in SLE and RA patients compared to normals (Table 3.1). Elevated Cls:Cl-INH 
levels have been described in SLE patients (Lockshin et ai, 1986) and Gawryl e ta! 
(1986) found elevated C5-9 complexes in RA and SLE patients. A single study on 
C3:P levels in SLE patients showed only 3 out of 29 had increased levels (Mayes e£al,
1984). This is a much lower frequency than that found in this study in which 53% of 
patients had levels above the upper limit of the normal range (Table 3.1). However, 
this discrepancy may be due to differences in the patient populations, levels of disease 
activity or both.
As levels of Cls:Cl-INH and C5b-9 in RA plasma ranked significantly with those 
in the paired synovial fluid samples (p<0.001 and p<0.0001 respectively, Spearman 
rank correlation; Fig 3.2.2) and the mean levels of each of these activation products in 
synovial fluid were not significantly different from those in plasma, it is possible that 
these complexes can diffuse freely between the synovial cavity and the intravascular 
compartment and vice versa. However, it is also possible that the degree of systemic 
complement activation is similar to that occurring within the joint. The failure of 
synovial fluid C3:P levels to correlate with those in plasma suggests that the production 
of this complex within the joint may occur independently of that in the systemic 
circulation.
Other workers have found increased synovial fluid levels of Cls:Cl-INH (Inman 
and Harpel, 1983) and C5b-9 (Gawryl fit al, 1986; Mollnes et al, 1986; Morgan £tM, 
1988), supporting increased local complement activation in the synovial cavity.
RA patients were divided, according to the presence of rheumatoid factors, into
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sero-positive and sero-negative groups. This grouping was performed in order to see if 
there is any effect of rheumatoid factor (IgM-RF, IgG-RF and IgA-RF) on the levels of 
complement activation complexes. Rheumatoid factors are known to bind IgG 
molecules leading to the formation of IC that may be involved in complement activation 
in rheumatoid patients and related to disease activity (Franklin et ai, 1957; Hay £t al, 
1979; Sabharwal, et al, 1982; Hack el ai, 1984). RA patients with RF had significantly 
higher levels of the three complement activation complexes compared to normals and 
sero-negative group (Table 3.1). In sero-positive patients the levels of Cls:Cl-INH, 
C3:P and C5b-9 correlated significantly with the levels of IgM-RF, IgG-RF and IgA- 
RF (Table 3.3). This relationship did not result from the interaction of IgM-RF with 
the ELISA system, as similar levels of activation complexes were obtained when 
F(ab')2 fragments or intact IgG was used to coat the ELISA plates. Furthermore, 
addition of purified IgM-RF at concentrations seen in RA patients did not alter the levels 
of complement activation products (Fig 3.2.3.). The findings of this study differ from 
those of other workers. Inman and Harpel (1983) found no relationship between RF 
and Cls:Cl-INH levels while other workers found no correlations between RF and 
C5b-9 levels in patients with RA (Mollnes et aL 1986) or juvenile RA (Mollnes and 
Paus, 1986). This discrepancy, however, may be related to the small number of 
individuals examined in these earlier studies, to differences in the disease activity of the 
patients, or to the use of semi-quantitative agglutination tests for the measurement of RF 
levels.
In this large group the relationship between antigenic levels of the commonly 
measured complement components (C3, C4, B and Cl-INH) and the complement 
activation complexes has been analysed. This was performed in order to study the 
relationship between in vivo complement activation and the levels of these complement 
components. There was no relationship between the serum levels of Cl-INH, C4, C3 
or factor B with levels of the three complement activation complexes in SLE patients 
(Table 3.5). However, in RA patients serum levels of Cl-INH correlated with
181.
Cls:Cl-INH, C3:P and C5b-9, and factor B with Cls:Cl-INH and C3:P (Table 3.6). 
This is the converse of what one would expect if complement activation led to increased 
catabolism of cleavage products. These correlations suggest that during in vivo 
complement activation the rate of synthesis of these complement components is in some 
way regulated by the level of complement activation. The lack of any correlation 
between levels of complement activation complexes and levels of C3 and C4 may have 
occurred as a result of the use of immunochemical measurements which detect 
inactivated components, because compensatory hypersynthesis may have masked 
complement activation or because the synthesis of these two components are not 
regulated by the level of ongoing complement activation.
Complement activation is thought to have a significant role in mediating the 
inflammatory responses and it is assumed that the level of complement activation should 
parallel the degree of tissue injury. Therefore, monitoring the levels of of complement 
activation products may provide additional information and allow prediction of the 
clinical status. One prospective study of the levels of the MAC in patients with adult 
respiratory distress syndrome (ARDS) has shown the predictive value of this test, with 
levels of MAC increasing prior to onset of ARDS (Laglois and Gawryl, 1988). In this 
situation it has been suggested that measurement of C5b-9 may provide a more sensitive 
indicator than measurement of CH50, C3a, C4a or C5a.
The result of this study suggest that all the three assays may be necessary for 
monitoring the disease activity and to provide an indication of which complement 
pathway is activated.
The observed correlations between the individual activation products in normals, 
RA and SLE patient groups clearly suggests that a well defined prospective study 
including serial studies is required to establish the role of these ELISA procedures as 
indices of disease activity.
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C l activation
a) Effect of IC concentration
As might be expected, increasing concentrations of both types of IC at all five 
antigen-antibody ratios resulted in dose-dependent increase in the generation of the 
Cls:Cl-INH complex and in the case of thyroglobulin anti-thyroglobulin IC, C4a 
generation. Thus, as the maximum concentration of IC used in this study (500|ig IgG 
antibody/ml) was probably far in excess of any IC formed normally, there must be a 
massive excess of Cl available in the plasma. This conclusion is supported by the 
observation that serum concentrations of Cl, when measured by haemolytic assay, are 
between 2X105 units/ml to 1.6xl06 units/ml (Whaley, 1985). The possibility that Cl 
transfer (that is Cl binds to one IC, activates C4 and C2 to form C3 convertase and 
then is transfered to another IC to repeat the process, Borsos et ai, 1968) could explain 
this finding is untenable, as in whole serum Cl is inactivated rapidly after its activation 
(Ziccardi, 1982b) with dissociation of the Cl macromolecule (Sim et al, 1979).
With the possible exception of BSA anti-BSA IC formed at equivalence, all 
concentrations of nascent IC produced greater concentrations of Cls:Cl-INH at all 
antigen antibody ratios than preformed IC. Similar results were obtained when C4a 
was used to quantify Cl activation. This more efficient activation of Cl by nascent as 
opposed to preformed IC probably reflects differing availability of the Fc regions of the 
antibody molecules in the two types of IC. As soon as IC are formed (nascent IC) and 
two IgG molecules are adjacent to each other, Cl binding and activation can occur 
(Borsos and Rapp, 1965; Cohen, 1968). In contrast, in the case of preformed IC a 
large lattice has developed which not only depends upon antigen-antibody cross- 
linking, but also on interactions between the Fc pieces of the different IgG molecules 
within the IC (Nisonoff and Pressman, 1958; Moller, 1979; Rodwell et ai, 1980). As a 
result of these Fc-Fc interactions, less Fc regions would be available to bind and 
activate Cl.
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b) Effect of antigen-antibodv ratio
Differences in the antigen-antibody ratio of IC had a significant effect on Cls:C l- 
INH formation. For thyroglobulin anti-thyroglobulin IC, Cls:Cl-INH formation was 
maximal at 4-times antibody-excess, whereas in BSA anti-BSA IC it was maximal at 
equivalence. With thyroglobulin anti-thyroglobulin IC, marked Cls:Cl-INH formation 
occurred with IC formed at 16-times antibody-excess and at equivalence, while little 
activation produced in antigen-excess. In contrast, when BSA anti-BSA IC were used 
the range of antigen-antibody ratio which produced high levels of Cls:Cl-INH was 
even more restricted, particularly with preformed BSA anti-BSA IC. Previous studies 
with IC formed with soluble antigens have shown that consumption of haemolytic 
complement was greater in antibody-excess (Lundqvist and Norden, 1960). However, 
the data presented in this thesis show that only in the case of thyroglobulin anti- 
thyroglobulin IC was Cls:Cl-INH generation and C4a generation greater in antibody- 
excess. In contrast to the result of this study, Ishizaka £t&l (1959) showed that only 
soluble IC formed in slight antigen-excess would consume complement. However, in 
that study IC were formed with a variety of different antigens (diphtheria toxoid, 
haemocyanin, chicken y globulin, type II and III pneumococcal polysaccharides and the 
hapten, sodium arsanilate) at different antigen-antibody ratios. Prior to performing 
experiments, the IC mixtures were centrifuged to remove insoluble IC. Thus, the 
majority of any IC at equivalence or in slight antibody-excess would be removed and 
only those IC in far antibody-excess or in antigen-excess would remain in solution. In 
this way the only complement consuming IC left in solution would be those formed in 
slight antigen-excess. This conclusion is supported by other data from this laboratory 
which showed that only soluble BSA anti-BSA IC formed at 4-times antigen-excess 
would bind solid-phase Clq (Scullion £t al, 1979).
An earlier study showed that the antigen in IC influenced the effect of antigen- 
antibody ratio on Cl activation (Fust & ai, 1978). Although both BSA anti-BSA and 
ovalbumin anti-ovalbumin IC activated Cl (measured by C4 consumption) more 
effectively at equivalence, Cl activation by the former IC was much reduced when they
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were formed at 2-times antigen-excess and 2-times antibody-excess. In contrast, 
ovalbumin anti-ovalbumin IC formed at these two antigen-antibody ratios produced 
almost as much Cl activation as those formed at equivalence. Thus, my data and those 
of Fiist (1978) show that the antigen incorporated into an IC influences 
complement activation. The way in which this influence is exerted is by no meaitfclear. 
However, one important factor must be epitope density on each antigen molecule 
(Garred gt al, 1989). The more epitopes per molecule, the more likely one is to have 
two IgG antibody molecules in sufficiently close proximity to allow two of the globular 
C lq heads of a Cl molecule to bind separate IgG Fc CH2 domains so that Cl activation 
can occur (Burton el ai, 1980). Such binding could occur as a result of the attachment 
of two IgG molecules to a single antigen molecule, or more likely by the cross-linking 
of two or three antigen molecules by at least two IgG molecules. The observation that 
IC formed in antigen-excess did not activate Cl terribly effectively can be explained on 
the basis that the greater the number of molecules of the antigen per IgG antibody 
molecule, the less likely one is to have antigen molecules cross-linked by IgG antibody. 
The epitope densities of thyroglobulin (650kD) and BSA (66kD) are approximately 
40/molecule and 10/molecule respectively (Heidelberger, 1938). The molar antigen- 
antibody ratio in thyroglobulin anti-thyroglobulin IC at 4-times antibody-excess 
(maximum Cl activation) was 1:24, while that for BSA anti-BSA IC at equivalence 
(maximum Cl activation) was 1:6. When one considers the differences of number of 
epitopes per molecule of both antigens, it is clear that the average distribution of IgG 
molecules on thyroglobulin anti-thyroglobulin IC at 4-times antibody-excess 
approximates to that for BSA anti-BSA IC formed at equivalence.
Although Cls:Cl-INH formation was clearly greater with thyroglobulin anti- 
thyroglobulin IC formed at antibody-excess, and little was formed with IC formed in 
antigen-excess, the effect of antigen-antibody ratio was far less pronounced when C4a 
production was measured. The explanation of the increased generation of C4a when IC 
were formed at 16-times antigen-excess compared with that occurring with IC formed at
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4-times antigen-excess is not obvious. Because of the expense of the anaphylatoxin 
assays kits, these results were obtained from duplicate determinations of a single 
samples and could therefore be due to a technical error. However, the observation that 
it occurred with nascent as well as preformed IC and with C3a generation suggests that 
this may not be the case.
c) Kinetics of Cls:Cl-INH formation
The rate and extent of Cls:Cl-INH complex formation were clearly temperature 
dependent, as shown by the reduced formation at 30° C and 20° C compared with 
37°C. Previous studies have shown that the initial step of Cl activation the binding of 
Cl to IC is temperature independent as it can occur at 0°C, but for activation to occur 
the IC-C1 complex must be incubated at higher temperature (Borsos et al, 1964). The 
initial rate of the Cls:Cl-INH complex was greater for preformed IC than for nascent 
IC and for BSA anti-BSA IC it was greater at equivalence than at other antigen-antibody 
ratios whereas with thyroglobulin anti-thyroglobulin IC it was greater when IC were 
formed at 4-times antibody-excess. The more rapid initial rate of formation of Cls:Cl- 
INH complex for preformed IC is due to the already assembled lattice to which Cl can 
bind whereas the slower rate of formation in the case of nascent IC reflects the time 
required for antigen and antibody to complex before Cl can bind and be activated.
Cls:Cl-INH formation reached a plateau very rapidly with preformed IC because 
the IC was fully formed at the time of exposure to serum. In contrast, the continued 
increase in Cls:Cl-INH during the incubation period with nascent IC probably reflects 
the continued formation of the IC throughout this time.
The effect of antigen-antibody ratio on complement activation has been observed 
previously (Hill and Osier, 1955). These authors, using IC containing the antigen type 
III pneumococcal polysacchride, stated that IC formed at equivalence consumed 
complement slightly more rapidly than IC formed in antibody-excess, while IC formed 
in antigen-excess consumed complement much more slowly. Their results are similar
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to those described here on the effects of IC on Cls:Cl-INH formation.
Interestingly, the rate of formation of C4a was greater than that of the Cls:Cl-INH 
complex with nascent IC, whereas when preformed IC were used the rate of C4a 
formation was slower than that of the Cls:Cl-INH complex. These differences 
emphasize that formation of C4a and Cls:Cl-INH occur independently and as a result 
of two distinct events. C4a is formed as a result of the activation of C4 by Cl (Budzko 
and Muller-Eberhard, 1970), whereas the Cls:Cl-INH complex is formed after 
activated Cl has been inactivated by Cl-INH (Laurell et al, 1978; Sim et al* 1979). 
Thus, with nascent IC one can conclude that Cl activation occurs quickly while 
inactivation occurs more slowly, whereas with preformed IC the more rapid inactivation 
of Cl results in a slower rate of C4a generation.
d) Effect of ervthrocvtes on Cls:Cl-INH generation
The finding that Cls:Cl-INH formation was increased when complement activation 
occurred in the presence of erythrocytes was unexpected. The increase did not reflect 
increased Cl activation as C4a levels were unaffected by the presence of erythrocytes. 
Thus in the presence of erythrocytes, IC-mediated Cl activation occurs normally but 
activated Cl appears to be inactivated more readily.
Although the results of many of the kinetic assays from this series of experiments 
do not give clear-cut results, the results for nascent BSA anti-BSA IC (Fig 3.5.9) 
demonstrates clearly that both the rate and extent of formation of the Cls:Cl-INH 
complex are increased in the presence of erythrocytes. It is interesting to note that 
Cls:Cl-INH formation was only increased significantly when nascent IC were used. 
This observation suggests that the properties of erythrocytes endow Cl which has 
bound and been activated by IC to be inactivated more rapidly. The data obtained using 
trypsinized erythrocytes and Fab anti-CRl show clearly that CR1 (the C3b receptor) is 
not involved in this phenomenon. There are data which show that IC can bind to 
human erythrocytes in the absence of complement by an Fc-dependent interaction 
(Virella £t al, 1983). Because the effect of erythrocytes was more pronounced with
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(Virella filal, 1983). Because the effect of erythrocytes was more pronounced with 
nascent IC, and as it is probable that Fc regions are more exposed on nascent IC (see 
above), an interaction between Fc region of the IgG molecules and a structure on the 
erythrocyte cell membrane could account for the effect of erythrocytes on Cls:Cl-INH 
formation.
e) Relationship between Cls:Cl-INH and C4a formation
During the study of Cl activation on a number of occasions it was noted that the 
change in the Cls:Cl-INH complex levels did not mirror those seen in C4a 
concentrations. These differences are listed below
1) Although the IC dose response curves for Cls:Cl-INH complex formation were 
similar to those for C4a generation, they were not always identical.
2) Although the changes seen in C4a levels with antigen-antibody ratio were similar 
to that for Cls:Cl-INH significant differences were sometimes observed.
3) Although the amount of Cls:Cl-INH complex produced correlated with the 
amount of C4a produced when IC were formed, in antigen-excess disproportionally 
more C4a than Cls:Cl-INH complex was formed.
4) The kinetic studies showed that levels of C4a were produced at different rates to 
those of the Cls:Cl-INH complex.
5) Erythrocytes did not affect C4a generation despite the increased rate and extent of 
Cls:Cl-INH formation when complement activation was triggered with nascent IC.
These findings clearly show that measurement of C4a gives different information to 
that of the Cls:Cl-INH complex. It has already been stated (see above) that C4a is a 
measure of Cl activation while Cls:Cl-INH formation is a measure of Cl inactivation. 
This distinction is important when applying them to measure complement activation in 
the experimental situation. Whether it is important to draw this distinction in the service 
laboratory remains to be clarified.
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C3 activation
a) Effect of IC concentration
Although there was a clear dose-dependent relationship between C3:P complex 
formation and IC concentration with preformed thyroglobulin anti-thyroglobulin IC 
formed at 16-times antigen-excess, this was not observed at other antigen-antibody 
ratios with nascent thyroglobulin anti-thyroglobulin IC or preformed BSA anti-BSA IC. 
Although some evidence of dose-dependent increase in C3:P was obtained with nascent 
BSA anti-BSA IC, this was only seen at the lower end of the dose response curve.
Usually after the peak value was reached, the level of C3:P stayed constant or 
decreased as higher concentrations of IC were used. This was in marked contrast to the 
clear dose-dependent relationship between IC concentration and the levels of C3a 
produced (with the exception of nascent thyroglobulin anti-thyroglobulin IC formed at 
16-times antigen-excess). The discrepancy between the dose-response curves for C3:P 
and C3a suggests that the level of C3:P in serum cannot be used to quantify C3 
activation. Further evidence will be discussed below.
b) Effect of antigen-antibodv ratio
The antigen-antibody ratio influenced the amount of C3:P formed for both 
thyroglobulin anti-thyroglobulin IC and BSA anti-BSA IC. However, the effect of 
antigen-antibody ratio was dependent upon the concentration of IC used. The lowest 
concentrations of IC at equivalence stimulated the greatest production of C3:P, whereas 
at higher concentrations the lowest C3:P levels were formed with IC at equivalence or at 
4-times antibody-excess. In the case of BSA anti-BSA IC, the former observation is in 
agreement with the observations on the effect of antigen-antibody ratio on Cls:Cl-IMH 
formation which suggests that Cl activation is related to C3:P formation. However, 
with thyroglobulin anti-thyroglobulin IC, the former observation is not in keeping with 
Cls:Cl-INH or C4a formation, both of which were greater with IC formed at 4-times 
antibody-excess. Interestingly, in the case of nascent thyroglobulin anti-thyroglobulin
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IC, the amount of C3a formed was greatest with IC formed at 4-times antibody-excess, 
which suggests that in this situation C3 turnover, but not C3:P formation, parallels 
activation of Cl. However, for preformed thyroglobulin anti-thyroglobulin IC, slightly 
greater quantities of C3a were usually produced in response to IC formed at equivalence 
than at 4-times antibody-excess whereas the converse was true for C4a production. 
This observation suggests that turnover of C3, as measured by C3a generation, is not 
totally dependent of the extent of C4 turnover. One factor which influences the 
turnover of C3 is the amount of C3 convertase (C4b2a) generated. Variations in the 
amount of C4 cleaved and the site of C4b binding to IC formed at different antigen- 
antibody ratios would influence the number of molecules of C4b2a produced. It is also 
possible that the site of C4b binding could influence the efficiency of any resulting 
convertase molecules; conceivably in some locations, access of C3 to the active site of 
the convertase could be impaired. The amount of C4a formed was only approximately 
one fifth that of C3a. Using a haemolytic system, it has been calculated that only 5% of 
C4b molecules bind to IC after C4 activation and only 20% of those that bind are 
involved in C3 convertase formation; therefore only 1 % of activated C4 molecules 
participate in C4b2a generation (Hughes-Jones, 1986). As C4a has a molecular weight 
of 6kD (Budzko and Miiller-Eberhard, 1970) compared with 9kD for C3a (Sim et al, 
1981; Tack et al, 1979) it can be calculated that in the system used in my studies, one 
molecule of C3 convertase activates 333 molecules of C3, whereas it has been 
calculated that 200 molecules of C3 are activated by one C3 convertase on haemolytic 
intermediates (Hughes-Jones, 1986). Considering the approximations used in my 
calculations and the different IC systems used, the two values are in reasonable 
agreement.
The reduced concentrations of C3:P at high IC concentrations formed at equivalence 
or in antibody-excess could be due to the following causes:
1) If C3:P was not bound to the IC, perhaps it might be less stable at higher IC
concentrations.
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2) At higher concentrations less C3:P formation occurs.
3) Binding of C3:P to IC, which at higher concentrations might be insoluble. Thus 
much of the C3:P formed would pellet with the insoluble IC.
4) If C3:P is bound to soluble IC perhaps at higher concentrations bound C3 
antigens are masked by properdin.
The first explanation is unlikely as the C3:P complex was shown to be stable during 
preliminary studies. It is also extremely improbable that the presence of a greater IC 
concentration would alter the stability of the C3:P complex.
The levels of all other measurements of complement activation showed a dose- 
related relationship with IC concentration. As the C3:P complex is thought to be the 
alternative pathway C3 convertase (C3bBbP) (Mayes et al, 1984; Asghar et al, 1987) 
the level should parallel complement activation. Thus, reduced complement activation 
can not account for reduced level of C3:P complex.
It is distinctly possible that the C3:P complex is bound to IC. C3b could bind 
covalently to IC and properdin then bind to the C3bBb complex (Fames et al, 1988a). 
However, the precise constituents of the C3:P complex have not been defined. The 
possibility that IC-bound C3:P were precipitated as part of insoluble IC was made less 
likely as the levels of the C3:P complex were the same before and after centrifugation to 
remove insoluble IC. Furthermore although the amount of C3:P formed in response to 
the highest concentrations of nascent BSA anti-BSA IC was reduced, the IC remained 
totally soluble. Thus, the latter possibility appears most likely to be correct. This 
possibility could be investigated by firstly defining precisely the constituents of the 
C3:P complex, and secondly by investigating the stoichiometry of the binding of C3b to 
antibody and antigen and that of properdin to C3b.
c) The role of the alternative pathway on C3:P formation
The reduced formation of C3:P in Mg++EGTA when IC were formed in 16-times 
antibody-excess and 4-times and 16-times antigen-excess, shows that the alternative 
pathway is partly responsible for C3.‘P formation under these conditions. In contrast,
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as C3:P levels were the same in Mg++EGTA-treated serum and normal serum when IC 
were formed at equivalence or 4-times antibody-excess, alternative pathway activation 
alone must be responsible for all the C3:P formation.
C3:P formation did not occur in EDTA-treated serum; thus the formation of this 
complex requires complement activation. As properdin binds to C3b in the presence of 
EDTA (Fearon and Austen, 1975b) the requirement for Mg++ supports the view that 
C3bBb formation (which requires Mg++) is a prerequisite for C3:P formation.
In comparison with the effect on C3:P formation, Mg++EGTA reduced C3a 
formation by approximately 50% at almost all IC concentrations and almost all antigen- 
antibody ratios. These data show that under most conditions the alternative and 
classical pathways usually contribute equally to C3 turnover by IC. They also confirm 
the results of the previous studies which showed that C3:P concentrations do not 
always parallel C3a levels.
d) Kinetics of C3:P formation
The rate and extent of C3:P formation were temperature dependent, which supports 
the previous conclusion (see above) that the formation of the complex is an active 
process involving the activation of C3 and the proteolysis of B by D prior to the binding 
of P. This conclusion is also supported by the observations of a distinct lag-phase prior 
to the formation of C3:P, particularly when thyroglobulin anti-thyroglobulin IC were 
used to activate Mg++EGTA-treated serum. This delay is due to the initial slow 
assembly of the alternative pathway C3 convertase prior to the formation of IC-bound 
C3 convertase which produces more rapid C3 activation. In normal serum the rapid 
formation of C3:P demonstrates the importance of the classical pathway for the early 
triggering of the alternative pathway. The studies of the kinetics of C3a formation with 
thyroglobulin anti-thyroglobulin IC support this hypothesis. The results show that 
although in normal serum the initial rate of increase is similar to that for C3.P in 
Mg44"EGTA-treated serum, C3a levels increase while C3:P levels remain unchanged.
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Thus, in this situation C3 turnover must occur before C3:P formation.
Although C3:P and C3a production occurred rapidly at 37° C in normal serum when 
complement activation was stimulated with thyroglobulin anti-thyroglobulin IC, this 
was not the case when BSA anti-BSA IC were studied. In the latter situation C3:P 
production was rapid, whereas C3a production occurred more slowly. These 
observations suggest that C3 activation varies with different types of IC. In the case of 
BSA anti-BSA IC, alternative pathway activation occurs reasonably rapidly, as 
confirmed by the much shorter lag-phase in Mg’1"* EGTA-treated serum, and most of the 
C3 turnover is due to alternative pathway C3 convertase activity. Unfortunately, I was 
unable to measure C3a levels in the experiments in which complement activation was 
stimulated using BSA anti-BSA IC in Mg++EGTA-treated serum. As discussed above 
with thyroglobulin anti-thyroglobulin IC the converse situation appeared to be the case, 
as classical pathway activation seemed to be responsible for most of the initial C3 
turnover with the alternative pathway playing a minor role.
e) Effect of ervthrocvtes
When complement activation occurred in the presence of human erythrocytes C3:P 
levels were reduced. The observations that trypsinization of erythrocytes or blockade 
of CR1 by Fab anti-CRl showed that CR1 was responsible for this effect. As IC were 
shown to bind to erythrocytes at least part of the reduction could be explained by the 
binding of IC to erythrocyte CR1. Thus, IC-bound C3:P would also be removed from 
the fluid-phase. The alternative possibility that erythrocyte DAF and CR1 regulated the 
activity of fluid-phase and IC-bound C3-convertase is unlikely as C3a generation was 
unaffected by the presence of erythrocytes. This finding is contradictory to those of 
Gronski £t gl (1986) who found that spontaneous complement activation occurring in 
Cl-INH depleted serum was reduced slightly by the presence of erythrocytes. This 
discrepancy could be due to the two different methods for activating the complement 
system. In my experiments IC were used and both the classical and alternative
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pathways were activated whereas in the study of Gronski el a! (1986) only the classical 
pathway was activated by depletion of Cl-INH. 
f) Relationship between C3:P and C3a formation
In these experiments it was seen that C3:P levels did not mirror those seen in C3a 
concentrations. These differences were seen in all the following experiments:
1) Dose-response curves
2) Studies of antigen-antibody ratios
3) Comparing complement activation in normal serum and Mg++EGTA- 
treated serum
4) Kinetic studies
5) Effect of erythrocytes
The levels of C3:P and C3a were not related in any of the experiments
It was originally suggested that the C3:P complex was a measure of alternative 
pathway activation (Mayes et al, 1984). In the narrow sense this is true as it probably 
contains Bb in addition to properdin. However, it appears that with thyroglobulin anti- 
thyroglobulin IC the major stimulus to C3:P complex formation was activation of the 
classical pathway. Thus, in the absence of an intact classical pathway very little C3:P 
complex was formed when complement was activated by these IC. Thus, the use of 
C3:P as a measure of alternative pathway C3 turnover is not strictly correct. Although 
C3 turnover is required for C3:P formation, once the alternative pathway C3 convertase 
has been formed it can activate more C3. Furthermore, we do not know what 
proportion of C3b is incorporated to C3b:P. Further studies on the nature of the C3:P 
complex are clearly necessary and must include: a) investigations into the constituents 
of the complex and b) why the complex is so stable. In the presence of factors H and I 
the convertase should be destabilised and C3b converted to iC3b which does not bind 
properdin (Farries et al, 1988a). The relationships between the C3:P complex and the 
multiple sedimented species of properdin described by Minta and Lepow (1974) and 
Smith et al (1984) must also be determined. These different species of properdin were
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complexed with C3, and appeared to occur spontaneously, in serum. Recent work has 
shown that complexes of C3 and properdin may be involved in the early stages of 
activation of the alternative pathway (Purkall and Ruddy; unpublished observations) but 
this has yet to be confirmed. It is unlikely that the C3:P complexes detected in this 
study were the same as those described earlier, as those detected by my techniques did 
not occur spontaneously. However, this can be proved only when the C3:P complexes 
are a) isolated and characterized and b) assembled in vitro using purified complement 
components and IC.
C5 activation
a) Effect of IC concentration
The dose-dependent increase in the concentration of C5b-9 and C5a were more 
pronounced with preformed than with nascent IC and with IC formed in antibody- 
excess. The highest concentration of C5a produced in these experiments was 
1.5(ig/ml. As C5a (12kD) comprises 6% w/w of C5 (200kD), 25p.g of C5 must be 
activated to generate this quantity of C5a. This represents approximately 33% of serum 
C5 (concentration 75(ig/ml). The amount of C5a produced was approximately 10% of 
the amount of C3a produced. Thus, for every 10|j.g of C3a generated, ljug of C5a 
would be produced. As the molecular weight of C3a and C5a are 9kD and 12kD 
respectively, it appears that 13 molecules of C3 are required to cleave one molecule of 
C5. However, only those molecules of C3b which bind to C4b in C4b2a can 
participate in C5 convertase activity (Kinoshita et ah 1987). As one molecule of C3b 
binds to a single C4b in the C5 convertase, and as one molecule of C3/C5 convertase 
will activate 333 molecules of C3 (see above), one molecule of convertase will activate 
26 molecules of C5. This figure is far higher than published figures which suggest that 
each molecule of convertase will only activate 2-3 molecules of C5 (Hughes-Jones, 
1986). The more likely explanation for this difference is that the earlier studies were 
performed using haemolytic intermediates and purified complement components,
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whereas in the present study complement activation occurred in whole serum and the 
alternative pathway activation would occur, with the formation of the alternative 
pathway C5 convertase. Evidence to support this argument is presented below.
b) Effect of antigen-antibodv ratios
Although with thyroglobulin anti-thyroglobulin IC the formation of both C5b-9 and 
C5a was greatest in antibody-excess and minimal in antigen-excess, C5b-9 formation 
was greater at 16-times antibody-excess, whereas C5a production was greatest at 4- 
times antibody-excess. Thus, it would appear that the conditions which are optimal for 
C5 activation (C5a generation) are not optimal for assembly of the C5b-9 membrane 
attack complex. However, it is possible that more C5b-9 complex is formed at 4-times 
antibody-excess but some is bound to the IC, a greater proportion of which are 
insoluble at this antigen-antibody ratio than at 16-times antibody-excess. Although it 
has been stated that C5b-7 cannot bind to IC formed with soluble proteins (Podack, 
1986), thyroglobulin, a large antigen, has regions of surface hydrophobicity which 
could permit binding of C5b-7. It is also possible that other proteins (eg lipoproteins, 
S^rotein), bind to thyroglobulin anti-thyroglobulin IC, and so indirectly promote 
binding of C5b-7 or C5b-9 to IC.
If one accepts the observation that C5b-9 formation is greater at 16-times antibody- 
excess, one must postulate that IC formed at this ratio are in some way able to promote 
the interactions of C5b with the later terminal components or, alternatively, when IC are 
formed at 4-times antibody-excess these interactions are inhibited. Although the newly 
generated labile C5b is capable of forming a stable, hydrophilic, bimolecular complex 
with C6 (Podack et al, 1978), there is no good reason to believe that antigen-antibody 
ratio could influence this reaction.
Interestingly with BSA anti-BSA IC, although the greater C5b-9 formation 
occurred in antibody-excess, there was little difference between IC formed at 16-times 
antibody-excess and those formed at 4-times antibody-excess. These data emphasize
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the point that the antigen in an IC can influence complement activation. Unfortunately, 
due to lack of anaphylatoxin assay kits, C5a assays were not performed in these 
experiments.
c) Role of classical and alternative pathways
The amount of C5b-9 formed in Mg++EGTA-treated serum and normal serum were 
almost the same for all types of IC. Although there was a reduction in C5a production 
in Mg++EGTA-treated serum, this was never greater than 25-30% with IC formed in 
antibody-excess. Thus, the alternative pathway must be responsible for most of the C5 
convertase activity which is generated when complement activation is produced by IC. 
As fluid-phase alternative pathway activation does not permit efficient C5 convertase 
formation (Pangbum, 1986), the C5 convertase formed in my experiments must be 
bound to the IC. As one molecule of C4b2a activates many (333 according to my 
calculations) molecules of C3, a number of C3b molecules could bind to both antibody 
and antigen moieties of IC. Once bound, each could bind factor B to form C3bBbP to 
cleave more C3, some of which would bind to the C3 convertase to form C5 convertase 
(Kinoshita ££ &1, 1987). Alternatively, as classical pathway activation would still be 
proceeding a second C3b molecule could bind to original bound C3b molecules. The 
subsequent binding of B and P would lead to the direct formation of an alternative 
pathway C5 convertase.
dl Kinetic studies of C5 activation
The rate and extent of C5b-9 and C5a formation were temperature dependent, 
showing that C5 activation is an active process. The kinetic studies with thyroglobulin 
anti-thyroglobulin IC showed that C5a was generated more slowly than C3a. This 
delay is probably due to the time required for conversion of C3 convertase to C5 
convertase. With nascent thyroglobulin anti-thyroglobulin IC C5a levels increased 
earlier than C5b-9. This delay probably reflects the time for assembly of the 
multimolecular C5b-9 complex following C5b formation. In contrast C5b-9 formation
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with preformed thyroglobulin anti-thyroglobulin IC occurred more rapidly. It is 
difficult to explain this discrepancy but it might be argued that preformed thyroglobulin 
anti-thyroglobulin IC allow the transient binding of C5b to promote its interaction with 
the later components. One would need to propose that although nascent IC form C5 
convertase and activate C5, they may not have acquired the ability to promote the 
interaction of C5b with the later components. Perhaps as IC increase in size this ability 
is acquired.
The kinetic studies of C5b-9 formation with BSA anti-BSA IC gave results which 
were intermediate between those of nascent and preformed thyroglobulin anti- 
thyroglobulin IC, providing evidence that the antigen plays a role in the generation of 
C5b-9 complex. Unfortunately C5a levels were not measured.
e) Effect of ervthrocvtes
When complement activation occurred in the presence of erythrocytes, the rate and 
extent of C5b-9 formation were increased. In contrast, the rate and extent of C5a 
generation was unchanged. Thus, erythrocytes do not affect C5 convertase formation 
or activity but do appear to promote the assembly of the C5b-9 complex.
f) Comparison of C5b-9 and C5a formation
Investigation of C5 activation had showed a linear relationship between the 
generation of C5a and C5b-9 (Fig 3.3.10). In spite of that correlation, some 
discrepancies were observed:
1) The dose response curves in the case of nascent and preformed thyroglobulin 
anti-thyroglobulin IC showed that C5b-9 generation was almost straight line, while that 
for C5a a plateau was observed during the two highest IC doses.
2) In thyroglobulin anti-thyroglobulin IC, the generation of C5a was always higher 
at 4-times antibody-excess, while that for C5b-9 was higher at 16-times antibody- 
excess.
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3) Kinetic studies showed that C5b-9 generation exhibited a lag-phase with nascent 
thyroglobulin anti-thyroglobulin IC, while C5a generation starts up much earlier. In 
case of preformed thyroglobulin anti-thyroglobulin IC levels of C5b-9 rose abruptly, 
while C5a was generated at a slower rate.
4) Erythrocytes did not affect the generation of C5a, despite the increased rate of 
C5b-9 generation
These findings reflect that in some situations, the measurement of C5a provides 
different information than that of C5b-9. Measurement of C5a expresses the activity of 
the classical and alternative pathway C5 convertases (Hugh and Mliller-Eberhard 1978; 
Hammerschmidt et al, 1980; Chenoweth et al, 1981; Gawryl et al, 1986), while the 
C5b-9 complex measured in this study is the fluid-phase form of the membrane attack 
complex which has incorporated S-protein (SC5b-9). The other fact is that the 
concentration of the C5b-9 complex does not necessarily reflect the total number of 
activated C5 molecules, as it is possible that some C5b molecules become hydrated with 
the C6 binding site being lost. It is also possible that some of the complexes are present 
at different stages of formation such as C5b6, C5b67 or C5b678, and all these 
complexes are undetectable by the ELISA used.
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Further studies
The results of the studies described in this thesis show that the measurement of 
multimolecular complement activation complexes in biological fluids is easily performed 
and could be undertaken in routine service laboratories. However, before being 
undertaken more information regarding their relationship to disease activity must be 
obtained by carefully performed prospective studies. In addition it is important to 
establish in each disease whether it is necessary to measure levels of one complex or a 
combination of two or more complexes.
At the research level it is important to define the composition of C3:P complex and 
to try explain its relationship to the spontaneously occurring serum C3:P complexes 
described earlier (Asghar et al, 1987) and its possible role in the initiation of alternative 
pathway activation. These studies would involve more complex ELISA assays using 
probes other than C3 and immunoblotting, to determine the constituents of the complex 
which could then be confirmed by assembling the complex in vitro using purified 
complement components.
Finally, the role of different antigens in complement activation could be investigated 
by extending the range of soluble antigens and investigating the composition (eg. 
protein, polysaccharide) and the molecular weight of antigens. Comparison between IC 
formed with soluble and cellular antigens could also be investigated.
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